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ABSTRACT 
 
 
Epstein-Barr virus (EBV) establishes a chronic infection, usually effectively controlled by the 
cellular immune response. However, EBV has the potential to escape immune control, such as 
during malaria exposure, or modulate the immune response. In this study, immune control of 
EBV was examined in Gambian children in two situations: during malaria exposure and early 
after EBV infection. Additionally, EBV infection may also inhibit vaccine induced antibody 
responses, hence its impact on a childhood pentavalent vaccine was studied, but infection had 
no effect. In contrast to historical studies, acute malaria infection was not associated with 
impaired immunity to EBV, a finding potentially explained by the declining malaria exposure 
in The Gambia. Children recently infected with EBV had evidence of activated EBV-specific 
T-cell responses, with latent and lytic epitope-specific responses of equal magnitude. Several 
donors identified as undergoing primary asymptomatic EBV infection had virus genome loads 
equivalent to those of acute infectious mononucleosis (AIM) patients. In contrast to AIM 
patients they did not show a peripheral lymphocytosis but did have significant expansions of 
activated EBV-specific CD8+ T-cells, which were lower or perhaps more focused than in 
AIM patients, suggesting that the highly expanded T-cell populations and not virus load 
drives AIM pathogenesis.  
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CHAPTER 1 : INTRODUCTION 
1.1 The development and survival of lymphocytes 
The adaptive immune response enables an individual to make immune responses against a 
wide variety of pathogens during their lifetime. Diverse repertoires of T- and B-cell receptors 
are generated during T- and B-cell development in central lymphoid tissues. Both T- and B-
cell lymphocyte precursors originate in the bone marrow, B-cells complete most of their 
development there whereas the majority of T-cells migrate to the thymus.   
 
Within the specialised microenvironment of the bone marrow signals from stromal cells act 
on the lymphocyte progenitors allowing subsequent differentiation of B-cells. The heavy 
chain locus is rearranged first and if successful combines with surrogate light chains. These 
undergo rearrangement and if productive form a complete immunoglobulin B-cell receptor.  
Immature B-cells are tested for autoreactivity before they leave the bone marrow. Cells that 
have no strong reactivity to self antigens are allowed to mature however if they are self 
reactive their development is arrested and the cell will not mature. There are several possible 
fates for self-reactive B-cells; cell death by apoptosis  (“clonal deletion”); the production of a 
new receptor by a process known as receptor editing, the induction of a permanent state of 
unresponsiveness or anergy to antigen and immunological ignorance.  
 
T-cell progenitors derive from pluripotent haematopoiectic stem cells in the bone marrow. 
They then migrate to the thymus where they mature. Similar to B-cells T-cells rearrange 
antigen-receptor genes. Two distinct lineages are generated !"#$%&'$(")$*+,-*../&0$'/.1/&21$%&1/0*&3-*2*,14-$0*&*.5$6&$7/0-%1/4&$14$18*$1897:.$;32*<<$,-*2:-.4-.$.,*&'$:,$14$%$
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1.2 Biology of Epstein-Barr virus  
Epstein-Barr virus (EBV) is one of eight known human herpesviruses, designated human 
herpesvirus 4 (HHV-4) and is a member of the gamma herpesvirus family. All gamma 
herpesviruses infect lymphoid cells, using these to establish the site of latency and also 
replicate in certain other cell types. For EBV the major host cells are B-lymphocytes, 
although it is capable of lytic replication in oropharyngeal epithelial cells (Greenspan et al., 
1985, Birkenbach et al., 1992, Li et al., 1992, Sixbey et al., 1983).  
 
EBV is a linear double stranded DNA virus (172-kilobase-pair) encoding approximately 100 
genes and was completely sequenced in the early 1980s (Baer et al., 1984). It has a toroid-
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shaped protein core and an icosahedral nucleocapsid (major capsid proteins range in size from 
28-160 kDa). A protein tegument surrounds the capsid and surrounding this is an outer 
envelope containing at least eight glycoproteins (Hutt-Fletcher, 2007, Dolyniuk et al., 1976, 
Roizman et al., 1993, Thorley-Lawson and Edson, 1979). 
 
Initial infection in the majority of humans occurs in the oropharynx via saliva transmission of 
the virus. The first cellular target of EBV infection, be it epithelial or B-cell, is unclear, 
however the virus will infect B-cells via the virus glycoprotein gp350/ B-cell surface 
molecule CD21 (CR2, complement receptor 2) interaction (Ahearn et al., 1988, Nemerow et 
al., 1987, Nemerow et al., 1986, Tanner et al., 1987). Further glycoproteins are involved in 
viral attachment and entry, amongst which are gp42, which binds the human leukocyte 
antigen (HLA) class II cell surface molecules of B-cells and gp85, which allows fusion of the 
viral envelope with the cell membrane. The fusion step releases the nucleocapsid into the cell 
cytoplasm where it subsequently dissolves (Haddad and Hutt-Fletcher, 1989, Miller and Hutt-
Fletcher, 1988, Wang and Hutt-Fletcher, 1998, Adams, 1987). The EBV genome is then 
transported to the nucleus where its replication can occur using cellular DNA polymerases 
during the cell cycle S phase (Adams, 1987).  
 
When the viral genome enters the nucleus a subset of genes may be expressed known as 
latency genes, the products of which endow EBV with growth-transforming ability for its 
principal target cell, the B lymphocyte, and ensure transfer of the genome to the daughter 
cells (Babcock et al., 2000, Miyashita et al., 1997). Thus, EBV colonises the B-cell system via 
a transient growth-transforming infection and then persists by down regulating expression of 
the growth transforming latency genes to establish an antigen-negative form of latent 
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infection in which the genome sits in the nucleus in a mostly quiescent state (Fields et al., 
2007). The cells in which EBV resides appear phenotypically as memory B-cells and these 
preferentially circulate between the blood and oropharyngeal lymphoid tissue, collectively 
known as Waldeyers ring, and the virus may reactivate at this site into its virion productive or 
lytic cycle (see below) (Hadinoto et al., 2009). 
 
EBV persists through the establishment of latent infection, a state of viral persistence with a 
lack of viral replication, although ability to reactivate and replicate is retained. The majority 
of viral DNA in latently infected cells is in a circular form (Hurley et al., 1991, Matsuo et al., 
1984). Latency allows the virus to evade host immune responses by limiting viral gene 
expression to the noncoding EBV-encoded RNA (EBER) and BamA rightward transcript 
(BART) RNAs, with no expression of protein-coding transcripts, which is sometimes termed 
latency 0 (Fields et al., 2007). The virus can reactivate from this state into the host cell growth 
transforming infection by expressing the latency genes, namely the six nuclear (EBNAs) and 
membrane proteins (LMP1 and LMP2) (Klein et al., 2007). However, EBV can adopt several 
latency programmes, which express characteristic sets of these genes, mostly described in 
relation to the clinical manifestations the virus causes. The full range of latent gene 
expression, seen in the growth transforming infection, also known as latency III, is observed 
in tonsillar B-cells during infectious mononucleosis (Laytragoon-Lewin et al., 1997), in 
postransplant lymphoproliferative disease (PTLD) (Young et al., 1991) and also in B-cell 
cultures infected with EBV in vitro, also known as B-lymphoblastoid cell lines (LCLs) (Rowe 
et al., 1992). Other latency forms are seen in certain EBV-associated disease states: latency I 
where only EBNA1 is expressed is seen in the B-cell malignancy eBL, while latency II gene 
expression patterns in which EBNA1, LMP1 and LMP2 are expressed are seen in the B-cell 
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malignancy Hodgkin lymphoma and the epithelial malignancy nasopharyngeal carcinoma 
(NPC) (Table 1.1).  
 
Table 1-1 EBV associated malignancies and latency patterns  
Malignancy  % EBV association 
(distribution) 
Patterns of latent gene 
expression  
Burkitt B-cell lymphoma  
 
Endemic 95% 
(Central Africa)  
Sporadic 10%  
(Worldwide)  
AIDS-associated 30%  
Type I  
EBNA1 expression  
(Subset express LMP1 
and EBNA2) 
Nasopharyngeal 
Carcinoma  
 
90% (China and South 
East Asia)  
Type II 
EBNA1 with variable 
levels of LMP proteins  
Hodgkin lymphoma  
 
40% (Worldwide)  Type II 
High level of LMP1 and 
no EBNA2 expression  
Post-transplant 
Lymphoproliferative 
disorder (PTLD) 
 
90% (Solid organ 
transplant recipients)  
Type III  
Full-set of latency genes 
expressed 
 
EBV is thought to frequently spontaneously reactivate into lytic cycle in vivo (Prang et al., 
1997, Tan et al., 1999) with expression of more than 80 viral genes. Identification of lytically 
infected cells has not been definitively demonstrated in healthy infected individuals, but virus 
has been detected in throat washings and persistence of antibodies to lytic cycle antigens 
suggest that there is reactivation in lytic cycle occurring in healthy carriers. What specifically 
triggers reactivation is yet to be elucidated, however Laichalk et al. have demonstrated that 
differentiation into plasma cells initiates EBV replication, but whether this leads to the 
production of infectious virus could not be determined (Laichalk and Thorley-Lawson, 2005). 
Antigen-driven plasmacytoid differentiation is therefore one possible trigger for reactivation 
and lytic cycle expressed proteins have been identified in rare plasma cells in tonsillar 
sections (Shaknovich et al., 2006).   
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During the lytic cycle there are three time dependent phases of viral lytic gene expression: 
immediate-early (IE), early (E) and late (L). The two IE proteins, BZLF1 and BRLF1, act as 
transcriptional transactivators for other lytic cycle genes. The second wave of genes expressed 
encoding E proteins have a wide range of functions including DNA replication, metabolism 
and blockage of antigen processing, whereas genes expressed in the late stage of lytic 
infection are mostly structural viral proteins such as VCA (Tsurumi et al., 2005). Potentially 
then, many gene products exist which the immune system can target.    
 
1.3 Epidemiology of Epstein-Barr virus 
EBV is a gamma herpesvirus estimated to infect more than 90% of the human adult 
population worldwide (Evans et al., 1968). There are two closely related subtypes of EBV, 
EBV-1 and EBV-2, with extensive homology throughout most of their genomes (Bornkamm 
et al., 1980, Sample et al., 1990, Zimber et al., 1986). The major differences that have been 
identified are between the latent infection EBNA genes, EBNA-2, EBNA-LP, EBNA-3A, -3B 
and -3C, with the relevant EBNA proteins sharing between 55-85% primary amino acid 
sequence identity, EBNA-2 being the most divergent (Sample et al., 1990, Raab-Traub and 
Flynn, 1986). The subtypes have been noted to have differing transforming capacities and 
altered abilities to spontaneously enter the lytic cycle, with type 2 viruses being less efficient 
transformers (Rickinson et al., 1987) and their derived cell lines slightly more permissive for 
virus replication (Buck et al., 1999). Sero-epidemiological studies have determined that in the 
United States and Europe, type 1 strains are the predominant circulating viruses, but that the 
two subtypes are more equally distributed in Africa (Nicholas et al., 1992, Zimber et al., 
1986).  
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 EBV is associated with occasional severe self-limiting primary infections, but it does not 
cause significant morbidity in the majority of immunocompetent infected individuals. 
However EBV is an important pathogen associated with several malignancies. EBV was the 
first isolated human tumour virus (Epstein et al., 1964), and is also the cause of significant 
pathology in immunosuppressed hosts.  
 
In developing countries, such as The Gambia, high rates of EBV infection are seen in infancy, 
in contrast to most developed countries where the majority of primary infection occurs at a 
much later stage, often in adolescence (Biggar et al., 1978a, Miles et al., 2007, Njie et al., 
2009, Balfour et al., 2013). EBV infection is most likely to be acquired in young children 
through close contact involving exchange of oral secretions (Hoagland, 1955), which is likely 
to be increased in multiple occupancy households such as is seen in developing countries, 
where overcrowding is common. EBV infection has also been acquired iatrogenically from 
peripheral blood (Gerber et al., 1969), transplanted haematopoietic cells (Alfieri et al., 1996, 
Shapiro et al., 1988) and solid organ transplant (Hanto et al., 1981). EBV naïve patients who 
receive a donor organ from an EBV-infected donor are at high risk for developing PTLD 
(Knight et al., 2009). Transmission through sexual intercourse has also been suggested and 
EBV has been recovered from male and female genital tracts (Crawford et al., 2006, Higgins 
et al., 2007, Enbom et al., 2001, Naher et al., 1992, Sixbey et al., 1986). Kissing and sexual 
intercourse are, however, virtually always carried out simultaneously, so it is difficult to 
completely exclude oral transmission in these cases, and more recently, transmission has been 
shown not to differ in subjects reporting deep kissing with or without penetrative sexual 
intercourse (Balfour et al., 2013).  
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1.4 B-cells and Epstein-Barr virus  
Naïve B-cells given CD4+ T-cell help proliferate in the spleen and lymph nodes and once 
activated can continue down one of two pathways, either remaining static and differentiating 
into short-lived plasma cells or migrating into B-cell follicles and initiating a GC reaction 
(Gourley et al., 2004, MacLennan, 1994, McHeyzer-Williams et al., 2001). During the GC 
reaction, B-cells generate diversity through somatic hypermutation of immunoglobulin genes 
to create a spectrum of cells with individual antibody genes that have different affinities for 
the antigen. These cells undergo clonal selection in which B-cells with the highest affinity 
receptors for the antigen are selected to produce antibody and form memory B-cells. 
(Leanderson et al., 1992, MacLennan, 1994, McHeyzer-Williams et al., 2001, Tarlinton and 
Smith, 2000, Ziegner et al., 1994). Ultimately this results in the production of high affinity 
memory B-cells. A common feature of somatically mutated B-cells subsets is the expression 
of the CD27 cell surface antigen and this is commonly regarded as a memory marker for B-
cells (Klein et al., 1998). Memory B-cells persist for decades after the initial antigen exposure 
through infection or vaccination. Periodic re-exposure boosts memory B-cell numbers be it 
through re-infection, chronic low-grade infection or a vaccination booster. However, memory 
B-cells and antibody levels can be maintained for years in the absence of antigen re-exposure 
(Crotty et al., 2003), but how this occurs remains to be elucidated.    
 
EBV establishes latency in the memory B-cell pool. In healthy carriers, between 1 in 104 and 
1 in 106 of memory B-cells are infected with EBV, however during acute infectious 
mononucleosis (AIM) it has been shown that as much as 50% of the memory B-cell pool 
harbours EBV latent virus (Babcock et al., 2000, Hochberg et al., 2004). As EBV infects both 
memory and naïve B-cells equally in vitro (Ehlin-Henriksson et al., 2003), how the virus 
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becomes restricted to the memory B-cell pool in vivo is a subject of much debate. One model 
suggests that EBV initially infects naïve B-cells, and by mimicking antigen stimulation 
utilises the physiological B cell germinal centre (GC) reaction to drive the B-cell into a 
memory cell (Thorley-Lawson, 2001, Thorley-Lawson and Babcock, 1999). Others dispute 
this model, as EBV has been isolated from non-isotype switched (IgD+CD27+) memory cells, 
that evidence suggests are GC independent in origin (Chaganti et al., 2009). They therefore 
favour the hypothesis that pre-existing memory B-cells are preferentially infected or that the 
virus infects both naïve and memory B-cells but the latter have a survival advantage 
(Chaganti et al., 2009, Kuppers, 2003).  
 
There have been few studies looking at the impact of EBV infection on total B-cell subsets 
and their functionality. Souza et al. looked at peripheral blood memory B-cells in AIM 
patients infected with EBV and compared them to uninfected B-cells. The EBV positive cells 
were found to accumulate more somatic hypermutations than EBV negative cells. EBV was 
also found to occupy a skewed niche within the memory compartment due to its exclusion 
from the IgM+IgD+CD27+ B-cell subset (Souza et al., 2007). Heath et al. demonstrated 
similar findings in vitro, with EBV infected B-cells displaying immunoglobulin heavy chain 
sequence changes similar to somatic hypermutations (Heath et al., 2012). 
 
1.5  Innate Immunity, Immune Evasion and Epstein-Barr virus 
The first line of defence against viral infections is provided by the innate immune system. 
Toll-like receptors (TLRs) are responsible for the recognition of specific pathogen-associated 
molecular intracellular patterns (PAMPs) expressed on viruses and other microorganisms. 
They act via multiple pathways, such as activation of the NF-$b pathway, to link the innate 
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and adaptive immune response.  Recent literature has demonstrated the involvement of 
several TLRs (TLR2 (Ariza et al., 2009), TLR3 (Iwakiri et al., 2009), TLR7 and TLR9 (Quan 
et al., 2010)) in response to EBV infection.  Further recent studies have suggested that EBV 
modulates TLR signalling pathways as an immune evasion strategy (van Gent et al., 2011, 
Younesi et al., 2010). In an in vitro model EBV down regulates TLR9 expression through 
RNA degradation and a further study demonstrates significant inhibition of proliferative 
responses to TLR7/8 and TLR9 agonists(van Gent et al., 2011, Younesi et al., 2010).  
 
The importance of host T-cell responses in maintaining an asymptomatic virus-host balance is 
clinically evident for EBV. In the West, T-cell-suppressed transplant patients are more 
vulnerable to potentially lethal EBV-driven B-cell expansions presenting as PTLD (Rezk and 
Weiss, 2007, Rickinson, 2002), and human immunodeficiency virus  (HIV-1) infected 
patients experience distinct lymphoproliferative diseases (Long and Sample, 2007). A large 
range of lytic cycle proteins have had CD8+ responses identified through screening of AIM 
derived clones. Responses have been found to focus on two IE proteins, BZLF1 and BRLF1 
with smaller sub dominant responses to the following E proteins; BMLF1, BMRF1, BALF2 
or BALF5. Clones reactive to other E or L proteins are a minor component of the CD8+ 
response (Hislop et al., 2002, Pudney et al., 2005, Steven et al., 1997).  As cells progress 
through the lytic cycle, their HLA class I antigen-processing capacity becomes impaired 
through the action of several viral proteins. For example, the EBV lytic cycle protein BNLF2a 
has been shown to block class I antigen presentation through inactivating the TAP1/TAP2 
peptide transporter as possible mechanism for the aforementioned impairment in processing 
(Croft et al., 2009, Hislop et al., 2007a). Despite potent T-cell responses during acute 
infection, EBV is able to evade the immune response and persist by employing such immune 
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evasion strategies (Bell et al., 2009, Horst et al., 2009, Thorley-Lawson, 2001, Thorley-
Lawson and Gross, 2004).  
 
 1.6 Primary Epstein-Barr virus infection: Acute infectious mononucleosis and 
asymptomatic primary infection  
Glandular fever was initially described in 1889 and later termed AIM in 1920 when 
describing six college students with a febrile illness and an atypical lymphocytosis (Evans, 
1974, Sprunt TP, 1920). Most studies suggest about a quarter of individuals undergoing 
primary EBV infection in adolescence will develop a sometimes severe disease, AIM 
(Crawford et al., 2006). In contrast, those infected in childhood either undergo an 
asymptomatic infection or have mild self-limiting illnesses, which largely go unrecognised; 
however rare instances of AIM in infancy have been reported (Chan et al., 2003, Crawford et 
al., 2006, Sumaya et al., 1975). More recently however, it has been suggested that far more 
adolescents than previously thought have AIM at the time of primary EBV infection (Balfour 
et al., 2013). However, this should be interpreted with caution since this study classified AIM 
symptomatic patients as having as least two out of the four following symptoms: sore throat, 
cervical lymphadenopathy, fever and fatigue, which are by no means pathognomonic for 
EBV. In addition they provided intensive follow-up on an eight weekly basis to screen for 
these symptoms, however the number of participants showing these symptoms who did not 
have evidence of serological primary EBV infection was not reported. Thus, other intercurrent 
infections such as cytomegalovirus (CMV), respiratory syncytial virus (RSV), adenovirus or 
streptococcal pharyngitis that are also common may also account for the quartet of symptoms 
they described (Balfour et al., 2013). 
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Typically AIM patients have a prodromal phase of malaise and headache with a mild fever 
prior to developing more specific symptoms and signs such as a pharyngitis, 
lymphadenopathy and an atypical lymphocytosis (Evans, 1989, Luzuriaga and Sullivan, 2010, 
Peter and Ray, 1998). A review of over 500 patients found that lymphadenopathy was present 
in all patients, fevers in 98% and pharyngitis in 85% (Hoagland, 1975, Rea et al., 2001). 
Interestingly, the very young or older adults often do not develop the classical clinical picture, 
with those aged 40-70yrs more frequently complaining of pharyngitis and myalgia and 
cervical lymphadenopathy being less common (Auwaerter, 1999, Horwitz et al., 1983). Other 
clinical manifestations can be seen such as splenomegaly (50-60% of patients) (Carter and 
Penman, 1969), hepatitis e.g. abnormal liver function tests (80% of patients) (Odumade et al., 
2011) and more rarely a generalised maculopapular, urticarial or petechial rash, Guillain-
Barré syndrome, facial or cranial nerve palsies (Johns and Hogikyan, 2000, Joki-Erkkila et al., 
2000, Long and Kerschner, 2001), meningoencephalitis (Schellinger et al., 1999), aseptic 
meningitis, transverses myelitis, peripheral neuritis, optic neuritis and encephalomyelitis 
(Tselis et al., 1997).  Recovery from AIM is gradual and although the median duration of 
illness is 16 days it can sometimes take months for an individual to feel entirely well with 
persistence of fatigue often being a prominent symptom (Rea et al., 2001).  
 
In primary symptomatic EBV infection, it is estimated that from the initial infection there is a 
period of five to seven weeks before a patient will develop AIM (Svedmyr et al., 1984). This 
lag time means that patients do not often present during the incubation period. AIM patients’ 
viral loads in the oral cavity, (oral cells and saliva) are higher than those found in peripheral 
blood or PBMCs and remain elevated for months (Balfour et al., 2005, Fafi-Kremer et al., 
2005, Hadinoto et al., 2008), whereas the latter are reduced more rapidly to levels typical of 
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healthy long-term virus carriers usually by week seven of illness (Balfour et al., 2005, Balfour 
et al., 2013).  
 
Another important arm of the innate immune system are natural killer (NK) cells. Expansions 
of NK cell numbers have been demonstrated during AIM and numbers inversely correlated 
with peripheral blood viral load (Williams et al., 2005) suggesting that NK cells could play a 
role in limiting viral replication. However, more recently the converse has been shown and 
NK cells numbers have been found to positively correlate with peripheral blood viral load and 
disease severity (Balfour et al., 2013). In addition the clinical evidence does not support the 
former theory, as recipients of T-cell depleted stem cell transplants commonly develop EBV 
driven PTLD in the first 3-6 months post-transplant at which point NK cells numbers have 
recovered but the patients are still T-cell deficient (O'Reilly et al., 1997, Hislop et al., 2007b).  
 
The antibody response to EBV is used in the diagnosis of AIM. In a recent study, 90% of 
patients with primary EBV infection had detectable levels of IgM antibody against the viral 
capsid (anti-VCA IgM) within seven days of onset of symptoms (Balfour et al., 2013). 
Following this they all subsequently developed anti-VCA IgG antibodies, which then 
persisted for life. IgM anti-VCA antibodies decline to lower levels and disappear within one 
to two months (Epstein and Achong, 1979, Fleisher et al., 1979). In terms of latent antigen 
responses, an anti-EBNA-2 response is regularly detectable in AIM whereas anti-EBNA-1 
antibodies are unusually delayed. This has recently been shown to correlate with the slow 
emergence of EBNA1-specific CD4+ T-cells compared to CD4+ T-cells specific to epitopes 
from other EBNA proteins in AIM patients (Long et al J Exp Med, in press). The heterophile 
antibody response, a cross-reactive antibody response, is seen in over 90% of adults with AIM 
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(Horwitz et al., 1975). However, this lacks sensitivity in childhood cases, as heterophile 
antibody responses are either minimal or not detectable (Epstein and Achong, 1979, Biggar et 
al., 1978a, Biggar et al., 1978b).  
 
Many studies over the years have characterised cellular immune responses, both to CD8+ and 
less so to CD4+ T-cells, during primary infections (AIM) in adults (Amyes et al., 2003, 
Callan et al., 1996, Callan et al., 1998b, Catalina et al., 2001, Faint et al., 2001, Hislop et al., 
2002, Hislop et al., 2005, Hislop et al., 2007b, Hoshino et al., 1999, Pudney et al., 2005, 
Steven et al., 1997, Steven et al., 1996, Woodberry et al., 2005). Individual lytic epitope 
responses seen in AIM can account for 1-40% of the total CD8+ T-Cell population. 
Responses to IE and E proteins of the lytic cycle usually dominate. The latent cycle protein 
responses tend to be smaller, accounting for only 0.1-5% of the CD8+ T-cell population. 
Typically they focus on epitopes derived from the EBNA3 family of proteins, namely 3A, 3B 
and 3C. In these donors EBV-specific CD8+ T-cells have been well described as displaying a 
phenotype consistent with recent antigen stimulation. Thus, they are perforin positive with 
direct ex vivo cytotoxic function (Callan et al., 2000, Steven et al., 1997, Steven et al., 1996), 
express activation markers such as CD38 and cell cycling marker Ki-67 (Callan et al., 1998b, 
Catalina et al., 2001, Hislop et al., 2002, Hislop et al., 2005). These cells die rapidly in vitro 
unless given an antigen stimulus or cytokines which signal through the common !-chain 
receptor, since they express high levels of the pro-apoptotic protein Bax and low levels of the 
anti-apoptotic molecule bcl-2 (Callan et al., 2000, Dunne et al., 2002, Tamaru et al., 1993). 
Consistent with this, in vivo CD8+ T-cells are rapidly culled in the weeks post infection, lytic 
responses declining more rapidly than latent. It is therefore not surprising that quantitative 
changes are seen when comparing the dominance hierarchies of lytic and latent epitope-
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specific responses between persistent infection and AIM (Hislop et al., 2002, Woodberry et 
al., 2005).  
 
The CD4+ T-cell pool is not typically expanded in AIM.  EBV-specific CD4+ T-cells have 
been less well characterised in view of the relative lack of well defined epitopes and the 
difficulties surrounding HLA class II tetramer manufacture.  However, as with the greater 
CD8+ responses, EBV-specific CD4+ T-cells have been identified during AIM against lytic 
(BZLF1 and BMLF1) and latent antigens (EBNA1 and EBNA3A) and decline rapidly within 
weeks (Hislop et al., 2007b, Precopio et al., 2003). A very recent study using EBV MHC class 
II tetramers has refined these earlier observations, all of which were based on detecting very 
small CD4+ T-cell responses to EBV peptide pools or protein preparations by cytokine-based 
assays. This shows that actual sizes of CD4 reactivities are five to ten fold underestimated by 
cytokine-based assays (Long et al JEM in press).  
 
In contrast to the wealth of immunological and virological data on primary infection in AIM 
patients, the study of subclinical primary EBV infection has proved challenging due to the 
logistical difficulties in identification of asymptomatic patients undergoing primary 
infections. Silins et al. fortuitously identified a subset of patients undergoing silent 
seroconversion in a phase I EBV vaccine trial and were able to demonstrate that in contrast to 
the large T-cell expansions seen during AIM, asymptomatic donors showed little evidence of 
alterations in their lymphocyte populations (Silins et al., 2001).  This was seen despite equally 
high EBV genome loads in both AIM and asymptomatic patients. More recently, in a cohort 
of adolescent university students (median age 18.6 years) followed prospectively, those who 
developed EBV infection were assessed at eight weekly intervals with intensive follow-up 
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measuring EBV viral genome loads, CD8 lymphocytosis and NK cell percentage (Balfour et 
al., 2013). These three markers were found to positively correlate with disease severity, as 
determined by a laboratory-documented severity of illness score (Balfour, 2007, Balfour et 
al., 2005). A higher than previously reported proportion of these students, 89%, were reported 
as having symptomatic AIM, but as noted above they did not report symptom detection rates 
in patients that were not seroconverting nor did they control for possible confounders such as 
co-infections. It has been proposed that differing forms of primary EBV infection could be 
responsible for causing AIM (Silins et al., 2001). It has also been suggested that reactivation 
of memory CD8+ T cells specific to previously encountered pathogens, but cross-reactive 
with EBV (and therefore a cross-reactive heterologous immune response), contributes to the 
expansions seen in AIM (Clute et al., 2005).  However what precisely dictates whether 
someone develops AIM or undergoes an asymptomatic primary infection remains elusive.  
 
1.7 Persistent Epstein-Barr virus infection: Life-long carriers  
During long-term asymptomatic EBV carriage, individuals often shed much lower levels of 
virus and have lower numbers of latently infected B-cells in the blood compared to levels 
seen during AIM. The low levels of persisting virus and intermittent viral reactivation likely 
maintain persistent low-levels of antigen stimulation. The immune responses in healthy adult 
carriers with persistent infection and no history of AIM have been previously explored 
(Amyes et al., 2003, Hislop et al., 2001, Hislop et al., 2007b, Tan et al., 1999). Asymptomatic 
virus carriers maintain T-cell memory both to latent and lytic cycle antigens. CD8+ T-cells 
specific for lytic cycle antigens generally constitute 0.2 to 2% of the CD8+ T-cell population, 
while the CD4 lytic antigen response is less well studied but again appears to be less 
numerous than the CD8+ response (Hislop et al., 2007b, Leen et al., 2001, Long et al., 2005). 
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With respect to latent antigen responses, CD8+ T-cells specific for known EBV-epitopes are 
relatively common, ranging from 0.05 to 1% of CD8+ T-cells in the blood and are typically 
ten-fold more numerous than their CD4+ counterparts. The CD8+ memory T-cells tend to 
display a resting phenotype, lacking activation markers and expressing much higher levels of 
bcl-2 than EBV-specific T-cells from AIM patients. There are, however, some that still 
express perforin and are cytotoxic ex vivo (Callan et al., 1998b, Catalina et al., 2002, Dunne et 
al., 2002, Faint et al., 2001, Hislop et al., 2001). The proportion of EBV-specific CD8+ T-
cells tends to remain reasonably stable over time with some variation from the mean over 
months (Crough et al., 2005). As age increases (over years rather than months), there is 
evidence of expansion of EBV-specific responses, which interestingly is not seen in patients 
who are co-infected with CMV (Khan et al., 2004, Ouyang et al., 2003).  
 
Recent work has shown that EBV-specific CD8+ T-cell populations in asymptomatic carriers 
are oligoclonal with dominance of a few prevalent clonotypes with high avidity (Price et al., 
2005). The peripheral TCR (T-cell receptor) repertoire acts as a reservoir for recruitment of 
diverse antigen-specific clonotypes with subdominant clonotypes with lower avidities also 
identified. Some common (public) antigen-specific clonotypes were observed in certain 
individuals, which differed at the nucleotide level, implying that there is an on-going selective 
process in vivo operating at the protein level. These observations suggest that such processes 
are present to optimise antiviral effector functions while maintaining clonotypic diversity 
within the reactive memory T-cell pool (Price et al., 2005).  
 
Differences between the CD4+ and CD8+ T-cell responses have been identified in EBV-
seropositive donors with no history of AIM.  Both CD4+ and CD8+ T-cell populations 
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broadly target all latent cycle antigens to some degree, although the EBNA-3A, B, C family 
of antigens elicit the strongest CD8+ T-cell responses in most individuals, while the EBNA-1 
antigen is the commonest, but by no means the only, target of the CD4+ T-cell (Leen et al., 
2001, Hislop et al., 2007b). These apparent trends in immunodominance of responses to latent 
antigens do not bear any relation to the order in which these antigens appear during EBV-
induced B-cell transformation, where EBNA-2 and EBNA-LP expression precedes that of the 
other latent proteins (Fields et al., 2007). This is in contrast to what is seen for lytic CD8+ T-
cell antigen responses where the hierarchy of immunodominance reflects the antigens’ order 
of appearance during the virus lytic cycle. Thus, IE and some E proteins tend to induce the 
numerically dominant responses and L proteins induce weaker responses. Interestingly this 
hierarchy reflects the efficiency with which these proteins are presented on the surface of 
lytically infected cells, since virus-coded evasion proteins progressively impair the antigen-
processing function as the cells move through lytic cycle. The correlation between 
immunodominance and timing of expression implies that direct interaction with lytically 
infected cells is the main driver of the expanding CD8+ T-cell response (Pudney et al., 2005, 
Rowe and Zuo, 2010). More recently lytic CD4+ T-cell antigen responses have been found to 
differ dramatically from their CD8 counterparts with responses widely distributed across IE, 
E and L antigen targets. This is as one would expect of a conventionally cross-primed 
response where antigens released from lytically infected cells are acquired and re-presented to 
the CD4+ T-cell repertoire by antigen-presenting dendritic cells (Long et al., 2011). 
 
1.8 Chronic viral infections  in childhood  
Children in developing countries are often exposed to high numbers of viral infections at an 
early age such as HIV, CMV and EBV. There is evidence to suggest that the virus host 
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balance in children infected with these viruses is altered compared to those who are infected 
later in development, possibly related to the maturation status of the immune system.  Indeed 
even in cases where viruses do not establish classic latent infections, like hepatitis B, primary 
infection in childhood leads to a much higher rate of chronic infection as opposed to clearance 
when compared to primary infection in adolescents and adults (Broderick and Jonas, 2003).  
 
A clear example of primary infection with a chronic virus establishing an altered virus host 
balance in children when compared to adults comes from studying HIV infection. HIV 
infection in childhood is known to behave differently to primary adult infection. In adults 
viral loads initially peak and subsequently decline to a set point, which in some cases can be 
undetectable. They tend to remain around this set-point until such time as the virus host 
balance shifts and progression to acquired immunodeficiency syndrome (AIDS) occurs 
(Pantaleo and Fauci, 1995). By contrast childhood HIV viral loads tend to be much higher 
than adults and the decline to a lower viral load set-point does not occur (Biggar et al., 2001). 
Slyker et al. recently showed that HIV-specific CD8+ T-cells activated during early infant 
infections fail to undergo a transition to a resting phenotype as observed in adult infections, 
but remain activated in a state potentially vulnerable to apoptosis. Furthermore the presence 
of activated and apoptosis vulnerable cells in these HIV infected children were associated 
with CMV co-infection (Slyker et al., 2009).  
 
Perhaps one of the most dramatic impacts on the infant immune system relates to early CMV 
infection in The Gambia, recently described by Miles et al. Here a profound effect on the total 
CD8+ T-cell compartment was demonstrated with an increase in the proportion and absolute 
number of terminally differentiated total CD8+ T-cells, which is maintained for a number of 
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years (Miles et al., 2008b, Miles et al., 2007, Miles et al., 2008c). The CD4+ T-cell 
compartment was also affected but less dramatically with only a small increase in cells 
expressing a highly differentiated phenotype (Miles et al., 2008a). Chronic infection of the 
elderly with CMV is associated with large expansions in the CD28%CD57+ subpopulation of 
CD8+ T-cells. This expansion of differentiated and potentially immunosenecent CD8+ T-cells 
may contribute to an ‘immune risk phenotype’, that is associated with poor responses to the 
influenza vaccine and to EBV (Brunner et al., 2011, Moss, 2010, Khan et al., 2004).  This 
subpopulation of CD8+ T-cells, CD28%CD57+, was also expanded in CMV infected 
Gambian infants studied by Miles et al. However, they were still able to mount a CD8+ T-cell 
response to measles vaccine equivalent to those of uninfected infants (Miles et al., 2008b). 
 
In terms of other chronic herpesvirus infections, which are known to induce large antigen-
specific responses, Njie et al. showed that healthy control children and adults in The Gambia 
have significantly higher EBV viral loads in PBMCs than healthy UK adults (Njie et al., 
2009). In healthy control Ghanaian children EBV-DNA has been detected in plasma, thought 
to be an indicator of active EBV replication, whereas no EBV-DNA was detected in plasma 
from control children recruited from Italy (Rasti et al., 2005). It has been readily postulated 
that acute malaria has an impact on EBV virus host balance, but it appears that regardless of 
malaria exposure, there is a difference in virus host balance with higher viral load set points 
seen in equatorial African settings in both children and adults. Recent work in Kenya 
demonstrated that through multilevel mixed modelling, younger age of EBV infection was a 
significant predictor for having a higher EBV load in childhood (Piriou et al., 2012). 
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The dynamics of the immune response to EBV infection when it occurs in childhood are not 
known. There is a paucity of data in the literature describing both primary and persistent EBV 
infection in infancy and its implications, which is not surprising given that infections in 
children are often asymptomatic or do not present with the typical AIM syndrome. The 
reasons for the age-specific variation in illness severity remain elusive. EBV infection in 
childhood in Africa has been shown to occur without a significant lymphocytosis and with 
reduced IgM anti-VCA antibody titres, further compounding the challenge of identifying 
these children (Biggar et al., 1978a, Biggar et al., 1978b). Fleisher et al. screened American 
children in an out patient setting to compare EBV serology and clinical presentations to that 
previously detected by Biggar et al in Ghana. The clinical symptoms detected in children with 
serological evidence of current EBV infection determined by the detection of IgM anti-VCA 
did not differ to those found in children that did not have serological evidence of current EBV 
infection (IgM anti-VCA negative)(Fleisher et al., 1979). A more recent study conducted by a 
group at the University of Massachusetts looked at responses in children, aged 20-35 months; 
indirectly assessing cytotoxic T lymphocyte (CTL) responses using recombinant vaccinia 
constructs expressing single latent genes (Tamaki et al., 1995). These children were 
serologically screened and referred to as having had prior exposure to EBV however it is not 
clear whether they detected antibodies to IgM or IgG anti-VCA nor how they determined their 
classification of EBV status. Nevertheless, with the caveat of a small sample size, they 
demonstrated that all children had CTL responses against one or more of the EBNA proteins 
3A, 3B and 3C, similar to the latent responses reported for adults. However, a comprehensive 
description of lytic and latent antigen responses, in the EBV-specific and total T- and B- cell 
compartments has not been conducted during primary or persistent EBV infections in 
childhood. 
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1.9 Epstein-Barr virus and Vaccination responses in childhood 
Since their genesis 200 years ago, when Edward Jenner demonstrated that the relatively 
innocuous cowpox could protect against small pox, vaccines have saved countless lives. 
There has been a marked increase in the proportion of the world’s children who receive their 
basic vaccines from 15% in 1974 at the start of the Expanded Programme for Immunisation 
(EPI), to a current 90%, although substantial regional, national and local differences remain 
(Greenwood et al., 2011). Vaccination has led to the elimination of poliomyelitis and measles 
from large parts of the world, and complete eradication of small pox.  Despite improved 
availability, some childhood vaccines such as measles have been noted to be less effective in 
sub-Saharan Africa than in higher income settings (Vitek et al., 1999, Aaby et al., 1990).  
 
EBV is harboured within the memory B-cell pool and it is therefore plausible that it could 
disrupt the homeostatic maintenance of this population or affect antigen-specific antibody 
secretion by memory B-cells, and there is some evidence to suggest this.  A recent study at 
the Sukuta field site in The Gambia showed that EBV-infected children had lower antibody 
responses to measles haemagglutinin and to meningococcus polysaccharide antigens 
compared to those that were uninfected (Holder et al., 2010). Despite the significant impact of 
CMV infection in infancy on the phenotype of the total CD8+ T-cell population as described 
above (Miles et al., 2007), CMV did not have any effect on response to vaccination (Holder et 
al., 2010, Miles et al., 2008b). As mentioned above, in sub-Saharan Africa certain childhood 
vaccines such as measles are less effective than in high-income settings, suggesting that 
exploration of the impact of EBV infection in infancy is highly relevant (Aaby et al., 1990, 
Vitek et al., 1999). 
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1.10 Burkitt Lymphoma, Lymphoproliferative disorders and other EBV associated 
Malignancies  
What is now known as eBL was discovered by Denis Burkitt in the 1950s during his original 
observations of a tumour, then thought to be a ‘sarcoma of the jaw’, occurring at a remarkable 
frequency in East African children (Burkitt, 1958, Burkitt, 1962). Prompted by the unusual 
restriction of eBL incidence to areas of Africa where arthropod–borne infections such as 
yellow fever and P. falciparum malaria were common, Epstein together with his PhD student, 
Yvonne Barr, and pathologist Bert Achong began examining tumour biopsies for evidence of 
infectious agents. While biopsy cells gave uniformly negative results, once permanent BL cell 
lines were established in culture, a small fraction of the cells were found to contain 
herpesvirus-like particles. This proved to be a new human herpesvirus, subsequently called 
EBV (Epstein et al., 1964, Epstein and Barr, 1964). A histologically and clinically very 
similar tumour was subsequently found in Papua New Guinea, another area holoendemic for 
P. falciparum malaria, and again this tumour proved to be EBV-positive (Moss et al., 1983). 
Subsequently a sporadic form of BL (sBL) has been observed worldwide as a rare childhood 
tumour, while in the 1980s an AIDS-associated form of the tumour (AIDS-BL) appeared at a 
remarkably high incidence in adult HIV-positive patients. All three epidemiologically distinct 
forms of BL contain the c-myc (proto-oncogene) translocation, but vary in EBV association. 
Thus, while 100% of the endemic tumours examined have been EBV genome-positive, the 
EBV association rates for sBL range from 15-20% in Western Europe, where incidence is 
around 100-fold lower than the endemic tumour, to 85% in some areas of North Africa and 
Brazil where other parasitic infections are common and where tumour incidence is 
intermediate between the above two extremes (Gutierrez et al., 1992, Kelly and Rickinson, 
2007). Somewhat distinct from this trend is AIDS-BL, which has a very high incidence 
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among HIV-infected individuals in the West, but where only 30-40% of tumours are EBV 
genome-positive. Crucially, the situation with respect to EBV and AIDS-BL in equatorial 
Africa is not yet resolved, but the few cases described so far have all been EBV-positive 
(Carpenter et al., 2008).  
 
NPC is another geographically restricted EBV associated tumour, occurring in high 
frequencies in Southern China, Northern Africa and Alaska. The incidence remains high 
among Chinese people who have emmigrated to Southeast Asia or North America, but is 
lower in Chinese people born in North America compared to those born in Southern China 
(Buell, 1974, Dickson and Flores, 1985). NPC is a squamous cell carcinoma occurring in the 
epithelial lining of the nasopharynx first reported in a group of patients in 1901 (Jackson, 
1901). Genetic associations with some Class I HLA alleles have been demonstrated in the 
Chinese population (2000, Lu et al., 2003, Lu et al., 2005, Lu et al., 1990, Ooi et al., 1997). 
The pathogenesis of NPC is multifactorial, combining genetic and environmental factors. 
 
EBV has been linked to a variety of malignancies over the years including eBL, NPC and 
Hodgkin lymphoma (Thorley-Lawson and Gross, 2004). EBV utilises multiple oncogenic 
mechanisms, some of which have been described such as activation of B-cell growth 
programs, immune evasion and inactivation of tumour suppressors (Young and Rickinson, 
2004). Transplant patients illustrate the importance of immune control of EBV reactivation in 
preventing transformation in vivo (Munz and Moormann, 2008). Immunosuppression can 
cause the immune system to lose control of EBV, which can result in PTLD with uncontrolled 
B-cell proliferation; whilst restoration of the immune response by relieving 
immunosuppression can provide a successful treatment (Gulley and Tang, 2010, Loren et al., 
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2003, van Esser et al., 2001). EBV is also known to cause lymphomas in those infected with 
HIV in addition to the aforementioned AIDS-BL. Additionally, an immunoblastic lymphoma, 
(post-transplant like, frequently involving the CNS) 100% EBV driven appears in the late 
stage of AIDS (Cote et al., 1997, Levine, 1993), that can be controlled upon initiation of anti-
retroviral therapy and restoration of immune function. 
 
EBV has different types of latent gene expression as previously mentioned and distinct forms 
have been found to manifest in differing tumours (Table 1.1). NPC tumour cells have been 
shown to express EBNA-1 together with variable levels of LMP proteins, typically LMP-2 
positive with some also LMP-1 positive (Fahraeus et al., 1988, Raab-Traub et al., 1983, 
Young et al., 1988). BL tumours and derived BL cell lines mainly display a Latency I form of 
infection with expression of a single viral protein, EBNA-1 (Gregory et al., 1990, Rowe et al., 
1987), possibly with LMP-1 and EBNA-2 sometimes detectable in a small number of cells; 
(Niedobitek et al., 1995); interestingly, a minority of BL tumours carry an EBNA-2 deleted 
virus genome and express EBNA-3A, 3B, 3C in addition to EBNA-1, though the cells retain a 
classical BL-like phenotype (Kelly et al., 2002, Kelly et al., 2005). In early onset PTLD in 
immunocompromised transplant patients, EBV generally expresses the full set of latency 
genes, latency III (Young et al., 1989), and thus appears to represent the in vivo counterpart of 
in vitro immortalised lymphoblastoid cells lines (LCLs). However, in later-onset tumours 
other forms of latency have occasionally been observed, and some EBV-negative forms of 
PTLD have been described (Dotti et al., 2000, Nelson et al., 2000). In the case of EBV 
positive Hodgkin disease, Reed-Sternberg cells express high levels of LMP-1 and LMP-2 
with EBNA-1 (Niedobitek et al., 1997) in the absence of EBNA-2 expression, which is a 
Latency II type pattern (Deacon et al., 1993, Murray et al., 1992, Pallesen et al., 1991).   
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In summary, persistent EBV infection is associated with several different malignancies, BL, 
NPC and a subset of lymphomas in addition to PTLD. The former, eBL, is found to be 
endemic in the malaria belt in Africa, peaking in children five to seven years of age. The 
likely contributing factors to the aetiology of eBL is early primary EBV infection alongside 
high levels of malaria exposure (Sumba et al., 2010) (Biggar et al., 1978a, Njie et al., 2009, 
Piriou et al., 2012); both of which are known to cause B-cell hyperplasia. 
 
1.11 P. falciparum Malaria: clinical disease and immune pathology  
In contrast to EBV’s widespread prevalence, malarial infection is clustered in areas 
determined by climate hospitability for the parasite vector, the anopheles mosquito. There are 
several species of plasmodium parasite that infect humans; ovale, malariae, vivax, knowlesi 
and falciparum.  The latter is responsible for most of the disease burden and deaths, with 
regions of high endemicity seen throughout sub-Saharan Africa. Malaria is estimated to cause 
between 300-500 million episodes of acute illness (Amador and Patarroyo, 1996) and more 
recently the annual mortality for children under five years of age in Africa was estimated at 
800 000 deaths (Rowe et al., 2006). Accurate baseline epidemiological data on malaria 
prevalence is difficult to obtain but remains a pressing issue in order to enable assessment of 
current control programs (Breman and Holloway, 2007). A recent retrospective analysis of 
original records in The Gambia demonstrated a progressive reduction in proportion of ward 
admissions and deaths attributed to malaria, in addition to declining positivity rates reported 
from out-patient clinics (Ceesay et al., 2008).  
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While the association between eBL and holoendemic malaria incidence stems back decades 
(Burkitt, 1969), the relative contributions of EBV infection and malaria exposure to the 
pathogenesis of eBL still remain to be elucidated. It has been postulated that malarial 
infections have immunosuppressive consequences; indeed the incidence of salmonella 
septicaemia is closely related to changes in malaria transmission (Mabey et al., 1987). 
Furthermore, Greenwood et al. demonstrated impaired vaccination responses to tetanus, 
typhoid and meningococcal vaccines during clinical and asymptomatic malaria infections 
(Greenwood et al., 1972, Williamson and Greenwood, 1978). Bed net usage decreases all 
cause mortality in children further suggesting the occurrence of non-specific effects of 
malaria infection (Phillips-Howard et al., 2003). 
 
The inference that malaria could cause depressed immunity to other infectious pathogens is 
consistent with early reports that EBV-specific immune responses are decreased during acute 
malaria infections (Whittle et al., 1984, Moss et al., 1983). A study in New Guinea comparing 
healthy EBV carriers resident in holoendemic malarial areas to non-malarial areas first 
suggested that malaria might cause a relative impairment of EBV-specific T-cell immunity. 
This was seen using an in vitro assay that measures the ability of T cells to cause regression of 
outgrowth of autologous EBV-infected B-cells (Moss et al., 1983). More importantly, Whittle 
et al. working in The Gambia found that PBMCs from patients with acute malaria were 
completely unable to control outgrowth in regression assays (Whittle et al., 1990, Whittle et 
al., 1984). This provided a plausible link between malaria and EBV in the pathogenesis of 
eBL. It has been shown that latent epitope-specific CD8+ T-cells are the main effectors 
responsible for the killing of EBV-infected B-cells in this experimental system (Gudgeon et 
al., 2005). However, there has been no direct work with modern methods to ask whether 
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EBV-specific CD8+ T-cells are depleted during episodes of acute malaria, or are present but 
rendered non-functional, or if the lack of regression reflects breakdown at some other point in 
the complex interactions between infected B-cells, CD4+ T-cells and CD8+ T-cells that 
precede the final effector phase in regressing cultures. 
 
The findings of Whittle et al. have been indirectly corroborated by further studies. Elevation 
in EBV VCA antibody titres was found to precede the onset of eBL, (de-The et al., 1978, zur 
Hausen et al., 1970). The addition of P. falciparum extract to PBMCs has been shown to 
increase EBV B-cell transformation rates in vitro (Kataaha et al., 1984, Whittle et al., 1990), 
and recently data from a smaller study suggests that the cysteine-rich inter-domain region 1 
alpha (CIDR1") of the P. falciparum membrane protein 1 could act as an antigen that can 
directly induce EBV reactivation, stimulating transition of cells from the latent to the lytic 
cycle of EBV infection (Chene et al., 2007).  
 
A further study of children in Kenya with differential malaria exposure showed that a smaller 
proportion of children, five to nine years of age, had EBV-specific IFN-" responses when 
living in malaria-holendemic areas compared to those living in areas where they are only 
sporadically exposed to malaria (Moormann et al., 2007). More recently diminishing T-cell 
immunity over time to EBV lytic but not latent antigens in Kenyan children with recurrent P. 
falciparum exposure has been demonstrated (Snider et al., 2012). Furthermore, in the same 
differentially malaria exposed Kenyan cohorts, no differences in EBV-specific CD8+ T-cell 
frequencies were seen, but children living in regions with holoendemic malaria exposure had 
more differentiated EBV-specific CD8+ T-cell populations than those in sporadically exposed 
areas (Chattopadhyay et al., 2013). Importantly this phenotypic variation was not detected in 
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CMV-specific CD8+ T-cells nor in the total CD8+ T-cell population. Deficiencies in EBNA-1 
specific IFN-" responses, the solitary viral antigen expressed in the majority of eBL tumours, 
have been detected in children with eBL residing in Kenya compared to healthy children 
residing in areas of holoendemic and sporadic malaria exposure (Moormann et al., 2009).  
 
Two main hypotheses have been proposed in order to explain how holoendemic malaria 
impacts on eBL pathogenesis. The first envisages malaria acting as a stimulus for B-cell 
proliferation, causing expansion of the latently infected B-cell pool, thus increasing both the 
number and the proliferative status of EBV-carrying B-cells and increasing their chances of c-
myc gene translocation and malignant change.  The second envisages malaria suppressing 
EBV-specific T-cell surveillance, again leading to over-expansion of the EBV-transformed B-
cell pool and increasing the chances of secondary events leading to lymphoma. Currently 
there is little direct evidence supporting either hypothesis, and of course it should be borne in 
mind that both processes could be acting synergistically (Rochford et al., 2005).  
 
Whittle et al. has previously suggested that numbers of EBV carrying B-cells were five times 
higher during acute malaria infections than on recovery and in fact equivalent to numbers 
seen during AIM (Lam et al., 1991). As noted above, it has also been suggested that the 
addition of P. falciparum extract to PBMCs increased EBV B-cell transformation rates 
(Kataaha et al., 1984). More recent studies utilising molecular methods have enumerated 
circulating EBV viral DNA loads in children living in areas holoendemic for malaria 
exposure and those with acute malaria infections (Donati et al., 2006, Moormann et al., 2005, 
Rasti et al., 2005, Yone et al., 2006). This heterogeneous group of studies has been conducted 
in varying sites, Uganda, Kenya, Gabon, The Gambia and Ghana, with EBV viral load 
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measurements made on various bodily fluids including plasma, whole blood and saliva. In 
Kenya, the Moorman group identified that children aged one to four years old, living in 
holoendemic malarious areas had higher EBV viral loads than those resident in an area where 
they are only sporadically exposed (Moormann et al., 2005). Yone et al. analysed whole 
blood and plasma viral loads in children with acute mild and severe malaria. They found a 
significant increase in EBV whole blood viral loads during acute mild malaria infection. This 
declined on convalescence and was lower still at six months post infection. A similar trend 
was seen with severe malaria but this did not reach significance. They found few children 
with detectable plasma viral loads but it was not clear if these were intact virions or fragments 
of DNA (Yone et al., 2006).  
 
More recently in The Gambia, Njie et al. looked at PBMC viral loads during acute malaria 
infection, but found no significant difference in acute versus convalescent viral loads. 
However, they did show a five-fold increase in EBV viral loads compared to the healthy 
control group of Gambian children (Njie et al., 2009). Rasti et al. and Donati et al. both 
assessed plasma EBV viral loads with the latter also looking at salivary loads. They both 
showed significant trends of decreasing plasma EBV viral loads on recovery. However, Rasti 
et al. did not use age and sex-matched controls and Donati demonstrated that the material they 
were measuring was naked DNA and not in intact virions (Donati et al., 2006). The source 
then of the viral DNA detected in the above studies is not yet clear.  Whether it reflects an 
increase in the numbers of circulating latently infected B cells, or the presence of lytic EBV 
replication in circulating cells, or the detection of EBV DNA fragments derived from latently-
infected cell death within tissues as is seen in patients with EBV-positive tumours, is not 
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known (Berger et al., 2001). The mechanism(s) behind the source of this apparent elevation in 
viral loads therefore need to be further characterised.  
 
1.12 Summary  
In relation to the pathogenesis of eBL, exploring the dynamics of the immune response to 
EBV during acute P. falciparum infection is of significant importance. It is of great interest 
then to determine how cellular immune responses to EBV behave in malaria exposed African 
children in terms of number, function and phenotype, using contemporary analytical methods 
to inform our understanding of the mechanisms controlling the pathogenesis of eBL.  
 
Furthermore, how primary EBV infection develops and how the cellular immune response 
controls it in African children is unknown. Primary asymptomatic EBV infection in childhood 
is known to differ from that seen in adolescence in that AIM is rarely seen in children upon 
primary EBV infection. Exploration of how cellular immune responses differ in childhood 
primary infections may shed light on the mechanisms behind the age-specific clinical 
presentation of primary EBV infection. An understanding of the immunodominant immune 
responses in childhood would aid vaccine development for this oncogenic virus, or allow the 
development of interventions to alter the virus host balance in these children potentially at 
risk of eBL. Similarly, whether early childhood EBV infection, which is known to encode 
proteins that can manipulate the immune system, affects the function of the immune system, 
in terms of responses to vaccination is of importance in view of its high incidence and 
prevalence at an age when African children are receiving their primary vaccination schedules.  
 
 35 
The data presented in this thesis were gathered firstly to further explore these questions. The 
first phase of the study examines EBV-specific CD8+ T-cell responses in Gambian children 
during acute malaria infection and at convalescence. T-cell function was studied by regression 
assay analysis and also more contemporary immune measures, namely tetramer staining and 
ELISPOT analysis. These assess numbers and functional competence of EBV-specific CD8+ 
T-cells in children respectively.  
 
In the second phase of this study, the dynamics of primary EBV infection in childhood is 
explored. This represents a detailed study of EBV-specific T-cell responses in a cohort of 
children followed longitudinally and describes cellular immune responses in Gambian 
children having undergone recent primary EBV infections. It also fortuitously captured 
several children undergoing asymptomatic ‘silent’ seroconversion. This provides a 
comprehensive analysis of EBV-specific T-cells in these children, including a characterisation 
of the immunodominant responses to a broad range of lytic and latent EBV antigens, viral 
genome loads and detailed ex-vivo phenotypic analysis of both total and EBV-specific CD8+ 
T-cells.  
 
Lastly, the potential impact of EBV infection in childhood, an infection that primarily infects 
and persists in B cells, on B-cell phenotypes and the response to a vaccine challenge with a 
pentavalent (Diphtheria, Tetanus, Bordetella pertussis, Hepatitis B and Haemophilus 
influenzae b (DTP, HepB and Hib)) booster vaccination given at 14-18 months is explored. 
This determined whether EBV infection in early life has any impact on the function of the 
humoral response to vaccine challenge.  
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CHAPTER 2 : METHODS 
 
The body of work contained in this thesis is broadly divided into two main sections, Phase I 
(Chapter 3) and Phase II (Chapters 4 and 5).  Although techniques used were similar in both 
phases of study there were some significant differences in the methodologies. These have 
been detailed under the appropriate section headings and as indicated in the text Phase I and II 
are dealt with separately where necessary.   
 
2.1 Study cohorts 
The study participants were from two peri-urban and one rural community based in The 
Gambia within West Africa, locations illustrated in Figure 2.1. 
 
Western Region (WR), North Bank Region (NBR), Lower River Region (LRR), Central River Region (CRR), Upper River 
Region (URR).  
 
Figure 2-1 Map of The Gambia showing the location of the study sites.   
Shown are the sites for Phase I, the MRC Laboratories Fajara and the Village of Brefet and 
for Phase II Sukuta.   
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Thirty-two Gambian children (aged 1–15 years) enrolled into studies of severe and 
uncomplicated malaria in the outpatient department of the Medical Research Council (MRC) 
in Fajara, a peri-urban area, were tested in the first phase of this study (Walther et al., 2009). 
All presented with uncomplicated P. falciparum malaria, defined as a temperature >37.5OC 
within the last 48 hours, and >5000 parasites/µl detected by slide microscopy in the absence 
of any signs defining severe malaria as defined by WHO (2000). Thirty-two age- and sex- 
matched healthy aparasitaemic controls were recruited from Brefet, a rural community where 
malaria transmission has dropped considerably over the last three years (Ceesay et al., 2008, 
Ceesay et al., 2010, Satoguina et al., 2009). Brefet is approximately 55km from Fajara, where 
the MRC laboratories are housed. All patients received standard care according to the 
Gambian Government Treatment Guidelines. 
 
Phase II of the study was conducted in a peri-urban MRC clinic, Sukuta, situated within the 
Government Sukuta Health Centre, serving a low income population living in crowded 
conditions. This is a distance of 10 km from Fajara. A cohort of 120 children aged between 14 
and 18mths were recruited when they attended the local government health Centre for their 
routine booster vaccination of DTP. All children were weighed, measured, had baseline 
observations (temperature, heart rate, weight and length) and a clinical examination 
performed.  Any child found to be unwell or have a weight below that specified on the local 
Infant Welfare Card Growth Chart was not recruited into the study. Treatment was provided 
where necessary by MRC nursing staff and the study clinician. Children were brought back 
one week later to receive the Easy Five Panacea Biotec vaccine (Pentavalent vaccination 
(DTP, HepB, Hib)).  They were subsequently invited to return a week after vaccination and 
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again at six months to undergo further blood sampling. All blood samples were batched and 
returned to the MRC laboratory in Fajara with in six hours of being drawn. 
  
2.2 Transport, PBMC isolation and cryopreservation 
For phase I P. falciparum infected children were bled on admission (D0) and after 28 days (± 
three days); controls were bled at one time point only. A 500µl volume of blood was collected 
into an EDTA microtainer ® (BD) for a full blood count (FBC) and DNA extraction. A 
further 4mls was collected into heparinised vacutainers# (BD). These were then batched and 
transported back from Brefet or deposited directly in the laboratory if taken in Fajara. A ‘thick 
and thin blood smear’ was prepared from the heparinised whole blood sample for all study 
participants to determine the species and magnitude of the parasitaemia. The whole blood was 
then centrifuged for 5 mins at 250xg at room temperature with low brake.  The plasma layer 
was collected and cryopreserved in 2ml aliquots for EBV VCA and 19-Kilodalton Merozoite 
Surface Protein 1 (MSP1-19) malarial antigen enzyme linked immunosorbent assays 
(ELISAs) to be performed (Section 2.8.1 and 2.8.2). The remaining blood was diluted 1:1 
with RPMI and then layered onto 4ml of NycoprepTM in 15ml falcon tubes. This was 
centrifuged at 800xg for 30 mins with no brake. The lymphocyte interphase was harvested 
and washed twice in RPMI by centrifuging at 250xg for 7 mins. These PBMCs were then 
used to set-up IFN-! ELISPOT assays to pools of lytic and latent EBV peptides (Table 2.3) 
and for tetramer and surface flow cytometric staining (Section 2.16).   
 
During phase II 5mls of blood was collected from each child into vacutainers# containing 
EDTA (BD).  A 500µl aliquot was removed and used to obtain a FBC on each child using a 
M-series M16/M20 Haematology Analyser (Medonic, Sweden). A further 250µl aliquot was 
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removed and whole blood flow cytometric staining performed (Section 2.13). The remaining 
blood was layered on to 4mls of LymphoprepTM (Axis-Shield, UK) in 15ml Leucosep® tubes 
(Greiner Bio-One, UK). These were centrifuged for 15 min at 800 x g with the brake off. The 
plasma layer was removed, and cryopreserved in 2ml aliquots and stored at -70°C for 
downstream serology (Section 2.8.1 and 2.8.3). The lymphocyte interphase was harvested and 
washed twice in RPMI by centrifuging at 250xg for 5 mins. Cells were counted and re-
suspended in freezing medium (FCS (Sigma-Aldrich) supplemented with 10% (v/v) dimethyl 
sulfoxide (DMSO)) at approximately 5 x 106/ml. Graded PBMC cryopreservation was 
undertaken utilising a ‘Mr Frosty’ freezing chamber (Thermo Fisher Scientific, UK) 
containing 100% Isopropan-2-ol. Cryovials containing PBMCs were placed in the freezing 
chamber and this placed in the -70°C freezer overnight, prior to transferring to liquid nitrogen 
(LN2) the following day. Cryopreserved PBMCs in LN2 and plasma (on dry ice) were 
transported to the Weatherall Institute for Molecular Medicine (WIMM) and the Institute for 
Cancer Studies in Birmingham for multi-colour flow cytometry staining  (Sections 2.14 and 
2.16) and estimation of EBV viral load (Section 2.6) respectively.  
 
2.3 Maintenance of B95.8 cell line and harvesting virus  
The B95.8 cell line, a cell line initiated by exposing marmoset blood leukocytes to EBV 
extracted from human leukocyte lines was cultured providing a continuous source of high titre 
transforming EBV for regression assays. Cryopreserved cells free of mycoplasma obtained 
from the Institute for Cancer Studies in Birmingham were thawed rapidly into 10mls of warm 
RPMI supplemented with 10% (v/v) heat-inactivated FCS, 2mM L-glutamine (Sigma), 1% 
Pen Strep (100U/ml penicillin and 0.1mg/ml streptomycin final concentration) (Sigma) (R10) 
and washed once in R10. The cells were re-suspended at 1.0-2.0x106 cells/ ml depending on 
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cell numbers recovered. They were sub-cultured twice a week by splitting cells 1:4 to 
maintain a density of approximately 1x106 cells/ ml. Some subcultures were not split for a 
period of one week and virus from their filtered supernatant was used to perform regression 
assays in real-time. The presumption was made that they contained saturating amounts of 
EBV.  
 
2.4 Regression Assays (Phase I)  
Regression assays were carried out on stored cryopreserved PBMCs from the 2008 malaria 
season and fresh cells ex vivo from healthy controls in parallel. Cryopreserved PBMCs from 
uncomplicated and severe P. falciparum malaria cases recruited from the same study platform 
(Walther et al., 2009) were used. Regression assays were performed by infecting PBMCs with 
B95.8 strain EBV preparations (Section 2.3) for one hour at 37°C, agitating every 15-20 mins 
and seeding six replicates into U-bottom micro test plates in doubling dilutions from 4 x 104 
to 1.2 x 103 cells/well in R10. In two replicate wells cyclosporine A (CSA) was added to a 
final concentration of 0.1µg/ml.  Parallel cultures of uninfected PBMCs were set up as 
controls. A half change of medium was performed weekly on all cultures and they were 
observed over a period of 4-5weeks. The strength of regression was expressed as the initial 
cell seeding necessary to give a 50% incidence of regression among replicate wells as 
calculated using the Reed-Muench formula (Reed, 1938). Previous methods (Gudgeon et al., 
2005) described used 10-fold greater cell numbers in flat bottom micro test plates, however 
for this study the assay was miniaturised with no significant difference in the magnitude of 
regression detected (Figure 2.2).  
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 Figure 2-2 Representative samples illustrating Standard (A) and miniaturised (B) Regression 
assays performed simultaneously on seropositive (D1-D5) and seronegative (N1-2) 
Caucasian Donors (n=5). Wilcoxon rank test, p=0.50. 
 
 
2.5 Extraction of DNA (human and viral)  
DNA was extracted from 200µl of whole blood and 1x106 PBMCs for phase I and phase II 
respectively using the QIAmp DNA Blood Mini kit (Qiagen, UK). A 20µl volume of 
proteinase K was pipetted into the bottom of a 15ml micro centrifuge tube and 200µl of 
sample (whole blood or 1x106 PBMCs in 200µl of phosphate buffered saline (PBS)) and 4µl 
RNase A stock solution (100mg/ml) were added. Following this 200µl buffer AL was added 
and mixed by pulse-vortexing for 15 secs. Samples were incubated at 56°C for 10 mins. A 
200µl volume of ethanol (96-100%) was added to the sample and mixed again by pulse-
vortexing for 15 seconds. The contents were then applied to the QIAamp mini spin column (in 
a 2ml collection tube) without wetting the rim and centrifuged at 6000xg (8000rpm) for 1 
min. The columns were then placed in a clean 2ml collection tube and the filtrate tube 
discarded. Each column was opened and 500µl of Buffer AW1 was added again without 
wetting the rim. The cap was closed and columns were centrifuged at 6000xg (8000rpm) for 
1min. The columns were placed in clean 2ml collection tubes and the filtrate discarded. Each 
0 1 2 3
N2
N1
D5
D4
D3
D2
D1
Regression Index
Ca
uc
as
ia
n 
La
b 
D
on
or
s 
0 1 2 3
N2
N1
D5
D4
D3
D2
D1
Regression Index
Ca
uc
as
ia
n 
La
b 
D
on
or
s 
A. Flat Bottom 
Wells 
B. U-Bottom Wells 
 42 
column was opened and 500µl of Buffer AW2 was added without wetting the rim. Caps were 
closed and the columns were centrifuged at full speed (20,000xg; 14,000 rpm) for 3 mins. 
Columns were placed in clean collection tubes and centrifuged at full speed for a further 
1min. Columns were then placed in DNase and RNase free 1.5ml micro centrifuge tube and 
the collection tubes containing the filtrate discarded. Each column was opened and 200µl of 
buffer AE was added. Columns were then incubated for 5 mins at room temperature and 
centrifuged at 6000xg (8000rpm) for 1min. The quantity (3-6µg per million cells) and quality 
(260/280 ratio >1.6-1.8) of DNA extracted from each sample was estimated by measurement 
on a Nanodrop spectrophotometer (Thermo Scientific, Nanodrop products, 3411 Silverside 
Rd, USA) and then stored at -20°C and shipped on dry ice to the Institute for Cancer Studies, 
Birmingham to determine the EBV viral loads (Section 2.6).  
 
2.6 EBV real time Quantitative PCR  
EBV genome loads were assayed by quantitative real-time PCR as previously described 
(Junying et al., 2003). Target DNA sequences were amplified and monitored in real-time by 
changes in fluorescence intensity of dual-labelled Taqman probes. Primers amplifying a 
fragment of the EBV DNA polymerase (Pol) gene in combination with a FAM-labelled probe 
detected EBV DNA. Human beta-2-microglobulin ($2m) gene in combination with a VIC-
labelled probe was amplified to determine the input of cellular DNA in each sample and 
normalise for variations in cell number input into the assay. Primer and probe sequences were 
obtained from Applied Biosystems (UK) (Table 2.1). A multiplex PCR reaction was used to 
detect EBV Pol and control $2m sequences simultaneously; the $2m reaction was primer 
limited to avoid depletion of PCR reagents. Reactions were conducted in triplicate in 25µl 
volumes containing 12.5µl Taqman Universal master mix (Applied Biosystems), 2.5µl 
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(2µM), forward and reverse Pol primers, 1µl (5µM) FAM-labelled Pol probe, 0.5µl (3µM) 
$2m forward primer, 0.5µl (4µM) $2m reverse primer, 0.5µl (5µM) VIC-labelled $2M probe 
and 5µl test DNA. The reaction mixtures were amplified for 40 cycles (15 secs at 95°C, 60 
secs at 60°C) following the activation of the uracil-N-glycosylase (2 min at 50°C) and the 
Amplitaq Gold (10 min at 95°C). The reactions were run on an ABI Prism 7500 real time 
PCR system (Applied Biosystems).  
 
 
Table 2-1 EBV real-time qPCR primer and probe sequences.  
 
EBV Polymerase  
Forward primer  5& CTT-TGG-CGC-GGA-TCC-TC 3& 
Reverse primer  5& AGT-CCT-TCT-TGG-CTA-GTC-TGT-TGA-C 3& 
POL probe  5& (FAM) CAT-CAA-GAA-GCT-GCT-GGC-GGC-CT (TAMRA) 3& 
$-2-microglobulin   
Forward primer 5& GGA-ATT-GAT-TTG-GGA-GAG-CAT-C 3& 
Reverse primer  5& CAG-GTC-CTG-GCT-CTA-CAA-TTT-ACT-AA 3& 
$2M probe  5& (VIC)-AGT-GTG-ACT-GGG-CAG-ATC-ATC-CAG-CTT-C 
(BHQ) 3& 
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Data was analysed using the 7500 system v1.4 software. The alterations in FAM and VIC 
fluorescence intensity (corresponding to the amplification of Pol and $2M, respectively) were 
used to determine the corresponding Ct value for each sample. This was defined as the cycle 
number at which the sample amplification curve crossed a threshold (Pol 0.08 and $2M 0.04). 
The Ct value is proportional to the number of copies of DNA fragment starting material and 
therefore allowed for the number of Pol and $2M copies in the sample to be deduced from a 
standard curve. Standards were prepared by serial dilutions (104, 103, 200, 40, 10, 5, 2) of 
Namalwa BL DNA (diploid Namalwa cells carry two EBV genomes and each cell contains 
6.6pg DNA); a calibration curve was plotted with Ct values (y-axis) against log10 of Pol or 
$2M copy number (x-axis). This was used to extrapolate Pol and $2M genomes in the 
unknown samples from their Ct values. All test samples were analysed in triplicate and each 
experiment included DNA samples from EBV-positive and EBV-negative donors, in addition 
to a no template control. Samples were considered negative if the Ct values exceeded 37 in 
'2/3 reactions. Results were expressed as EBV genome copies per 1 x 106 PBMCs correcting 
for the PBMC percentage using the FBC where whole blood was used for extraction (phase I). 
This assay reproducibly detects as little as two EBV genomes (Junying et al., 2003).  
 
2.7 Plasmodium falciparum parasite PCR 
P. falciparum parasite loads were assayed in the Gambia using a previously described 
quantitative PCR method (Rougemont et al., 2004). The 157- to 165-bp segment of the 
plasmodial 18S genes was amplified using primers and probes kindly donated by Davis 
Nwakanma, Malaria Programme, MRC Gambia (Table 2.2). 
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Table 2-2 Plasmodium falciparum parasite PCR primers and probes.  
P.falciparum 18S gene  
Forward primer  5& GTTAAGGGAGTGAAGACGA TCAGA 3& 
Reverse primer  5& AACCCAAAGACTTTGATTTC TCATAA 3& 
Probe 5’ (FAM) AGCA ATCTAA AAGTCACCTC GAAAGATGAC 
T (TAMARA) 3’ 
 
 
Single assays were performed in final volumes of 25µl containing 5µl of DNA, 0.3µM of 
forward and reverse primers, 0.08µM probe and 12.5µl Qiagen master mix per reaction. 
Amplification and detection of the amplified product was performed on an ABI Prism 7700 
(Applied Biosystems, UK). The following conditions were used for the PCR: an initial step at 
95°C for 15 mins and 45 cycles of 94°C for 15secs and 60°C for 1min. If the fluorescence 
signal did not increase within 40cycles, the sample was considered to be negative.  
 
2.8 Serology 
2.8.1 ELISA and Immunofluorescence assays for EBV  
For phase I, IgG reactivity to EBV VCA was measured using a commercial ELISA kit 
(DeMeditech, DEEBV01) performed in the MRC laboratories, Fajara. All plasma samples 
were diluted 1:101 with sample diluent prior to being assayed in duplicate. A 100µl volume 
of each kit calibrator (10, 20, 110 and 170 AU/mL) and sample were dispensed into 
respective wells pre-coated with EBV VCA p18 synthetic peptide and incubated for 1hour at 
37°C. Well contents were then discarded and wells washed five times with 300µl wash buffer 
(PBS Tween® 20 and preservatives). A 100µl volume of enzyme tracer (affinity –purified IgG 
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raised in goats to human IgG conjugated to horseradish peroxidase (HRP), TRIS buffer, BSA, 
stabilisers and preservatives) was added to all except the blank well and incubated for 1hour 
at 37°C. Then 100µl of chromogen/substrate solution (tetramethylbenzidine/hydrogen 
peroxide) was added to all wells and incubated for 30 mins at room temperature away from 
direct sunlight. A 200µl volume of stop solution (0.4N sulphuric acid solution) was added 
into all wells in the same order and at the same rate as the chromogen/substrate solution was 
added. The absorbance of the specimens was measured with a photometer at 450/630 and 
405/630nm within 30 mins of adding the stop solution. A calibration curve was calculated, 
using kit calibration samples, with absorbance on the y-axis and concentration of IgG to VCA 
on the x-axis expressed in AU/mL. Cut off for positivity was calculated using the upper limit 
of the 99% confidence interval obtained from simultaneously screening ten known EBV 
negative medical student plasma samples kindly donated by Alison Leece, Institute for 
Cancer Studies, Birmingham.  
 
In the Phase II study immunofluorescent staining was performed to detect EBV IgG VCA 
antibody’s using an in-house assay at the Institute for Cancer Studies in Birmingham. P3HR1 
(EBV IgG +ve) and BJab (EBV IgG –ve) cells were cultured, spun down and re-suspended in 
PBS at approx. 107/ml. 10µl of cell suspension (105 cells) was placed in each hole of an 
SMO11 microscope slide. The slides were air dried in a warm room and fixed in ice-cold 
acetone for 10 mins. Slides once dry were stored at -20oC. The test plasma was diluted 1/10, 
1/20 and 1/40 then 20µl of diluted plasma was placed into the respective holes and slides were 
incubated in a moist chamber at 37oC for one hour. Slides were then washed in PBS twice for 
10 mins at a time, using a Coplin jar and magnetic stirrer. Slides were wiped avoiding cell 
smear and 10µl of Sigma F0132 anti-human IgG (" chain specific) affinity isolated 
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fluorescein isothiocyanate (FITC) antibody added to each hole (1/50) and incubated at 37oC 
for one hour. Slides were washed twice in PBS for 10 mins at a time, mounted using Dabco, 
glycerol and PBS and viewed under an ultraviolet (uv) microscope. Patients were identified as 
either positive or negative.   
 
The phase II IgM VCA immunofluorescence assays were kindly performed by Karen 
McAulay at The LRF Virus Centre, Centre for Virus Research, University of Glasgow using 
their in-house method (Macsween et al., 2010). Annette Pachnio using an in-house ELISA at 
the Institute for Cancer Studies, Birmingham, kindly determined CMV antibody status.  
 
2.8.2 ELISA assay for MSP1-19 antibody (Phase I) 
Total IgG to MSP1-19 was measured on Phase I control and study plasma samples using an 
in-house ELISA method at MRC Gambia. Immulon4 plates were coated overnight at 4oC with 
100µl of MSP1-19 antigen in coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.3) at a 
concentration of 0.5µg/ml (donated by the MRC Gambia malaria programme).  After three 
washes with wash buffer (PBS with 0.05% Tween20 (Sigma)), the plates were blocked with 
200µl blocking buffer (1% skimmed milk (Marvel UK) in wash buffer) for three hours at 
room temperature. The plates were washed a further three times and plasma added diluted at 
1:1000 in blocking solution and incubated overnight at 4oC. Plates were washed six times and 
incubated for three hours at room temperature with 100µl of anti-human IgG HRP (Dako Ltd, 
Ely. UK) diluted 1:5000 in blocking solution. The plates were washed six times and 100µl of 
substrate (0.4mg/ml o-phenylenediamine dihydrochloride (OPD) Sigma); 0.08% H2O2 
(Sigma) in developing buffer (24.5mM citric acid monohydrate, 52mM Na2HPO4, pH 5.0) 
was added for a further 20 min incubation at room temperature. The reaction was stopped 
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with 50µl of 2M H2SO4 and the optical density (OD) measured at 490nm. All samples were 
run in duplicate. A pool of sera from 20 malaria-exposed donors was used as a positive 
control. A seven point standard curve using a five-fold serial dilution of the pool (starting at 
1:50) was used to convert OD values into arbitrary units. Antibody levels in sera from 20 non-
exposed Europeans were used to define a cut-off (mean OD plus two standard deviations) for 
a positive response.  
 
2.8.3 ELISA for Hepatitis B antibody (Phase II)  
In phase II, Hepatitis B surface antibody (anti-HBs) was measured using commercial ELISA 
kits (DiaSorin, ETI-AB-AUK-3, P001603) at the MRC laboratories, Fajara. All pre-
vaccination (visit one) plasma samples were assayed neat and post-vaccination plasma 
samples were diluted 1:4 and 1:100 with negative control serum supplied in the kit. A 100µl 
volume of incubation buffer (PBS, Bovine serum albumin, Triton X-705 and preservatives) 
was dispensed in all wells except the blank. A 100µl of each calibrator, sample and negative 
control were dispensed into respective wells pre-coated with heat-treated human Hepatitis B 
surface antigen (HBsAg) and incubated for two hours at 37°C. Well contents were then 
discarded and wells were washed five times with 300µl wash buffer (PBS Tween® 20 and 
preservatives). A 100µl volume of enzyme tracer (heat treated human HBsAg conjugated to 
horseradish peroxidase (HRP), TRIS buffer, BSA, stabilisers and preservatives) was added to 
all except the blank well and incubated for one hour at 37°C. Then 100µl of 
chromogen/substrate solution (tetramethylbenzidine/hydrogen peroxide and citrate buffer) 
was added to all wells and incubated for 30mins at room temperature away from direct 
sunlight. A 200µl volume of blocking solution (1N sulphuric acid solution) was added into all 
wells in the same order and at the same rate as the chromogen/substrate solution was added. 
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The absorbance of the specimens was measured with a photometer at 450/630 and 405/630nm 
within 30 mins of adding the stop solution. A calibration curve was calculated with 
absorbance on the y-axis and concentration of anti-HBs on the x-axis expressed in AU/mL. 
Sample measurements were then multiplied by a dilution factor where appropriate. It is 
generally accepted that anti-HBs concentration above 10AU/L is indicative of either 
resolution of a past infection or positive response to vaccination.  
 
2.9 Multiplex immunoassay for simultaneous quantification of serum IgG antibodies to 
Bordetella pertussis, diphtheria and tetanus  (Phase II) 
Pre- and post-vaccination serum IgG antibody levels against Diphtheria toxin (Dtx) and 
Tetanus toxin (Ttx), and the Bordetella pertussis antigens Pertussis toxin (Ptx), Filamentous 
Haemagglutinin (FHA), Fimbriae and P69 Pertactin (Prn), were performed with the assistance 
of Pieter G.M. van Gageldonk at the Laboratory for Infectious Diseases and Perinatal 
Screening, National Institute of Public Health and the Environment (RIVM), Bilthoven, The 
Netherlands using their in-house assay as previously described (van Gageldonk et al., 2008). 
Reagents, reference and control sera, purified Ptx, FHA, Prn, Fimbriae, Dtx and Ttx coupled 
to activated carboxylated microspheres were kindly donated by the RIVM. Pre- and post 
vaccination plasma and in-house control sera were diluted 1/200 and 1/4000 in PBS 
containing (v/v) 0.1% tween-20 and (w/v) 3% BSA. Each dilution of 25µl of standard and 
plasma sample was mixed with an equal volume of conjugated microspheres 
(4000/beads/region/well) in a 96-well Multiscreen HTS filter plate (Millipore Corporation, 
Billerica, MA) and incubated for 45mins at room temperature in the dark at 600rpm on a plate 
shaker. The beads were collected by filtration through a vacuum manifold and washed three 
times in a 100µl of PBS. A 50µl volume of a 1/200 dilution of R. Phycoerythrin (R-PE) 
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conjugated anti-human IgG in PBS was added to each well and incubated while shaking for 
30 mins. After two washes beads where re-suspended in 100µl of PBS and shaken before 
analysis on a Bio-Plex 200, using Bio-Plex manager software version 4.1.1 (Bio-Rad 
Laboratories, Hercules, CA). For each of the IgG antibody levels the median fluorescence 
intensity (MFI) was converted in to EU/ml or IU/ml using a 5-parameter logistic standard 
curve (log-log) for each bead region/standard.  
 
Pre- and post-vaccination serum IgG antibody levels against Hib polysaccharide were kindly 
performed by Gaby P. Smits at the RIVM.  
 
2.10 HLA typing 
In Phase I low-resolution class I HLA typing was performed at The MRC Gambia 
laboratories using sequence-specific primers (SSP) for the HLA-alleles of interest, namely 
A2, B35, B8 and B53. These were selected based on their frequency in the Gambian 
population (Figure 2.3), determined by serological typing (Allsopp et al., 1992) and recently 
confirmed using high resolution sequence typing (Louis-Marie Yindom, unpublished data), 
and availability of known immunodominant EBV epitopes restricted through these class I 
HLA alleles (Table 2.3).  
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Figure 2-3 Frequencies of HLA-alleles in 900 Gambian Donors.  
Grey bars represent HLA restrictions for known EBV-specific CD8+ epitopes used in phase I  
 
 
Table 2-3 Known CD8+ EBV peptides restricted through common HLA-alleles in The 
Gambia. 
 
EBV Protein Peptide Pool Epitope sequence Epitope  
co-ordinates 
HLA 
restriction 
EBNA1 
 
Latent  HPVGEADYF 407-415 B53 
EBNA1 
 
Latent HPVGEADYFEY 407-417 B35 
EBNA3A 
 
Latent QAKWRLQTL 158-166 B8 
EBNA3A 
 
Latent YPLHEQHGM 458-466 B35 
LMP2 
 
Latent  FLYALALLL 356-364 A2 
LMP2 
 
Latent CLGGLLTMV 426-434 A2 
BRLF1 
 
Lytic YVLDHLIVV 109-117 A2 
BZLF1 
 
Lytic EPLPQGQLTAY 54-63 B35 
BMLF1 Lytic GLCTLVAML 280-288 A2 
Note. – EBNA, Epstein-Barr Nuclear Antigen. LMP, Latency Membrane Protein.  
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The reagents and primer mixes for the HLA-alleles of interest and control primers, to a 796 
base pair fragment from the third intron of HLA-DRB1, were kindly donated by Dr Louis-
Marie Yindom. The PCR method was based on previously described methods for HLA 
phototyping (Bunce et al., 1995).  Relevant primer mixes (5µl) were aliquoted into 1-16 wells 
of a non-skirted 96-well PCR plate. Each reaction contained 10xbuffer pH8.5 (Tris-HCl, 
(NH4)2SO4, 1% Tween20®), MgCl (50mM), deoxynucleotide triphophates (dNTPs) (25mM), 
1µg of sample DNA and 0.8µl Bioline Taq. The reaction mix (5µl) was added to the primer 
mixes giving a final reaction volume of 10µl per well. Plates were then sealed and run on a 
thermocycler with a heated lid. The cycling parameters were as follows: 1 minute at 96 oC 
followed by 5cycles of 50 seconds at 96 oC, 50 seconds at 70 oC, 50 seconds at 72 oC, 
followed by 21 cycles of 50 seconds at 96 oC, 50 seconds at 65 oC, 50 seconds at 72 oC 
followed by 4 cycles of 50 seconds at 96 oC, 50 seconds at 55 oC and 130 seconds at 72 oC. 
The final product (8µl) plus loading buffer was then run on a 2% agarose gel (400ml 0.5M 
TBE, 8g agarose, 8µl ethidium bromide) at 300v for 20-30 mins and viewed under a uv light 
(Figure 2.4). The pattern of wells containing product allowed us to determine if the sample 
was one of the HLA-types of interest.  
 
In Phase II HLA typing limited to five alleles was performed on donors identified as being 
IgM VCA positive by serology and found to be responders in the IFN-! ELISPOT Assay. 
Annette Pachnio at the Institute for Cancer Studies, Birmingham kindly performed this assay 
(Figure 2.5). 
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Figure 2-4 Examples of low resolution HLA typing for donors ID751, ID740 and ID746 
illustrating HLA types A2 and B8, B35 and B53 respectively (phase I) 
 
Figure 2-5 HLA mini-typing illustrating that samples ID007, ID061 and ID082 are A2, B8 
and B8 respectively (phase II) 
1      2     3     4     5      6      7     8     9      10   11    12   13   14    15   16 
1      2     3     4     5      6      7     8     9      10   11    12   13   14    15   16 
A2 
B8 B8 
B35 
1      2     3     4     5      6      7     8     9      10   11    12   13   14    15   16 
B53 B53 
ID 751 
ID 740 
ID 746 
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2.11 Thawing cells (Phase II)  
Cryopreserved PBMCs were thawed rapidly by drop-wise addition of 10mls warmed (37°C) 
FCS. Following centrifugation at 1600rpm for 5 min, cells were incubated in RPMI (R0) and 
60(g/ml DNase solution (Type IV (Sigma)) for 15 mins at 37°C. Cells were washed and re-
suspended in R10 and viable cells counted by trypan blue exclusion. Cells for ELISPOT 
assays were rested for an additional four hours at a concentration of 106/ml, after which cells 
were washed once in R10. Viable cells were quantified and re-suspended in R10 at 106 viable 
cells /ml. Only samples with cell viabilities ' 80% were used in ICS assays. The majority 
(76%) of samples had cell viabilities of 80–99% after resting for four hours. Cells were 
immediately used in stimulations for intracellular cytokine staining or tetramer multi-colour 
flow cytometry assays (Section 2.14 and 2.16). Rested cells were used for the IFN-! 
ELISPOT assays.  
 
2.12 Interferon-gamma (IFN-!) Enzyme-linked ImmunoSpot (ELISPOT) assays  
Based on polymorphisms in genes, some of which encode known CD8+ epitopes, two types 
of EBV can be distinguished. Epitopes used in this study have been defined based on work 
with type 1 EBV strains in Caucasians. While we did not sequence the Gambian strains of 
EBV in our donors, Njie et al. described previously that 90% of Gambian donors they studied 
carried type 1 EBV (Njie et al., 2009) indicating that the use of peptides derived from type 1 
EBV is a reasonable choice. In addition there is extensive homology between the two 
subtypes and cross-reactive responses have been recognised (Bornkamm et al., 1980, Sample 
et al., 1990, Zimber et al., 1986, Brooks et al., 2000).   
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In Phase I, IFN-! producing EBV-specific lymphocytes were enumerated using the ELISPOT 
technique at MRC Laboratories, The Gambia.  PBMCs were cultured in growth medium 
(RPMI, containing 10% human AB serum). 96-well, flat-bottomed (Millipore, Bedford, Mass, 
USA) plates were pre-coated with anti-IFN-! mAb 1-DIK (MABTECH, Stockholm, Sweden) 
at 37°C for four hours. Plates were then washed six times with RPMI and blocked with R10 
for 30 mins at 37°C. Ex vivo responses against lytic and latent pools of EBV peptides (Table 
2.3, obtained from the WIMM, Oxford), and Phytohaemagglutinin (PHA), both at a final 
concentration of 5µg/ml, were screened at 105 PBMCs per well in duplicate. An equivalent 
concentration of DMSO was used as the negative control. Plates were incubated overnight at 
37°C, 5% CO2. The cells were discarded the following day, and a biotinylated anti-IFN-! 
mAb, 7-B6-1 biotin (MABTECH), was added at 1µg/ml for three hours at room temperature, 
plates were then washed six times with PBS and streptavidin-conjugated alkaline phosphatase 
(MABTECH) added for two hours. A further six washes were performed with PBS and 
cytokine-producing cells were detected after a 15min reaction with 5-bromo-4-chloro-3-
indolyl phosphate and nitro blue tetrazoliym using an alkaline phosphatase-conjugate 
substrate kit (Bio-Rad, Richmond, CA), and the reaction stopped by rinsing wells with tap 
water. Plates were then air-dried and the number of spot forming cells (SFC) was counted 
using an automated AID (Autoimmune Diagnostika GmbH) ELISPOT plate reader%. 
Negative control background values were subtracted from all responses. Negative values 
(background greater than response) were set to zero and classified as non-responders and 
analyses performed both excluding and including these values.  
 
In phase II ELISPOT assays were performed at the WIMM, on thawed and rested (4hours) 
cryopreserved cells using a two-dimensional matrix of 21 peptide pools of known CD8+ 
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restricted lytic and latent EBV epitopes identified in Caucasian donors (Table 2.4 and 2.5). 
Peptides, synthesised at the WIMM, were solubilised in DMSO at a stock concentration of 
40mg/ml and stored at -20°C. Working dilutions in RPMI of 200µg/ml were used to create 
the pools giving a final concentration of peptide per well of 2µg/ml (Figure 2.6).
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Table 2-4 EBV Latent protein known CD8+ restricted epitopes identified in Caucasian 
donors 
 
LATENT 
proteins  
Peptide ID  Epitope Sequence Epitope Coordinate HLA Restriction  
 
EBNA3A LA-1 QAKWRLQTL 158-166 B8 
 LA-2 AYSSWMYSY 176-184 A30.02 
 LA-3 RYSIFFDY 246-253 A24 
 LA-4 FLRGRAYGL 325-333 B8 
 LA-5 KRPPIFIRRL 378-387 B27 
 LA-6 RPPIFIRRL 379-387 B7 
 LA-7 LEKARGSTY 406-414 B62 
 LA-8 HLAAQGMAY 450-458 - 
 LA-9 YPLHEQHGM 458-466 B35.01 
 LA-10 VFSDGRVAC 491-499 A29 
 LA-11 VPAPAGPIV 502-510 B7 
 LA-12 SVRDRLARL 596-604 A2 
 LA-13 RLRAEAQVK 603-611 A3 
 LA-14 VQPPQLTLQV 617-625 B46 
EBNA3B LA-15 HRCQAIRKK 149-157 B27.05 
 LA-16 TYSAGIVQI 217-225 A24.02 
 LA-17 RRARSLSAERY 244-254 B27.02 
 LA-18 VSFIEFVGW 279-287 B58 
 LA-19 AVFDRKSDAK 399-408 A11 
 LA-20 IVTDFSVIK 416-424 A11 
 LA-21  AVLLHEESM 488-496 B35.01 
 LA-22 VEITPYKPTW 657-666 B44 
EBNA3C LA-23 EGGVGWRHW 163-171 B44.03 
 LA-24 QNGALAINTF 213-222 B62 
 LA-25 LRGKWQRRYR 249-258 B27.05 
 LA-26 RRIYDLIEL 258-266 B27 
 LA-27 HHIWQNLL 271-278 B39 
 LA-28 EENLLDFVRF 281-290 B44.02 
 LA-29 LLDFVRFMGV 284-293 A2.01 
 LA-30 LDFVRFMGV 285-293 B37 
 LA-31 KEHVIQNAF 335-343 B44.02 
 LA-32 FRKAQIQGL 343-351 B27.05 
 LA-33 QPRAPIRPI 881-889 B7 
LMP1 LA-35 FWLYIVMSD 38-46 - 
 LA-36 FRRDLLCPLGA 72-82 B40 
 LA-37 YLLEMLWRL 125-133 A2 
 LA-38 YLQQNWWTL 159-167 A2 
 LA-39 TLLVDLLWL 166-174 A2 
 LA-40 DPHGPVQLSYYD 375-386 B51.1 
LMP2 LA-41 MGSLEMVPM 1-9 B35.01 
 LA-42 EDPYWGNGDRHSDYQ 61-75 - 
 LA-43 NPVCLPVIVAPYLF 121-134 - 
 LA-44 LPVIVAPYL 125-133 B53 
 LA-45 PYLFWLAAI 131-139 A23 
 LA-46 ASCFTASVSTVVTA 141-154 - 
 LA-47 FTASVSTVV 144-152 A68 
 LA-48 IEDPPFNSL 200-208 B40.01 
 LA-49 RRRWRRLTV 236-244 B27.04 
 LA-50 RRWRRLTVC 237-245 B14.02 
 LA-51 RRLTVCGGIMF 240-250 B27 
 LA-52 TVCGGIMFL 243-251 A2.01/06 
 LA-53 MFLACVLVLIVDAV 249-262 - 
 LA-54 LIVDAVLQL 257-265 A2 
 LA-55 GLGTLGAAI 293-301 A2 
 LA-56 LLWTLVVLL 329-337 A2.01 
 LA-57 SSCSSCPLSK 340-349 A11 
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 Table 2-5 EBV Lytic protein known CD8+ restricted epitopes identified in Caucasian donors 
 
LYTIC proteins  Peptide ID  Epitope Sequence  Epitope 
Coordinate  
HLA 
Restriction   
BRLF1 LY-1 LVSDYCNVLNKEFT 25-39 B18 
 LY-2 LVSDYCNVL 25-33 A2.05 
 LY-3 DYCNVLNKEF 28-37 A24 
 LY-4 AENAGNDAC 91-99 B45 
 LY-5 IACPIVMRYYVLDHLI 101-115 A24/C2 
 LY-6 YVLDHLIVV 109-117 A2.01 
 LY-7 FFIQAPSNRVMIPAT 121-135 - 
 LY-8 ATIGTAMYK 134-142 A11 
 LY-9 KHSRVRAYTYSKVLG 145-159 A3 
 LY-10 RALIKTLPRASYSSH 225-239 A2 
 LY-11 ERPIFPHPSKPTFLP 393-407 Cw4 
 LY-12 QKEEAAICGQMDLS 529-543 B61 
 LY-13 EVCQPKRIRPFHPPG 441-455 - 
BZLF1 LY-14 LPEPLPQGQLTAY 52-64 B35.08 
 LY-15 EPLPQGQLTAY 54-63 B35.01 
 LY-16 APENAYQAY 81-89 B35.01 
 LY-17 LQHYREVAA 101-115 C8 
 LY-18 DSELEIKRYKNR 172-183 B18 
 LY-19 RKCCRAKFKQLLQHYR 186-201 C6 
 LY-20 RAKFKQLL 190-197 B8 
 LY-21 SENDRLRLL 209-217 B60 
BMLF1 LY-22 KDTWLDARM 265-573 - 
 LY-23 GLCTLVAML 280-288 A2.01 
 LY-24 DEVEFLGHY 397-405 B18 
 LY-25 SRLVRAILSP 435-444 B14 
BMRF1 LY-26 CYDHAQTHL 20-28 A2 
 LY-27 FRNLAYGRTCVLGKE 86-100 C3/C10 
 LY-28 RPQGGSRPEFVKL 116-128 B7 
 LY-29 TLDYKPLSV 208-216 A2.01 
 LY-30 YRSGIIAVV 268-276 C6 
 LY-31 LPLDLSVILF 286-295 B53 
BAF0 LY-32 LLWAARPRL  A2 
BCRF1 LY-33 RRLVVTLQC 3-11 B27 
BALF2 LY-34 ARYAYYLQF 418-426 B27 
BILF2 LY-35 RRRKGWIPL 240-248 B27 
BLLF1 (gp350) LY-36 VLQWASLAV  A2 
BALF4 (gp110) LY-37 FLDKGTYTL 276-284 A2 
 LY-38 ILIYNGWYA  A2 
 LY-39 VPGSETMCY  B35 
 LY-40 APGWLIWTY  B35 
BXLF2 (gp85) LY-41 TLFIGSHVV  A2.01 
 LY-42 SLVIVTTFV  A2.01 
 LY-43 LMIIPLINV  A2.01 
(Hislop et al., 2007b)
 LA-58 ILLARLFLY 349-358 29 
 LA-59 FLYALALLL 356-364 A2 
 LA-60 TYGPVFMCL 419-427 A24 
 LA-61 CLGGLLTMV 426-434 A2.01 
 LA-62 VMSNTLLSAW 442-451 A25 
 LA-63 LTAGFLIFL 453-461 A2.06 
 LA-64 LLSAWILTA 447-455 A2 
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 pool-11 pool-12 pool-13 pool-14 pool-15 pool-16 pool-17 pool-18 pool-19 pool-20 pool-21 PROTEIN 
pool-1 LA-1 LA-2 LA-3 LA-4 LA-5 LA-6 LA-7 LA-8 LA-9 LA-10 LA-11 EBNA3A 
pool-2 LA-12 LA-13 LA-14 LA-15 LA-16 LA-17 LA-18 LA-19 LA-20 LA-21  LA-22 EBNA3A/3B 
pool-3 LA-23 LA-24 LA-25 LA-26 LA-27 LA-28 LA-29 LA-30 LA-31 LA-32 LA-33 EBNA3C 
pool-4 X LA-35 LA-36 LA-37 LA-38 LA-39 LA-40 LA-41 LA-42 LA-43 LA-44 LMP1/LMP2 
pool-5 LA-45 LA-46 LA-47 LA-48 LA-49 LA-50 LA-51 LA-52 LA-53 LA-54 LA-55 LMP2 
pool-6 LA-56 LA-57 LA-58 LA-59 LA-60 LA-61 LA-62 LA-63 LA-64 x x LMP2 
pool-7 LY-1 LY-2 LY-3 LY-4 LY-5 LY-6 LY-7 LY-8 LY-9 LY-10 LY-11 BRLF1 
pool-8 LY-12 LY-13 LY-14 LY-15 LY-16 LY-17 LY-18 LY-19 LY-20 LY-21 x BRLF1/BZLF1 
pool-9 LY-22 LY-23 LY-24 LY-25 LY-26 LY-27 LY-28 LY-29 LY-30 LY-31 LY-32 BMLF1/BMRF1/BAF0 
pool-10 LY-33 LY-34 LY-35 LY-36 LY-37 LY-38 LY-39 LY-40 LY-41 LY-42 LY-43 BCRF1/BALF2/gp350/gp1
10/gp85  
 
Figure 2-6 Two dimensional matrix used illustrating peptide pools and proteins screened.  
Highlighted in red is an example of deconvolution of a positive single peptide IFN-! response detected by reactivity to peptide pools 8 and 18. 
Peptides correspond to the codes defined in Tables 2.4 and 2.5. x indicates where an equal volume of the diluent was added containing no 
peptide. 
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PBMCs were screened against each of the 21-peptide pools with a final concentration of 
2µg/ml of peptide per well. After the streptavidin-conjugated alkaline phosphatase 
(MABTECH) was added and washed off, 50µl per well of BCIP (5-bromo-4-chloro-3’-
indolyphophate)/NBT (nitro-blue tetrazolium) plus developer (Moss inc/ Europa Bioproducts 
MO711A) was added and plates were incubated for 15 mins and the reaction stopped by 
rinsing wells with tap water. Plates were air-dried and the number of SFC was counted using 
an automated AID (Autoimmune Diagnostika GmbH) ELISPOT plate reader! (Figure 2.7). 
 
The visit one samples from 96 of 114 (84%) of the children were screened using the peptide 
pool matrix. To quantify the antigen-specific responses, background values from the negative 
control wells (DMSO) were deducted. Responses were regarded as positive if they were if >3 
times the mean of the quadruplicate negative control wells per plate and !50 SFU/106 
PBMCs. If negative background wells had !30 SFU/106 or the positive control wells were 
negative, had "30 SFU/106, the assay would have been classified as ‘failed’. This however 
was not the case for any of the donors screened (Figure 2.7). 
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Figure 2-7 Example of donor ID044 screening positive to peptide pools 9 and 20 
corresponding to epitope Ly-31 LPL 
 
Pool 9 
21 
PHA 
DMSO 
Pool 20 
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Cell numbers did not permit further screening of individual peptides when multiple wells 
responded. For further analysis in these instances it was not possible to determine which 
proportion of the response within the pool was attributable to which epitope, therefore these 
responses are presented as coming from either of the relevant proteins. 
 
2.13 Ex vivo flow cytometric staining of human cells by the lysed whole blood method 
(Phase II)  
 T and B-cell surface antibody panels were used to directly stain whole blood (Table 2.6). For 
the B-cell antibody panel the whole blood was washed twice with PBS to remove any 
circulating immunoglobulin (Ig). A 100µl volume of whole blood for each donor was stained 
with the surface antibody panels for 30 min at 4°C. Red blood cells were then lysed using 
1:10 FACS Lysing Solution (BD Biosciences) incubating for 10 min at room temperature. 
Cells were then washed twice in FACS buffer (PBS, 5% BSA, 5% EDTA) and re-suspended 
in Cytofix (BD, Biosciences). Samples were acquired on a Cyan™ ADP flow cytometer using 
Summit software (Beckman Coulter) at MRC Gambia. Compensation for fluorescence ‘spill-
over’ was performed using the BD CompBead Anti-Mouse Ig set (BD Biosciences) and panel 
antibodies (Table 2.6). Briefly, antibodies were added to separate tubes containing one drop 
each of Anti-Mouse Ig beads and the negative control beads (which do not bind # light chain-
bearing immunoglobulin). Following a 30 min incubation at 4°C, beads were washed and re-
suspended in FACS buffer. Analysis was performed using FlowJo (Tree Star Inc.) and isotype 
controls were used to set the gating for cell surface markers (Figure 3.0). 
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Table 2-6 Flow cytometry antibody panels used for ex vivo, intracellular and tetramer 
staining protocols using the CyAn flow cytometer.  
Grey shading indicates an unused channel. 
  
Channel  Laser 
(nm)  
Phase I  
Ex vivo panel  
Phase II  
Ex vivo whole 
blood T-cell 
panel 
Phase II  
Ex vivo whole 
blood B-cell panel 
Phase II  
Intracellular 
cytokine panel 
FL-1 Argon 
488 
PD-1 FITC 
(BD 
Biosciences)  
CD28 FITC 
(BD 
Biosciences) 
IgD FITC 
(BD Biosciences)  
Perforin FITC 
B-D48 
(Gen-probe) 
FL-2 Argon  
488 
 
Tetramers PE 
 (A2, B35, 
B8)  
CD3 PE 
(BD 
Biosciences) 
CD21 PE 
(BD Biosciences)  
IL-2 PE 
(Ebiosciences)  
FL-3 Argon  
488  
CD28 ECD 
(Beckman 
Coulter) 
  CD8 qdot605 
(Invitrogen)  
FL-4 Argon  
488  
 
CD4 PerCP 
(BD 
Biosciences)  
 
CD4 PerCP 
(BD 
Biosciences) 
CD20 PerCP 
(BD Biosciences)  
MIP1" PerCP-
Cy5.5 
(BD 
Biosciences)  
FL-5 Argon  
488  
 
CD19 PE-
Cy7 
(BD 
Biosciences)  
CD62L PE-Cy7 
(Ebioscience)  
CD38 PE-Cy7 
(BD Biosciences)  
IFN# PE-Cy7 
(Ebioscience)  
FL-6 Violet  
405 
CD8 PB 
(Ebioscience)  
CD8 efluor450 
(Ebioscience)  
CD19 efluor450 
(Ebioscience)  
TNF$ 
efluor450 
(Ebioscience) 
FL-7 Violet  
405 
CD3 Cas 
Yellow 
(Dako) 
  Live/Dead% 
Aqua 
(Invitrogen)  
FL-8  Red 
635 
 
CD38 APC 
(BD 
Biosciences)  
CD45RO APC 
(BD 
Biosciences)  
IgM APC 
(BD Biosciences)  
CD107a APC  
(BD 
Biosciences) 
FL-9 Red 
635 
CD27 APC-
alexafluor750 
(Ebioscience)  
CD27 APC-
alexafluor750 
(Ebioscience) 
CD27 APC-
alexafluor750 
(Ebioscience)  
CD4 efluor780 
(Ebioscience)  
FITC - Fluorescein Isothiocyanate, PE -Phycoerythrin, PerCP – Peridinin-chlorophyll-protein 
complex, PB – pacific blue, CY – cascade yellow, APC – Allophycocyanin, Cy –Cyanine dye, IL -
Interleukin  
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2.14 Intra-cellular cytokine staining (ICS) following peptide stimulation (Phase II)  
 
Overlapping BLZF1 and EBNA3A synthetic peptides 
Overlapping peptide sets representing the entire EBV BZLF1 protein, a transcriptional 
activator that plays a critical role in the disruption of latency, and EBV EBNA-3A, essential 
for efficient immortalisation of B-cells, (n = 30 for BZLF1 and n = 117 for EBNA-3A) were 
used for peptide stimulation and ICS. In this study 18-mer peptides, overlapping by 10 amino 
acids were designed. Peptide sequences were based on EBV subtype 1. Overlapping peptides 
were designed using the Los Alamos National Library website’s program PeptGen (http://hiv-
web.lanl.gov) and synthesised by the PEPscreen services from Sigma-GenoSys (0.5-5mg, 
70% purity).   
 
Intra-cellular Cytokine Stimulation assay 
Cells were aliquoted at 5 x 105 in 500$l R10 and stimulated with either an overlapping 
BZLF1 peptide pool or overlapping EBNA-3A peptide pool, both at 2$g/ml (each peptide), 
and co-stimulatory antibodies anti-CD28 and anti-CD49 (BD Bioscience, UK) at 1$g/ml 
each. Cells stimulated with Staphylococcus Enterotoxin B (SEB, Sigma) at 2$g/ml (positive 
control) and co-stimulatory antibodies alone (negative control) were included in the assay. 
Unstimulated cells were used for the unstained control and SEB-stimulated cells for 
fluorescence-minus-one (FMO) staining for perforin to aid with gating during flow cytometric 
analysis. Following incubation for one hour at 37°C, protein transport inhibitors Brefeldin A 
and Monensin (Ebioscience, UK, final concentrations 3$g/ml and 2$M respectively) and pre-
titrated anti-CD107a-PE-Cy5 were added to stimulations. Following a further five hours 
incubation at 37°C, cells were washed using FACS wash buffer, supernatant discarded after 
 65 
centrifugation, cells re-suspended in the residual volume and incubated for 10 mins in the 
dark at 4°C with LIVE/DEAD® fixable Aqua Dead Cell Stain (for 405nm excitation) 
(Invitrogen, UK). Surface stains with pre-titrated antibodies (Table 2.6) were then added and 
cells incubated for a further 30 mins at 4°C. Cells were then washed and fixed/permeabilised 
using Cytofix/CytopermTM (BD Biosciences). Briefly, 250$l Cytofix/CytopermTM was added 
and the sample incubated for 20 min at 4°C. Following permeabilisation, cells were washed 
with Perm/WashTM buffer (BD Biosciences) and stained intra-cellularly with pre-titrated 
antibodies (Table 2.6) for 30 min at room temperature. Anti-perforin staining was excluded in 
the perforin-minus-one condition. Following staining, cells were washed twice in 
Perm/WashTM buffer, once in FACS buffer and re-suspended in FACS buffer prior to analysis 
by flow cytometry within 12 hours.  
 
Cells were analysed using a CyAn flow cytometer (Dako, Beckman Coulter). Flow cytometric 
compensation for fluorescence ‘spill-over’ was performed using the BD CompBead Anti-
Mouse Ig, # set (BD Biosciences) and antibodies used for cell staining (Table 2.6). Between 
300,000 and 400,000 events were acquired in the lymphocyte gate for all samples. Data 
analysis was performed using FlowJo version 9.1 (Treestar, San Carlos, CA). Forward scatter 
(FSC)-area versus FSC-height parameters were used to exclude cell doublets, followed by 
exclusion of dead cells and subsequent gating on the lymphocyte population using FSC and 
side scatter (SSC) properties. CD4+ and CD8+ T-cells were then identified. For functional 
analysis, gates were created for each measured marker (CD107a, IFN-#, tumour necrosis 
alpha (TNF-$), interleukin-2 (IL-2), macrophage inflammatory protein 1 beta (MIP1%)) and 
perforin). Boolean/combinatorial gate arrays were then created using FlowJo software, these 
determined the frequency of each possible response pattern based on all possible 
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combinations of the markers of interest, Figure 2.8 illustrates the gating strategy used. 
Responses detected in the negative (anti-CD28/anti-CD49d) control were subtracted from 
responses observed in stimulated samples. In cases where the value in the stimulated sample 
is smaller than that of the anti-CD28/anti-CD49d control, negative values arise following 
background subtraction. These were set to zero, but to avoid systematic bias with this 
approach, a threshold was set below which all positive values were also zeroed on the 
assumption that the distribution of background values is symmetric around zero (Roederer et 
al., 2011). This threshold was chosen based on the distribution of negative values for each 
dataset (CD8+ and CD4+ responses), by using the same absolute value as the 90th centile 
negative value. We detected a significant amount of CD107a background CD4+ and CD8+ T-
cell staining in our unstimulated samples from Gambian children, Figure 2.8. This population 
of cells was excluded from further analysis, resulting in an analysis of 30 distinct functional 
populations as opposed to 31 populations. The BZLF1 cut off values were 0.09 and 0.04 for 
the CD8+ and CD4+ datasets respectively and 0.07 and 0.05 respectively for EBNA-3A.  
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Figure 2-8 Plots from a representative donor illustrating flow cytometric gating strategy used 
for the intra-cellular cytokine staining following stimulation with EBV BZLF-1 in Phase II.  
Plots shown demonstrate staining on the total CD8+ T-cell population, with negative controls 
and fluorescence minus one (FMO) used for setting the gates. 
 
2.15 Tetramer Synthesis  
The tetramers used for phase I were as follows: A2-CLGGLLTMV (LMP2), A2-
GLCTLVAML (BMLF1), B35-EPLPQGQLTAY (BZLF1) and B8-RAKFKQLL (BZLF1). 
All except A2-CLGGLLTMV (LMP2) were also used in phase II.  
 
A2-GLCTLVAML (BMLF1) and B35-EPLPQGQLTAY (EBV BZLF1) class I tetramers 
were synthesised using the following procedure. A. Hislop from the Institute for Cancer 
Studies in Birmingham donated HLA-A2 and HLA_B35 MHC Class I heavy chains and "2-
 68 
microglobulin cloned into vectors. These proteins were amplified and purified from bacterial 
inclusion bodies and solubilised in eight molar urea. These were refolded with the appropriate 
epitopes A2-GLCTLVAML (BMLF1) and B35-EPLPQGQLTAY, biotinylated and purified 
by Fast Protein Liquid Chromatography (FPLC). The monomeric complexes (50$g) of 
peptide/MHC class I, %2-microglobulin and biotin were freshly conjugated to streptavidin-PE 
(Sigma-Aldrich) at 4:1 molar ratio to produce tetrameric peptide-MHC complexes. The 
remaining class I tetramers used in this work were produced by Yanchun Peng at the WIMM, 
except for an A2-GLCTLVAML (BMLF1) conjugated to streptavidin-APC that was provided 
by Heather Long from the Institute for Cancer Studies in Birmingham.  Tetramers were tested 
against a seronegative donor and two seropositive donors, HLA matched and mismatched 
prior to use on samples (Figure 2.9). 
 
Figure 2-9 Example of tetramer staining for B35 EPLPQGQLTAY (BZLF1) and B8 
RAKFKQLL (BZLF1) on seronegative (A), seropositive HLA mismatched (B) and HLA 
matched (C) donors.  
Percentage indicates tetramer percentage as a proportion of CD8+ T-cell population.  
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2.16     Tetramer staining assays 
For Phase I ex vivo, 1 x 106 PBMCs per MHC Class I tetramer (for lower cell counts all four 
tetramers were pooled) were stained for one hour at 40C in the dark. MHC class I Tetramers 
containing GLCTLVAML (A2_GLC), CLGGLLTMV (A2_CLG), EPLPQGQLTAY (B35_ 
EPL) and RAKFKQLL (B8_RAK) peptides were used, conjugated to PE (A2_GLC 
synthesised at the Institute for Cancer Studies, University of Birmingham, the others from the 
WIMM, Oxford). Tetramer staining was followed by surface marker staining (30 min, 40C in 
the dark) using pre-titrated surface antibodies (Table 2.6, Phase I ex vivo panel). Appropriate 
isotype control antibodies, IgG1 FITC, IgG1 PerCP, IgG1 PE-Cy7, IgG1 APC, (BD 
Biosystems) IgG2a Pacific Blue, IgG1 APC-Alexa750, (Ebioscience) and IgG1 Cascade 
Yellow (Dako), were used. For Phase I a set of compensation tubes was run for each donor 
using donors cells and the same antibodies as the panel where possible. Samples were 
acquired on a Cyan™ ADP flow cytometer using Summit software (Beckman Coulter) at 
MRC Gambia. Analysis was performed using FlowJo (Tree Star Inc.). FSC-area and FSC-
height were used to exclude cell aggregates, followed by gating on CD3+ cells. FSC and SSC 
were then used to gate on lymphocytes, followed by isolation of CD8+ cells and EBV-
specific tetramer-positive cells for further gating to examine expression of specific markers 
with isotype controls used for gating (Figure 2.10). 
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Figure 2-10 Flow cytometry plots from a representative donor illustrating gating strategy 
used in Phase I.   
Plots demonstrate gating used to identify CD8+ and Tetramer positive populations and use of 
isotype controls for gating on total CD8+ population. These gates were then applied to EBV-
specific Class I tetramer positive cells.  
 
 
In Phase II, tetramer staining was performed on cryopreserved cells (see Table 2.7 for  
antibody panels used). Unconjugated CD57 monoclonal antibody (mAb) (clone NK-1, BD 
Biosciences) was conjugated in-house by Dr. T de Silva to Quantum dot 565 stain obtained 
from Invitrogen according to the manufacturer’s protocol. The conjugated antibody was 
stored at 4°C prior to further use. All antibodies had been pre-titrated by Dr. T de Silva in an 
iterative process to obtain optimum volumes required for flow cytometric staining, until full 
panels to be used in final experiments were complete.  
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The cells were thawed (Section 2.11) and then stained with LIVE/DEAD% fixable Aqua 
Dead Cell Stain for 30 min at 4°C, washed and stained with 1$g of tetramer-PE for 15min at 
37°C. Following two further washes, surface staining with CD3-Qdot655, CD4-Qdot605, 
CD8-Qdot705, CD14-V500, CD19-V500, CD27-efluor780, CD45RO-PETexasRed, CD57-
Qdot565 and PD-1-PE-Cy7 were performed in all test samples. Additional surface staining 
with 2B4-PE-Cy5.5 and CD160-efluor647 in one panel (i), and CD38-APC and HLA-DR-
Alexafluor700 in another panel (ii) were performed. Following fixing and permeabilisation as 
described above, intracellular staining with Perforin-FITC, Granzyme B-Alexafluor700 and 
T-bet (T-box transcription factor) -Brilliant Violet in panel (i) and Ki67-Alexafluor488 and 
Bcl-2 (B-cell lymphoma 2) -V450 in panel (ii) was performed. FMO samples were included 
to aid gating during subsequent flow cytometric analysis. 
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Table 2-7 Antibody panels used on the LSRII.  
Grey Shading indicates an unused channel. 
 
Detector   Laser Phase II  
Tetramer Panel (i)  
Phase II Tetramer Panel 
(ii) 
B710-A Blue 488  Ki67 alexafluor488 
(BD Biosciences)  
B515-B Blue 488 Perforin (D48) FITC 
(Diaclone)  
 
G780-A Green 532 PD-1 PE-Cy7  
(Biolegend)  
PD-1 PE-Cy7  
(Biolegend)  
G710-B Green 532 2B4 PE-Cy5.5 
(Biolegend)  
CD4 PE-Cy5.5 
(Invitrogen)   
G610-D Green 532 CD45RO PE-Texas Red 
(Invitrogen)  
CD45RO PE-Texas Red 
(Invitrogen)  
G560-E Green 532 Tetramers PE 
(A2, B35, B8) 
Tetramer PE  
(A2, B35, B8)  
R780-A Red 633 CD27 APCefluor780 
(Ebioscience)  
CD27 APCefluor780  
(Ebioscience)  
R710-B Red 633  HLA-DR alexafluor700 
(Biolegend) 
R660-C Red 633 CD160 APC 
(Biolegend)  
CD38 APC  
(Biolegend)  
V705-A Violet 407 CD8 Q705 
(Invitrogen)  
CD8 Q705 
(Invitrogen)  
V655-B 
 
Violet 407 CD3 Q655 
(Invitrogen)  
CD3 Q655 
(Invitrogen)  
V605-C Violet 407 CD4 Q605 
Invitrogen 
 
V565-E Violet 407 CD57 Q565 (in-house 
conjugation) 
CD57 Q565 (in-house 
conjugation) 
V505-G Violet 407 CD14/CD19 V500 
Live/Dead% Aqua 
(Invitrogen)  
CD14/CD19 V500 
Live/Dead% Aqua 
(Invitrogen) 
V450-H Violet 407 T-bet Brilliant Violet 
(Biolegend) 
Bcl-2 V450 
(BD Biosciences)  
FITC - Fluorescein Isothiocyanate, PE -Phycoerythrin, APC - Allophycocyanin 
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Compensation for fluorescence ‘spill-over’ was performed using the BD CompBead Anti- 
Mouse Ig set (BD Biosciences) and antibodies as described above.  Between 500,000 and 
800,000 events were acquired for each sample. Data analysis was performed using FlowJo 
version 9.1 (Treestar). FSC-area and FSC-height were used to exclude cell aggregates, 
followed by removal of CD14+, CD19+, dead cells and gating on CD3+ cells. FSC and SSC 
were then used to gate on lymphocytes, followed by isolation of CD8+ cells and tetramer-
positive cells for further gating to examine expression of specific markers (Figure 2.11 and 
2.12). Similar approaches have been shown to reduce background staining during detection of 
tetramer-positive populations (Chattopadhyay et al., 2008).  
 
 
 
 
Figure 2-11 Representative donors illustrating gating strategy used to identify EBV-specific 
Class I tetramer positive cells and CD8+ T-cells.  
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Figure 2-12 Representative donor illustrating setting of gates using fluorescence minus 
one samples applied to total CD8+ T-cell populations.  
Gates were then copied and applied to EBV-specific Class I tetramer positive cells. 
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2.17 Statistics analyses  
Viral genome load, serology, ELISPOT and flow cytometry data were plotted and statistically 
analysed using GraphPad Prism software (Version 5; GraphPad). Wilcoxon rank and Mann-
Whitney U non-parametric tests were used for comparisons of matched and unmatched data 
respectively. STATA (version 11) was used to calculate Spearman’s rank correlation 
coefficients for Phase I.   
 
All statistical analyses and graphical presentations in Phase II were performed using 
Microsoft Excel for Macintosh 2011 and Graphpad Prism version 5.0 for Macintosh 
(GraphPad Software, San Diego California, USA, www.graphpad.com). Comparisons 
between variables were performed using the Mann-Whitney U test (two-tailed) and Wilcoxon 
matched pair test (for comparisons between total CD8+ and virus-specific CD8+ T-cells made 
within individuals). Correlations between non-normally distributed data were made using the 
Spearman’s rank correlation coefficient.  
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CHAPTER 3 : THE EFFECT OF ACUTE P. FALCIPARUM MALARIA ON 
EPSTEIN-BARR VIRUS: HOST BALANCE IN THE SETTING OF REDUCED 
MALARIA ENDEMICITY 
 
3.1 Introduction 
EBV first colonises the B-cell system through a growth-transforming infection, where 
coordinate expression of specific latent cycle genes drives the expansion of infected B-cell 
clones. These expansions are controlled by the EBV-specific T-cell response but it appears 
that some infected cells survive by extinguishing latent gene expression; thereby generating a 
reservoir of latently infected resting B-cells, through which the virus persists (Babcock et al., 
2000).  Reactivations from this reservoir do nevertheless occur and, if not controlled by virus-
specific T-cells, can lead to further B-cell transformation events and greatly increased loads of 
latently-infected B-cells in the blood (Speck et al., 1997). In the West, this is most apparent in 
heavily T-cell suppressed transplant patients, where high circulating EBV loads often precede 
the appearance of EBV-positive PTLD (Rezk and Weiss, 2007, Rickinson, 2002). A 
somewhat analogous situation is thought to occur in Africa, where the similar geographic 
distributions of eBL, an EBV-associated childhood B-cell tumour, and holoendemic malaria 
suggests that malaria may predispose to eBL through suppression of EBV-specific T-cell 
surveillance leading to increased viral loads (Rochford et al., 2005).  
 
Several studies conducted in areas with high malaria endemicity have indeed implied that 
malaria exposure can cause a reduction in EBV-specific T-cell responses (Whittle et al., 
1984). Early assays quantifying the regression of EBV-infected B-cell outgrowth in PBMC 
cultures, an effect mediated by in vitro reactivation of EBV latent antigen-specific CD8+ 
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cytotoxic T-cells (Gudgeon et al., 2005), showed a slight relaxation of T-cell control in 
healthy adults from holoendemic malarial versus non-endemic malarial areas of New Guinea 
(Moss et al., 1983). Subsequently, a study of healthy children in Kenya with differential 
malaria exposure has shown that a smaller proportion of children, five to nine years of age, 
had EBV-specific IFN-# ELISPOT responses (PBMC), when living in malaria-holoendemic 
areas, compared to those living in areas where exposure is only sporadic (Moormann et al., 
2007).  EBV genome loads in whole blood of these children were also significantly higher in 
the holoendemic malaria group, but only in children one to four years of age (Moormann et 
al., 2005). Turning to acute malaria itself, T-cell control as measured by the regression assay 
appeared to be completely abrogated in children from an area at the time considered to be 
holoendemic, The Gambia, during an episode of acute malaria, but recovered to some extent 
after treatment and the resolution of symptoms (Whittle et al., 1990, Whittle et al., 1984). 
More recently EBV-specific CD8+ T-cell responses restricted through two HLA alleles, 
B*3501 and B*5301, were measured by IFN-# ELISPOT in Gambian children with acute 
malaria and compared to results obtained up to six weeks post-treatment. With the caveat of a 
small sample size in mind, this comparison suggested that responses were impaired during 
acute disease, but it was not clear whether this reflected a reduction in the numbers or in the 
functional competence of EBV-specific T-cells in the circulation (Njie et al., 2009). A further 
heterogeneous group of studies have looked at EBV viral load dynamics during malaria 
exposure (Donati et al., 2006, Rasti et al., 2005, Yone et al., 2006). Comparability of these 
results is limited, as the assays have been conducted on differing sample types, either whole 
blood, plasma alone or PBMC preparations. Yone et al. saw significantly higher whole blood 
viral loads in acute uncomplicated malaria cases compared to convalescence, with a similar 
non-significant trend for complicated malaria cases (Yone et al., 2006). In The Gambia, 
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PBMC EBV genome loads did not differ between acute and convalescent malaria cases, but 
were elevated in the cases compared to healthy controls (Njie et al., 2009).    
 
Since the original observations of impaired EBV control in The Gambian population in a 
setting of holoendemic malaria were made in the 1980’s (Whittle et al., 1984) the intensity of 
malaria infection had reduced substantially in this geographical region (Satoguina et al., 2009, 
Ceesay et al., 2008, Ceesay et al., 2010). This study examines immune control of EBV in this 
setting of reduced malaria exposure by studying T-cell function using regression assays. More 
contemporary immune measures of MHC Class I tetramer staining and IFN-& ELISPOT 
analysis in children during acute malaria infection and on convalescence were also included 
to assess numbers and functional competence of EBV-specific CD8+ T-cells.  
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3.2 Methods  
3.2.1 Study Design and Donors  
Children were serially recruited in The Gambia during the 2008/9 malaria season infected 
with acute uncomplicated P. falciparum malaria defined as a temperature >37.50C within the 
last 48hours, and !5000 parasites/µl detected by slide microscopy. Samples were obtained 
from MRC Fajara outpatient clinic and the Jammeh Foundation for Peace Hospital in 
Bundung. Assays were conducted in real time during acute (Day 0) and convalescent (Day 
28) stages of the P. falciparum infection in children aged 1-15yrs. Healthy age- and sex- 
matched control children without malaria were recruited during the subsequent dry season 
(May 2009). Chapter 2, section 2.1 and 2.2 details sites, samples taken and processing in 
depth. Matching of controls was performed according to sex- and age- by identifying 
appropriate children using data from a demographic survey conducted in Brefet by a previous 
PhD student (O. Finney). Children were then sought out by field-workers and recruited into 
the study until sufficient numbers of control patients were reached.  
 
3.2.2  Sickle cell trait diagnosis   
Sickle cell status was determined by metabisulfite test and a positive result was confirmed by 
cellulose acetate electrophoresis to determine the exact genotype (Hicksg et al., 1973). The 
MRC Gambia Haematology Laboratories performed this, in addition to a FBC on all study 
participants. 
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3.2.3 Malaria Diagnosis by Slide 
Thick blood films were prepared with 10µl of blood, and stained with Giemsa following 
standard methods. At the health clinics, 50 high power fields (HPF) for each thick film from 
the malaria cases were screened. These were then confirmed on a thin film by reading of a 
further 100 HPF under oil emersion (1000x). For the controls 200 HPF for each thick film 
were screened. Malaria PCR was also performed on all donors (Methods section 2.7).  
 
3.2.4  EBV Genome loads and Cellular Immunological Assays 
EBV viral genome loads were performed on DNA extracted from 500µl whole blood see 
Methods Chapter 2, section 2.6. EBV-specific CD8+ T-cell responses were assessed using 
two functional assays (regression and IFN-# ELISPOT) that had been used separately in 
earlier work (Njie et al., 2009, Whittle et al., 1984), and numbers of EBV epitope-specific 
cells were enumerated by HLA class I-peptide tetramer staining. Laboratory methods used are 
detailed in Methods Chapter 2, Sections 2.12, 2.15 and 2.16.  
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3.3  Results 
3.3.1 Demographics and characteristics of study populations  
Table 3.1 shows that the two groups of infected and uninfected children were similar with 
regard to age and sex, indicating successful matching. None of the study participants were 
found to be Sickle Cell positive on screening. As expected there was a significant decline in 
haemoglobin levels during the acute phase of malaria, which on convalescence is not 
significantly different to that found in uninfected controls. Leucocyte counts did not 
significantly differ from convalescent or uninfected matched control samples during acute P. 
falciparum infection. The percentage of lymphocytes was significantly higher on 
convalescence, at which time it did not significantly differ from uninfected controls. This is 
consistent with what has been previously described (Lisse et al., 1994).   
 
Table 3-1 Characteristics of uncomplicated P. falciparum cases and controls 
 Acute 
P.falciparum 
Convalescent 
P.falciparum 
Aparasiteamic 
Controls 
Acute versus 
Convalescent
1 
Convalescent 
versus 
Controls2 
Age (yrs) 7 
(4.8-10.0) 
- 7 
(4.5-9.5) 
- 0.95 
 
Male: 
Female Ratio  
1.91 - 2.00 - - 
 
Haemoglobin 
(g/dl) 
11.25 
(9.83-12.63) 
12.50 
(11.40-
12.93) 
12.40 
(11.65-13.20) 
0.0038 0.65 
 
Leucocyte 
Count 
(x109/L) 
6.96 
(4.90-11.13) 
6.40 
(5.20-8.90) 
6.10  
(5.30-7.70) 
0.31 0.87 
Lymphocytes 
(%)  
33.35 
(22.30-41.83) 
52.30 
(46.90-
56.93) 
51.45  
(45.23-63.30) 
<0.0001 0.92 
Lymphocyte 
Count 
(x109/L) 
2.00 
(1.53-2.75) 
3.25 
(2.68-4.90) 
3.15  
(2.60-4.35) 
0.0004 0.72 
For age and haemoglobin levels the median value and inter-quartile range are shown in brackets.  
1 p value calculated using Wilcoxon rank statistical comparison of matched pairs 
   2 p value calculated using Mann-Whitney U statistical comparison of unpaired data 
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Of the P. falciparum infected children 84% had at least one of the HLA alleles of interest 
(A2, B35, B8, B53), as did 81% of the control children. The HLA types detected were of a 
similar frequency in both case and control groups (Figure 3.1).  
 
Figure 3-1 Percentage of children with HLA types of interest in cases (n=32) and controls 
(n=33).  
 
All malaria cases were both slide and PCR positive with a geometric mean slide parasite 
density of 135,878/µl (95% CI 91,194 – 202,456). All controls were slide and PCR negative 
for P. falciparum parasites. In order to establish whether the control children had undergone a 
recent P. falciparum infection, ELISAs were performed to MSP-1(19) on both the infected 
(Day 0) and uninfected control children. The uninfected children had significantly lower anti-
MSP-1(19) antibody levels, when compared to the P. falciparum infected cases (Figure 3.2). 
Using the upper limit of the 99% Confidence Interval of values obtained from 20 non-exposed 
individuals as a cut off, on Day 0, 97% of infected children were classified as seropositive 
compared to 24% of the control children. 
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P value calculated using Mann-Whitney U comparison of unpaired data. 
Figure 3-2 Comparison of the magnitude of P. falciparum merozoite surface protein-
1(19), (MSP-1(19)), antibody levels in acute uncomplicated P. falciparum  cases (n=32) 
and healthy controls (n=33).  
Solid lines indicate median values and the dotted line indicates the cut off value for positivity, 
the upper limit of the 99% confidence interval obtained from sera from 20 non-exposed 
individuals.  
 
All of the malaria cases and all except one of the uninfected controls, who was excluded from 
further analysis, were EBV positive by IgG VCA ELISA (Figure 3.3). Comparisons were 
made to a group of EBV naïve university students as an additional control as described in the 
Methods section 2.8.1.  
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P value calculated using Mann-Whitney U comparison of unpaired data. 
 
Figure 3-3 Comparison of the magnitude of EBV VCA IgG levels in acute 
uncomplicated P. falciparum cases (n=32), healthy controls (n=33) and EBV uninfected 
students (n=19).  
Solid lines indicate median values and the dotted line indicates the cut off value for positivity, 
the upper limit of the 99% confidence interval obtained from plasma from 19 uninfected 
students.  
 
3.3.2 Frequencies of total cellular populations in P.falciparum infected and uninfected 
children 
Absolute total CD4+ and CD8+ T-cell counts were significantly lower during acute (Day 0) 
P. falciparum infection compared to convalescence (Day 28) consistent with previous 
findings (Lisse et al., 1994, Walther et al., 2009).  The total number of B-cells however did 
not significantly differ between acute and convalescent samples or between infected (Day 0 or 
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Day 28) and uninfected control children (Figure 3.4). The number of CD19+CD27+, memory 
B-cells, also did not significantly differ between acute, convalescent and uninfected control 
samples with median values of 0.16 x 109/L (0.08-0.31), 0.12 x 109/L (0.07-0.22) and 0.16 x 
109/L (0.11-0.27) respectively. 
 
 
a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
Figure 3-4 Total cellular frequencies in P. falciparum infected and uninfected children. 
There is a significant decrease in the numbers of CD3, CD8 and CD4 positive cells in acute 
uncomplicated P. falciparum malaria (D0), compared to cell numbers during convalescence 
in the same donors (D28). The number of CD4 positive cells on convalescence remains 
significantly lower than age- and sex- matched healthy controls. The number of CD19 
positive B-cells does not significantly differ.  
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3.3.3 EBV genome loads did not significantly change during acute uncomplicated P. 
falciparum malaria infection  
In contrast to previous findings documented in the literature (Njie et al., 2009), no differences 
were found in EBV genome loads between children with acute (Day 0) P. falciparum malaria 
and age- and sex- matched healthy controls (p=0.749). Likewise, the EBV genome loads did 
not change significantly between D0 and D28 (p=0.2173) (Figure 3.5). Considering the 
number of B-cells remained constant (Figure 3.4) it is unlikely that an increase in the total 
number of B-cells would have obscured an increase in total EBV genome load. There were 7, 
2, and 9 donors with undetectable viral loads in acute (D0), convalescent (D28) and control 
groups respectively, although all had a positive EBV serology. 
 
Consistent with previous findings (Moormann et al., 2005, Njie et al., 2009) there was a 
significant inverse correlation between EBV genome load and age in the uninfected controls 
and cases during convalescence (Figure 3.6). With the caveat of a small sample size, the 
analysis of these data looking at subgroups of different age ranges (0-7yrs and 8-15yrs) also 
showed no significant differences in EBV genome loads between children with acute (Day 0) 
P. falciparum malaria and age- and sex- matched healthy controls. Likewise, the EBV 
genome loads did not change significantly between D0 and D28 (Figure 3.7). 
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a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
 
Figure 3-5 EBV genome loads during acute uncomplicated P. falciparum malaria infection 
(n = 31), on convalescence in the same donors (n = 24), and from healthy age- and sex- 
matched controls (n = 32).  
The median values, illustrated by the solid black lines, for the groups were 253, 249 and 296 
EBV copies/106 PBMCs respectively. The dashed line represents the lower limit of detection 
for EBV genomes in the assay. Donors below the dashed line had undetectable viral loads 
 
Day 0 Day 28 Healthy Controls 
100
101
102
103
104
105
106
EB
V
 C
op
ies
/1
06
 P
BM
Cs
p = 0.217 a
p = 0.749  b
 88 
 
Spearman correlation co-efficient was calculated excluding values below the limit of detection of the assay.  
 
Figure 3-6 Detectable EBV genome loads declined with age in uninfected controls (A) and 
P. falciparum infected cases at convalescences (B).  
 
 
 
a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
Figure 3-7 EBV genome loads during acute uncomplicated P. falciparum malaria 
infection, on convalescence in the same donors, and from healthy age- and sex- matched 
controls in children age 0-7years (A) and 8-15years (B).  
The solid black lines illustrate the median values and the dashed line represents the lower 
limit of detection for EBV genomes in the assay.  
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3.3.4  EBV-specific T-cell IFN-#  ELISPOT responses to lytic and latent CD8+ 
restricted epitopes did not significantly change during acute uncomplicated P.falciparum 
infection  
Of the of case and control donors assessed respectively, 84% and 81% had appropriate HLA 
types for the EBV lytic and latent epitope peptide pools screened. For the EBV lytic peptide 
pools there were 7 (29%), 7 (30%) and 8 (31%) non-responders in the acute (Day 0), 
convalescent (Day 28) and control groups, respectively. Numbers of non-responders were of a 
similar magnitude for the EBV latent epitope peptide pool, being 6 (25%), 9 (39%) and 8 
(31%) for acute (Day 0), convalescent (Day 28) and control groups, respectively. Background 
values were of a similar magnitude in all groups, with medians of 15 SFU/106 PBMCs in Day 
0, 28 and control groups. Consistent with the observations made for viral loads, EBV-specific 
IFN-# ELISPOT counts did not differ between children with acute (Day 0) P. falciparum 
malaria and age- and sex- matched healthy controls to both EBV lytic (p=0.6191) and latent 
(p=0.5305) epitope peptide pools. Likewise, there was no significant difference between Day 
0 and Day 28 to both EBV lytic (p=0.5129) and latent (p=0.2808) epitope peptide pools when 
negative values (non-responders) were counted as zero (Figure 3.8; see Methods Section 
2.13). The results did not alter when all non-responders were excluded from the analysis, 
when analysed without deduction of the background values and when analysed taking into 
account the difference in CD8% between Day 0 and Day 28. The CD8% at Day 0 and Day 28 
as measured by flow cytometry was used to calculate the SFU per 106 CD8+ T-cells from the 
values detected for total PBMCs (Figure 3.9).  
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a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
 
Figure 3-8 IFN-!  ELISPOT assays during acute uncomplicated P. falciparum malaria 
infection (n = 27), on convalescence in the same donors (n = 23), and from healthy age- 
and sex- matched controls (n = 32).  
The solid black lines indicate the median responses for each group.  
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a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
 
Figure 3-9 IFN-!  ELISPOT assays during acute uncomplicated P. falciparum malaria 
infection, on convalescence in the same donors, and from healthy age- and sex- matched 
controls with A. non-responders excluded, B. without the background subtracted and C. 
corrected for CD8+ T-cell percentage.  
The solid black lines indicate the median responses for each group.  
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Again with the caveat of a small sample size the analysis of these data looking at subgroups 
of different age ranges (0-7yrs and 8-15yrs) also showed no significant differences in IFN-# 
ELISPOT responses between children with acute (Day 0) P. falciparum malaria and age- and 
sex- matched healthy controls. Likewise, the magnitude of IFN-# ELISPOT responses did not 
change significantly between D0 and D28 (Figure 3.10). 
 
 
a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
 
 
Figure 3-10 IFN-!  ELISPOT assays during acute uncomplicated P. falciparum malaria 
infection, on convalescence in the same donors, and from healthy age- and sex- matched 
controls from children aged 0-7 years (A) and 8-15 years.  
The solid black lines indicate the median responses for each group.  
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3.3.5 EBV-specific responses, detected by use of MHC Class I Tetramers and regression 
assays, did not significantly differ between P. falciparum infected and uninfected 
children 
Consistent with both the viral load and IFN-# ELSPOT data there were no significant 
differences between the percentages of EBV-specific MHC Class I tetramer positive cells 
during acute (Day 0) infection and age- and sex- matched healthy controls (p=0.360). In 
addition no significant difference was seen in tetramer percentage between Day 0 and Day 28 
(p=0.469) (Figure 3.11).  
 
To corroborate these findings regression assays were carried out on cryopreserved PBMCs 
from a subset of acute uncomplicated and severe P. falciparum infected children (n=9) from 
the following malaria season. Briefly, PBMCs were infected with B95.8 strain of EBV and 
seeded in doubling dilutions from 4x104 to 1.2x103 cells per well. In two replicate wells CSA 
was added and parallel cultures of uninfected PBMCs were set up as controls. For details of 
the regression assay see Methods Section 2.4. The strength of regression was expressed as the 
initial cell seeding necessary to give a 50% incidence of regression among replicate wells as 
calculated using the Reed-Muench formula. Consistent with our current EBV genome load, 
IFN-# ELISPOT analysis and MHC Class I Tetramer data, but in contrast to the original 
findings by Whittle et al. (Whittle et al., 1984) we saw no significant loss (p=0.5955) of 
regression during acute (Day 0) P. falciparum malaria. These assays were conducted on 
cryopreserved PBMCs but the magnitude of regressive capacity in acute (D0) P. falciparum 
infected children did not significantly differ from those detected using ex vivo assays on 
healthy control children (p=0.2115, Figure 3.12). 
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a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
 
Figure 3-11 EBV-specific Tetramer analysis of PBMC from acute P. falciparum malaria 
infected, convalescent and control groups  
A. Flow cytometry plots from a representative donor displaying MHC Class I tetramer 
(B*3501 EPL) against CD8 T-cells during acute P.falciparum infection (left) and on 
convalescence (right), B. The percentage of EBV MHC Class I tetramer (B*3501 EPL, 
A*0201 GLC, A*0201 CLG or B*0801 RAK) positive CD8+ T-cells in acute uncomplicated 
P.falciparum infection (n=8), on convalescence in the same donors and in age- and sex- 
matched health controls (n=10). C. The kinetics of paired MHC Class I tetramer responses, 
with individual donors at acute infection (Day 0) and on convalescence (Day 28). 
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Figure 3-12 Regression assays performed on PBMCs.  
A. Cryopreserved cells collected during acute (open bars) and convalescent phases (patterned 
bars) of uncomplicated and complicated P. falciparum malaria infection. The last two donors 
are seronegative controls (black bars). B. Ex vivo regression assays performed on freshly 
isolated PBMCs from healthy control children.   
 
3.3.6 Immune activation in P. falciparum infected and uninfected children  
As no differences were seen in T-cell effector responses, next the cell surface phenotype of 
the EBV-specific T-cells was examined for evidence of activation marker expression, in this 
case CD38, in the different donor groups. Furthermore, as polyclonal B-cell activation and 
hypergammaglobulinaemia are recognised as prominent features of malaria (Donati et al., 
2004, Whittle et al., 1990) CD38 expression on B-cells was also examined in the different 
donor groups, a marker of functional maturity on B-cells.  
  
A significantly greater percentage of total CD8+ T-cells (p=0.001), EBV-specific CD8+ T-
cells (p=0.015), and CD19+ B-cells (p=0.019) expressed CD38 at the time of presentation 
with acute P. falciparum malaria (Day 0) compared to samples taken at convalescence (Day 
28) (Figure 3.13). A similar albeit non-significant trend was seen in CD38 expression on 
CD4+ T-cells (p=0.068) (data not shown). 
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a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
 
 
Figure 3-13 CD38 expression is up-regulated on CD8+, EBV-specific MHC Class I 
tetramers and CD19+ cells during acute P.falciparum infection.   
A. Representative examples demonstrating increased CD38 APC MFI on CD8+ T-cells (top 
row), EBV-specific MHC Class I tetramers (middle row) and CD19+ B-cells (bottom row) on 
Day 0 (red), Day 28 (blue) and on unstained PBMCs (solid grey). B. The percentage of CD38 
expressing CD8+, EBV-specific MHC Class I tetramer and CD19+ cells in acute 
uncomplicated P. falciparum malaria infection (red box), on convalescence in the same 
donors (blue box) and in age- and sex- matched healthy Controls (white box). 
A. B. 
100 101 102 103 104
CD38
0
20
40
60
80
100
%
 o
f M
ax
100 101 102 103 104
CD38
0
20
40
60
80
100
%
 o
f M
ax
100 101 102 103 104
CD38
0
20
40
60
80
100
%
 o
f M
ax
Total CD8+T-cells 
EBV-specific CD8+ T-cells 
CD19+ B-cells 
Day 0  
Day 28 
Unstained 
D0 D28 Controls 
0
20
40
60
80
100
p=0.001
1 a
%
 o
f C
D
8+
 T
-c
el
ls 
ex
pr
es
sin
g 
CD
38
D0 D28 Controls 
0
20
40
60
80
100
p=0.019 a
%
 o
f B
-c
el
l e
xp
re
ss
in
g 
CD
38
D0 D28 Controls 
0
20
40
60
80
100
p=0.015 a
%
 o
f E
BV
-s
pe
ci
fic
 C
D
8+
 T
-c
el
ls
 e
xp
re
ss
in
g 
CD
38
 97 
3.3.7 Programmed Death-1 (PD-1) expression in P. falciparum infected and uninfected 
children  
During chronic viral infections the PD-1/ PD-L pathway has been shown to play a major role 
in regulating T-cell exhaustion, a state of T-cell dysfunction defined by poor effector function 
transcriptionally distinct from functional effector or memory T-cells (Wherry, 2011, 
Blackburn et al., 2010). Cells expressing this exhausted phenotype are thought to prevent 
optimal control of infections and tumours. Acute malaria has been shown to have an 
immunosuppressive effect (Enwere et al., 1999, Kalmbach et al., 2009, Riley et al., 1989a, 
Riley et al., 1989b), with increased incidence of specific tumours such as eBL in populations 
experiencing holoendemic malaria exposure (Rochford et al., 2005). The phenotype of the 
cells in these study groups was further examined to determine whether PD-1 expression 
altered during acute P. falciparum malaria infection. Both cellular and humoral immunity are 
thought to play important roles in the immune response to malaria (Beeson et al., 2008) 
therefore surface expression of PD-1 was looked at on both T- and B-cells in the different 
donor groups.  
 
During acute P. falciparum infection the percentage of PD-1 expressing CD19+ B-cells 
(p=0.04) and CD4+ T-cells (p=0.0085) was significantly higher than in convalescent samples 
(Figure 3.14). This trend remains when results are expressed based on absolute numbers of 
CD19+ B-cells or CD4+ T-cells (Figure 3.14). During acute P. falciparum malaria infection 
numbers of PD-1 expressing CD19+ B-cells (p=<0.0001) and CD4+ T-cells (p<0.001) were 
significantly higher than in healthy controls and during convalescence this number remained 
significantly higher than seen in the controls. A similar albeit non-significant trend was seen 
in PD-1 expression on CD8+ T-cells (p=0.064) (data not shown).  
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Figure 3-14 Programmed Death-1 (PD-1) expression is up-regulated on CD4+ and CD19+ 
cells during acute P. falciparum infection in children.   
A. Flow cytometry plots demonstrating increased expression of PD-1 on CD4+ T-cells (top 
row) and CD19+ cells (bottom row) on Day 0 (red) compared to Day 28 (blue) and on 
unstained PBMCs (solid grey). B. The percentage of PD-1 expressing, CD4+ and CD19+ 
cells in acute uncomplicated P. falciparum malaria infection (red box), on convalescence in 
the same donors (blue box) and in age- and sex- matched healthy controls (white box). C. The 
absolute number of PD-1 expressing, CD4+ and CD19+ cells in acute uncomplicated P. 
falciparum malaria infection (red box), on convalescence in the same donors (blue box) and 
in age- and sex- matched healthy controls (white box). All gates were set using appropriate 
isotype controls. 
 
a P value calculated using Wilcoxon rank statistical comparison of matched pairs.  
b P value calculated using the Mann-Whitney U comparison of unpaired data.  
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PD-1 has however also been shown to be a marker of activation and differentiation (Sauce et 
al., 2007). Therefore I looked to see if PD-1 expression correlated with CD38 expression on 
T- and B-cells. I found that during acute disease (D0) both the percentage and MFI of CD38 
expression significantly correlated with PD-1 expression on CD8+ T-cells (Spearman’s 
correlation coefficient R2=0.502, p=0.029 and R2=0.51, p=0.017 respectively, Figure 3.15) 
and also on CD4+ T-cells (Spearman’s correlations coefficient R2=0.488, p=0.040 and 
R2=0.66, p=0.003 respectively). This supports the hypothesis that PD-1 expression is 
associated with cellular activation and is not purely a marker of functional exhaustion in these 
cells. However, this was not found to be the case for CD19+ cells (Spearman’s correlation 
R2=0.4298, and p=0.0663), data not shown. 
 
 100 
 
 
Figure 3-15 PD-1 expression correlates with CD38 expression during acute (Day 0) 
uncomplicated P. falciparum infection.  
PD-1 expression is shown on the y-axis and CD38 expression on the x-axis, each dot 
represents a single donor during acute (Day 0) uncomplicated P. falciparum malaria. There 
is a significant correlation between the percentage of CD38 and PD-1 expression  (left) as 
well as the MFI for CD38 and PD-1 (right) on A. CD8+ T-cells and B. CD4+ T-cells.  
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3.4 Discussion  
This work directly assesses the effect of acute P. falciparum infection on the number and 
function of EBV-specific CD8+ T-cells ex vivo, in parallel with viral genome loads and 
traditional cell culture-based techniques measuring T-cell mediated regression of outgrowth 
of autologous EBV transformed B-cells. This study demonstrates that the effect of acute P. 
falciparum infection on cellular immune responses to EBV in The Gambia differs from earlier 
reports (Njie et al., 2009, Whittle et al., 1984). Now, children with acute uncomplicated 
P.falciparum malaria experience no elevation in EBV genome load in PBMCs compared to 
age- and sex-matched healthy controls, nor do they have any evidence of reduced numbers or 
functional impairment of their EBV-specific CD8+ T-cells. These different findings may be 
due to a recent decline in chronic exposure to malaria in infancy and early childhood in The 
Gambia (Ceesay et al., 2008, Ceesay et al., 2010).  
 
Primary EBV infection, like CMV infection occurs in early childhood in The Gambia (Miles 
et al., 2007) and more recent data indicates that the age of EBV seroconversion continues to 
be low with 87% of children between 14 and 18mths of age in The Gambia being EBV 
seropositive in 2010 (S. Jayasooriya, unpublished data). This is in contrast to recent data from 
Balfour et al. who found that only 63% of college entrants screened in the USA were EBV 
seropositive leaving 37% still remaining EBV naïve (Balfour et al., 2013).  
 
Loss of regression of EBV-infected B-cell outgrowth during acute malaria was first 
demonstrated in Gambian children over 25 years ago (Whittle et al., 1984), at a time when the 
entomological inoculation rate in the country was several fold higher than the current day 
(Finney et al., 2009, Thomson et al., 1994). Furthermore, work conducted in 2003, Njie et al. 
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detected high EBV loads from PBMCs from Gambian children in the throes of acute malaria. 
Interestingly these did not fall in convalescent samples taken six weeks later but remained 
significantly higher than those detected in a cohort of healthy control children, albeit not 
matched for age- or sex in that report. In the present study, the EBV genome loads (using the 
same assay as Njie et al.) from malaria cases, both in acute and convalescent samples, are 
lower and not significantly different from those of age- and sex- matched controls, although 
they remain significantly higher than the range typically seen for healthy virus carriers in the 
UK population (Njie et al., 2009). Notably, there has been a considerable fall in malaria 
exposure in The Gambia from 2003 onwards (Ceesay et al., 2008, Ceesay et al., 2010). The 
likely difference in malaria exposure between the cohorts used by Whittle et al. and Njie et al. 
and the current study is highlighted by the dramatic change in entomological inoculation rates 
from Brefet, a rural community where part of the current study was based:  3.21 in 1991 to 
0.62 in 2006 (Finney et al., 2009, Thomson et al., 1994). It therefore seems possible that at the 
time of these earlier studies the life-long history of P. falciparum infection in childhood was 
still sufficiently chronic/recurrent as to render the EBV-host virus balance susceptible to 
modulation during a renewed bout of acute malaria.  By contrast, given the recent decline in 
malaria incidence and increasing peak age of P. falciparum related hospital admissions in The 
Gambia (Ceesay et al., 2008, Ceesay et al., 2010), it is plausible that most of our cases were 
experiencing a primary P. falciparum infection. Taken together, this suggests that a single, 
primary P. falciparum infection is not sufficient to impair immunological control of EBV 
infection.  
 
The work by Moormann et al., who studied two cohorts with differential malaria exposure in 
the Kisumu and Nandi areas of Western Kenya, is relevant here. They noted higher EBV 
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genome loads in children, one to four years of age, living in areas holoendemic for malaria, 
compared to those only sporadically exposed (Moormann et al., 2005). This is consistent with 
our data and supports the idea that chronic repeated exposure to malaria throughout a child’s 
early years is required to alter the EBV-host balance, leading to high EBV loads and a greater 
likelihood of further increases linked to acute malarial episodes. To investigate this further 
would require following up children living in a holoendemic area from birth, to capture their 
first and subsequent malaria episodes, and to longitudinally examine EBV-specific immune 
responses and EBV viral loads.  
 
When functionality of EBV-specific CD8+ T-cells was measured by IFN-# ELISPOT, no 
significant differences between malaria cases, in acute stage or convalescence, and age- and 
sex- matched healthy controls were observed. Moormann et al. studying Kenyan children 
found that fewer children between five and nine years of age responded to pools of EBV 
peptides when coming from an area of high rather than sporadic malaria transmission. They 
have also suggested that the loss of responses is to EBV lytic but not latent antigens 
(Moormann et al., 2007, Snider et al., 2012). More recently they have demonstrated no 
differences in EBV-specific CD8+ T-cell frequencies between both cohorts of children, but 
children living in regions with holoendemic malaria exposure had more differentiated EBV-
specific CD8+ T-cell populations than those in sporadically exposed areas (Chattopadhyay et 
al., 2013). Importantly this phenotypic variation was not detected in CMV-specific CD8+ T-
cells nor in the total CD8+ T-cell population. The fact that bed net programmes target 0-5 year 
old children and that malaria prevalence in The Gambia peaks in children above this age (16 
years) make it conceivable that the most pronounced difference is detected in children above 
this age group (Satoguina et al., 2009). Of additional interest, despite a preservation of EBV-
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specific CD8+ T-cell responses, we find that PD-1, a marker reported to signify cellular 
exhaustion, is significantly up-regulated in acute malaria and does not decline to control 
levels by day 28. However, PD-1 expression significantly correlates with CD38 expression on 
CD4+ and CD8+ T-cells, which supports recent findings in HIV that PD-1 is not purely a 
marker of cell exhaustion (Sauce et al., 2007) and reflects recent activation.  
 
The work in this Chapter has limitations that are worth discussion. Although previously 
reported data suggest a dramatic decline in malaria exposure in the country as a whole, the 
study design precludes exact knowledge of the exposure history of the study participants. 
However, of note 95% of three year old children followed up longitudinally in a birth cohort 
adjacent to our study’s catchment area had no serological evidence of malaria exposure 
(Ceesay et al., 2008), and a cohort study conducted in Brefet in the 2009 transmission season 
only identified one clinical case of malaria (Nogaro et al., 2011). In addition to this we found 
that only 24% of control children, mean age 7 years (range 1.5-16 years), were MSP-1(19) 
seropositive (Figure 3.2). This is lower than previously quoted figures (30%, 0-7 years and 
46%, 8-10 years) (Corran et al., 2004). Recent publications from The Gambia from differing 
peri-urban sites also confirm this decline (Satoguina et al., 2009), with one study 
demonstrating only a 4% seropositivity to MSP-1(19) in 0 to 14 years olds in 2009 (Ceesay et 
al., 2010). 
 
Previous case-control studies have demonstrated that acute malaria infection can alter EBV 
host balance leading to an increase in EBV genome loads (Donati et al., 2006, Rasti et al., 
2005, Yone et al., 2006). The cross-sectional cohort studies conducted by Moormann et al. 
indicate that chronic malaria infection also plays a role in tipping the balance in favour of the 
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virus (Moormann et al., 2005, Moormann et al., 2007, Snider et al., 2012). Our findings 
suggest that there is no impairment of EBV immunity during an acute P. falciparum malaria 
infection and therefore suggest that alteration in EBV host balance is likely to be dependent 
on cumulative prior infections. A further longitudinal study of primary and cumulative acute 
P. falciparum infections and their impact on EBV host balance would be required to test this 
hypothesis.  
 
Our findings, however, have more general implications adding to the mounting evidence that 
the decline in malaria seen in some parts of sub-Saharan Africa have wider implications than 
a reduction in morbidity and mortality from malaria alone. Additional changes have been seen 
in the rates of invasive bacterial diseases such as non-typhoidal salmonella in The Gambia 
(Mackenzie et al., 2010, Obaro and Greenwood, 2011), and all cause mortality in children 
within regions where a reduction in malaria has been demonstrated (Snow and Marsh, 2010). 
Data to establish whether our observation translates into a reduced incidence of eBL in The 
Gambia are needed. 
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CHAPTER 4 : PHENOTYPIC AND FUNCTIONAL CONSEQUENCES OF EPSTEIN-
BARR VIRUS INFECTION IN INFANCY 
 
4.1 Introduction  
EBV is a ubiquitous gamma herpesvirus associated with occasional severe primary infections, 
several malignancies and significant pathology in immunosuppressed hosts, but it does not 
cause significant morbidity in the majority of those infected. In The Gambia most people are 
infected in infancy in contrast to most developed countries where the majority of primary 
infections occur at a much later stage, often in adolescence (Biggar et al., 1978a, Hislop et al., 
2007b). Paradoxically it is estimated that about a quarter of those infected in adolescence will 
develop a sometimes-severe disease, AIM, whereas those infected in infancy tend to have 
minor self-limiting illnesses that often go undetected.  Persistent EBV infection is associated 
with malignancies, BL, NPC and a subset of Hodgkin lymphomas. The former is found to be 
endemic in the malaria belt in Africa peaking in children 5-7years of age. A likely factor 
contributing to the aetiology of eBL is early primary EBV infection alongside high levels of 
malaria exposure (Rochford et al., 2005). In addition the low age of EBV seroconversion is 
thought to play a significant role in increasing the risk of developing subsequent B-cell 
malignancies (Chabay and Preciado, 2012). 
 
In contrast to a paucity of studies of EBV infections in infancy and childhood, many studies 
in adults have characterised cellular immune responses, both to CD8+ and to a lesser extent 
CD4+ T-cells, in vivo during primary infections (AIM) (Amyes et al., 2003, Callan et al., 
1996, Callan et al., 1998b, Catalina et al., 2001, Faint et al., 2001, Hislop et al., 2002, Hislop 
et al., 2001, Hislop et al., 2005, Hoshino et al., 1999, Long et al., 2005, Long et al., 2011, 
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Mautner and Bornkamm, 2012, Pudney et al., 2005, Steven et al., 1997, Steven et al., 1996, 
Woodberry et al., 2005). There are unusually large numbers of CD8+ T-cells during AIM 
(Callan et al., 1998b). Lytic epitope responses seen in AIM can account for 1-40% of the total 
CD8+ T-Cell population. Responses to IE and E proteins of the lytic cycle usually dominate. 
The latent cycle protein responses tend to be smaller accounting for only 0.1-5% of the CD8+ 
T-Cell population. These usually focus on the family of EBNA proteins, 3A, 3B and 3C.  
These CD8+ T-cells have been well described in adults and display a phenotype consistent 
with recent antigen stimulation. They are perforin positive with direct ex vivo cytotoxic 
function (Callan et al., 2000, Steven et al., 1997, Steven et al., 1996), express activation 
marker CD38 and cell cycling maker Ki-67 (Callan et al., 2000, Catalina et al., 2001, Hislop 
et al., 2002, Hislop et al., 2005). These cells die rapidly in vitro unless given an antigen 
stimulus, expressing high levels of pro-apoptotic protein Bax and low levels of the anti-
apoptotic bcl-2 (Callan et al., 2000, Dunne et al., 2002, Tamaru et al., 1993). Consistent with 
this, CD8+ T-cells are rapidly culled in the weeks post infection, lytic responses more heavily 
than latent. It is therefore not surprising that quantitative changes are seen in the dominance of 
lytic and latent epitope responses with the picture seen during persistent infection often 
varying greatly from that of AIM (Hislop et al., 2002, Woodberry et al., 2005). The CD4+ T-
cell pool is not greatly expanded in AIM, but as with the greater CD8+ T-cell responses, there 
is a rapid peak and then decline of EBV-specific CD4+ T-cells within weeks (Callan, 2003, 
Hislop et al., 2007b, Precopio et al., 2003). EBV-specific CD4+ T-cells have been less well 
characterised in view of the relative lack of well-defined epitopes and the difficulties 
surrounding HLA class II tetramer manufacture. 
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Immune responses in adult healthy carriers with persistent infection and no history of AIM 
have been described (Amyes et al., 2003, Hislop et al., 2001, Hislop et al., 2007b, Tan et al., 
1999). Asymptomatic virus carriers maintain T-cell memory both to latent and lytic cycle 
antigens. With respect to latent antigen responses, CD8+ T-cells specific for known EBV 
epitopes are relatively common (ranging from 0.05-1% of CD8+ T-cells in the blood) and are 
typically ten-fold more numerous than their CD4+ counterparts. CD8+ T-cells specific for 
lytic cycle antigens are generally even higher (0.2-2%), while the CD4+ lytic antigen 
response is less well studied but again appears to be less numerous than the CD8+ response. 
(Hislop et al., 2007b, Leen et al., 2001, Long et al., 2005) The CD8+ memory T-cells tend to 
display a resting phenotype, lacking activation markers and expressing much higher levels of 
bcl-2 than AIM T-cells. There are however some which still express perforin and are 
cytotoxic. (Callan et al., 1998b, Catalina et al., 2002, Dunne et al., 2002, Faint et al., 2001, 
Hislop et al., 2001) 
 
There is a paucity of data in the literature looking at asymptomatic primary infections largely 
due to the difficulty in identifying donors without any clinical symptoms undergoing a 
primary EBV infection. Four patients undergoing silent seroconversion were incidentally 
identified within a vaccine trial and found not to have the massive T-cell expansions seen in 
AIM, but in contrast maintained homeostatic T-cell control, despite having high EBV genome 
loads in the blood equivalent to those seen in AIM. There is less known about the 
immunological and virological response to EBV infection when it occurs in infancy except 
that it has been shown to occur without significant lymphocytosis and with reduced and 
delayed viral antibody responses (Fleisher et al., 1979). One previous study conducted by a 
group at the University of Massachusetts looked at responses in nine children indirectly 
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assessing cytotoxic T lymphocyte (CTL) responses using recombinant vaccinia constructs 
expressing single latent genes only (Tamaki et al., 1995). With the caveat of the sample size, 
they demonstrated that all children had CTL responses against one or more of the EBNA 
proteins 3A, 3B and 3C, similar to the latent responses reported for adults.   
 
The impact that early EBV infection might subsequently have on immune function has again 
been little explored. Recent work by Miles et al. on infants in The Gambia looked at CMV 
infection, another member of the herpes virus family, demonstrating a profound effect on the 
CD8+ T-cell compartment with an increase in the proportion and absolute number of 
differentiated CD8+ T-cells (Miles et al., 2008b, Miles et al., 2008c). The CD4+ T-cell 
compartment was also affected but less dramatically with only a small increase in cells 
expressing a highly differentiated phenotype, and little change in the total CD4+ T-cell 
frequencies (Miles et al., 2008a). Whether EBV has any effect on the CD8+ T-cell 
compartment and how this might interact with what is know about early CMV infection is not 
known.  
 
This chapter represents a detailed study of EBV-specific T-cell responses from a cohort of 
120 children followed longitudinally and describes cellular immune responses in Gambian 
children having undergone recent primary EBV infections and also captures six children 
undergoing silent seroconversion.  It provides a comprehensive analysis of EBV-specific 
CD8+ T-cells in these children, including a description of the immunodominant responses 
seen to a broad range of lytic and latent EBV antigens, viral genome loads and detailed ex 
vivo phenotypic analysis of both total and EBV-specific CD8+ T-cells. 
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4.2 Methods  
4.2.1 Study Design and Donors  
Gambian children (n=120), aged between 14 and 18 months, were initially recruited into the 
study cohort from the MRC Sukuta field site when they were attending for their routine DTP 
vaccination booster. They were invited to participate by field-workers who obtained informed 
consent from their mothers in their local languages. Ethical approval was obtained from the 
Scientific Coordinating committee, MRC Gambia, and local Gambian government ethics 
committee. Children underwent a clinical assessment prior to enrolment into the study and 
were excluded if their weight was below the normal expected range for their age as indicated 
on their Infant Welfare Growth Chart or had abnormal findings, such as a fever or signs and 
symptoms were detected during clinical assessment. Children were followed up at weekly 
intervals for the first three visits, with a fourth visit conducted six months after the third 
(Figure 4.1).  Study recruitment continued from June 2010 until April 2011.  
 
Study participants were allocated ID numbers and a card detailing this number enabling us to 
identify them and allowing them to access the clinical services provided by the MRC at the 
Sukuta field site for the duration of the study. Chapter 2, sections 2.1 and 2.2 details samples 
taken and processing.  
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Figure 4-1 Study timeline.  
 
4.2.2 Rapid Malaria Test (RMT)  
When clinically indicated, children were tested with rapid malaria tests (OptiMAL-IT) which 
detect parasite lactate dehydrogenase (pLDH)). If positive children were then transported to 
the clinical services at MRC Fajara for further treatment as indicated.  
 
4.2.3 Cellular immunological Assays 
Ex-vivo screening IFN-& ELISPOT responses of thawed PBMCs to 21 peptide pools 
combining 63 latent and 43 lytic-cycle antigens covering a broad range of HLA types were 
performed. Laboratory and flow cytometry methods and analysis are detailed in Chapter 2, 
sections 2.8, 2.13-2.17. 
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4.3 Results  
4.3.1 Demographics and categorisation of study population  
As Figure 4.1 illustrates 120 children between the ages of 14 and 18 months were enrolled 
into the study at baseline. Of these, 99 (83%) children remained in the study until completion 
at the six-month time point. Table 4.1 illustrates that the children who did not continue to 
participate in the study did not significantly differ in age, sex, weight, haemoglobin, leucocyte 
and lymphocytes counts, from those who continued to participate.  
 
Only one child at enrolment screening was found to be malaria parasite positive by rapid 
testing following their initial clinical assessment prior to consent. They were not enrolled into 
the study and received appropriate treatment as per current guidelines from the MRC Clinical 
Services. 
 
Table 4-1 Age, sex, haemoglobin, weight and cell counts in study participants and dropouts.  
Baseline 
Characteristics 
Study Participants 
(n=99) 
Drop outs 
 (n=21) 
P valuea 
Age  
(mths) 
15  
(14 – 17) 
15  
(14 – 16.50) 
0.79 
Sex 
(F: M) 
1:1.5 1:2 - 
EBV negatives  
 
13 (13%) 7 (33%) - 
Weight (kg) 
 
9.52  
(8.90-10.24) 
9.28  
(8.85 -9.65) 
0.14 
Haemoglobin (g/dl) 
 
10.10 
(9.28-11.00) 
9.8 
(8.18-11.03) 
0.40 
Leucocyte Count 
(x109/L) 
10.90 
(8.85-12.63) 
11.40 
(10.35-13.48) 
0.15 
Lymphocyte (%) 
 
56.85 
(49.80-63.33) 
61.90 
(50.03-65.35) 
0.18 
Median values are stated and inter-quartile ranges are shown in brackets 
a  p value calculated using Mann-Whitney U statistical comparison of unpaired data 
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In order to determine the EBV serological status of the 120 study participants they were 
screened using IgG and IgM VCA immunofluorescence assays (Methods section 2.8.1). For 
simplicity children are referred to in the groups determined by their serological status. There 
were six children for whom the results were ambiguous, since they were serologically 
negative but with detectable EBV viral genome loads (median 4500, range 363-12300). It is 
possible that these could represent very early infections and consistent with this they all 
become IgM'IgG+ by the visit four-time point, however they could have seroconverted at 
any time over the six-month follow-up period. Three of these donors had sufficient cell 
numbers that enabled them to be screened using the IFN-& ELISPOT assays (Methods section 
2.12), and no responses were detected at visit one. As the status of these six children could not 
be confidently resolved they were conservatively excluded from further analysis reducing the 
usable number enrolled to 114.  
 
At visit one 71 (62%) children were classified as EBV infected with IgM'IgG+ serological 
responses (Table 4.2).  From previous studies conducted at the Sukuta field site it is known 
that by nine months of age only 24% of children are EBV infected (David Miles, Personal 
Communication) one can therefore assume that most had been infected within the last 6-12 
months.  There were three (2.6%) children that were IgM+IgG '/+ and 40 (35%) children that 
were IgM'IgG' with confirmatory undetectable viral loads at visit one. At the visit four-time 
point, of the 40 previously IgM'IgG' visit one donors, 18 (45%) became IgM'IgG+, two 
(5%) became IgM+IgG+, 13 (33%) remained IgM'IgG' and seven dropped out. The three 
children that were IgM+IgG '/+ at visit one had become IgM'IgG+ by visit four. 
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Table 4-2 Serological status of study participants at baseline (visit one) and six months later 
(visit four).  
 
Serological Status  
 
Visit one  
(n=114) 
Visit four  
(n=93) 
IgM'IgG– 
 
40 (35%) a 13 (14%) 
IgM+IgG' 
 
2 (2%) b 0 
IgM+IgG+ 1 (1%) b 
 
2 (2%) 
IgM'IgG+ 71 (62%) c 78 (84%) 
Number of children stated, percentage of total population given in brackets.  
Shaded cells indicate children considered EBV infected and no shading those that are EBV negatives 
 
a Out of the 40 IgM!IgG! children at visit one 13 remained seronegative, two became 
   IgM+IgG + 18 became IgM!IgG + and seven dropped out  
b All three IgM+IgG !/+ donors at visit one became IgM!IgG + 
c Out of the 71 IgM!IgG+ donors at visit one 14 dropped out 
 
4.3.2 Size of lymphocyte populations in the blood of IgM!IgG+ children compared to 
IgM!IgG! children 
The overall leucocyte counts did not differ between the IgM'IgG+ and IgM'IgG' children 
with medians of 11.30 x 109/L (range 5.8-21.90) and 10.50 x 109/L (range 6.9-17.70) 
respectively, being of a similar order to the overall counts seen in the total cohort, see Table 
4.1. Lymphocyte populations in children found to be IgM'IgG+ at the visit one time point, 
i.e. those assumed to have acquired EBV within the last six months to a year were examined 
and compared to the subsets found in IgM'IgG' children. Figure 4.2 demonstrates that the 
total absolute CD4+, CD8+ and CD19+ cell counts did not significantly differ between 
IgM'IgG+ and IgM'IgG' Gambian children. For five IgM'IgG' children and one 
IgM'IgG+ there was no white cell count available. There was one donor with a very high B-
cell count and percentage, they were serologically positive with an undetectable viral load and 
did not have an expansion in their memory B-cell population. Although the median absolute 
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number of CD19+ CD27+ memory B-cells also did not significantly differ, expansion of this 
population’s cell number was only seen in some IgM'IgG + children.  
 
 
 
Figure 4-2 Size of Gambian children lymphocyte populations in the blood of 
 IgM!IgG ! (n=35) compared to IgM!IgG + children (n=70). 
 
4.3.3 EBV genome loads in PBMCs 
The EBV viral genome loads at visit one and six months later at visit four were compared in 
Gambian children found to be IgM'IgG+. Figure 4.3 demonstrates that there was a spread of 
values with a median of 3607 copies per 106 PBMCs at visit one, which dropped a significant 
7-fold by visit four to a median of 505 copies per 106 PBMCs (p<0.001). The fact that the 
IgM'IgG+ children had high EBV genome loads at visit one, which subsequently dropped 
over the following six months, supports the premise that these children are likely to have 
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undergone recent primary infections within the last six months to a year.  The EBV genome 
loads seen at the six-month time point were equivalent to those previously described in 
healthy Gambian children by Njie et al. albeit from older children, aged three to fourteen 
years of age (Njie et al., 2009).  
  
These EBV genome loads were compared to donors from the United Kingdom, both in long-
term carriers and those with a diagnosis of AIM. EBV genome loads in Gambian children 
who were IgM'IgG+ were significantly higher than those seen in UK medical students (18-
25yrs). The IgM'IgG+ Gambian children for whom EBV genome loads were repeated after a 
six month time period remained significantly higher than UK medical students (18-25yrs) 
(UK medical student viral genome loads kindly provided by A. Pachnio performed using the 
same viral genome assay used in this study at the University of Birmingham Institute for 
Cancer Studies). The EBV genome loads in IgM'IgG+ Gambian children did not 
significantly differ from those seen in UK donors with AIM (AIM viral genome loads kindly 
provided by Dr. A. Hislop performed using the same viral genome assay used in this study at 
the University of Birmingham Institute for Cancer Studies)  (Figure 4.3).  
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P values calculated using Dunn’s Multiple Comparison Test (one way analysis of variance 
(ANOVA)). ** P<0.01 *** P<0.001 
 
 
Figure 4-3 EBV genome loads at visit one (n = 70) and at visit four after six months (n=58) 
in IgM!IgG+ Gambian children, adolescent Caucasian medical students (n=94), and 
Caucasian adults with acute infectious mononucleosis (AIM) (n=6).  
The dashed line represents the lower limit of detection for EBV genomes in the assay. Donors 
below the dashed line had undetectable viral loads.   
 
 
In view of current literature demonstrating the significant impact of early CMV infection on 
the CD8+ T-cell compartment (Miles et al., 2008b, Miles et al., 2008c) the CMV status of all 
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CMV seropositive. This is consistent with D. Miles et al. data that demonstrated CMV 
infection in 85% of his infant cohort at 18mths of age in The Gambia (Miles et al., 2008b). 
EBV viral genome loads in the majority CMV positive versus CMV negative Gambian 
children were compared, excluding those children classified as IgM'IgG' (n=40). Figure 4.4 
shows no significant difference in EBV genome loads between the two CMV groups.   
 
 
P value calculated using the Mann-Whitney U comparison of unpaired data. 
 
Figure 4-4 EBV genome loads at visit one according to CMV status.  
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4.3.4 CD8+ T-cell subset distributions in IgM!IgG+ children compared to IgM!IgG! 
children 
The phenotype of the total CD8+ T-cells of IgM'IgG+ donors was assessed using ex vivo 
flow cytometry staining at visit one. Cells stained for the co-stimulatory molecules CD27 and 
CD28 were divided into early (CD27+ CD28+), intermediate (CD27+ CD28'), and fully 
differentiated (CD27' CD28') to determine the differentiation status of the total CD8+ T-cell 
population (Appay et al., 2002a, Hamann et al., 1999, van Lier et al., 2003). Figure 4.5A 
demonstrates representative flow plots for IgM'IgG ' and IgM'IgG+ donors illustrating that 
the ‘intermediately differentiated’ subset (CD27+ CD28') of total CD8+ T-cells was 
significantly larger in the IgM'IgG+ group compared to those who were IgM'IgG ' (Figure 
4.5B) and as a consequence the early differentiation  (CD27+ CD28+) subset was lower in the 
IgM'IgG+ group. 
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Percentages of total CD8+ population given in top right-hand corner of plots. 
Figure 4-5 CD27 and CD28 co-staining on IgM!IgG ! and IgM!IgG+ children. 
 A. Representative flow cytometry plots demonstrating CD27 and CD28 co-staining of CD8+ 
T-cells from an IgM!IgG! (left) and IgM!IgG+ (right) Gambian child. B. Differentiation 
status of total CD8+ T-cell populations in IgM!IgG! and IgM!IgG+ Gambian children 
displaying percentage of total CD8+T-cells expressing early (CD27+CD28+), intermediate 
(CD27+CD28+), and fully differentiated (CD27+CD28+) phenotypes.  
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A potential confounder here is CMV infection. Miles et al. has shown that CMV infected 
Gambian infants have more terminally differentiated total CD8+ T-cells than uninfected 
infants. As previously mentioned CMV status was determined at visit one on all Gambian 
children in this study. Table 4.3 illustrates both combined CMV and EBV status on all of the 
children in the study. The majority of children (56%) were found to be dually CMV and EBV 
infected. 
 
A previous study shows that Gambian children in the study site of Sukuta, tend to be infected 
earlier with CMV than with EBV, 66% and 18% of children were CMV and EBV infected 
respectively at nine months of age (Holder et al., 2010). CD8+ T-cell differentiation status 
was therefore assessed according to EBV and CMV status in the following groups, 
CMV'EBV', CMV+EBV', CMV'EBV+ and CMV+EBV+, to determine the effect of single 
and co-infection with CMV and EBV on CD8+ T-cell differentiation status (Figure 4.6). 
Consistent with previous findings (Miles et al., 2007), CMV infection alone significantly 
reduces the percentage of ‘early differentiated’ CD8+ T-cells and increases the percentage of 
fully differentiated CD8+ T-cells. With the caveat of a small sample size, there is a non-
significant decline in the percentage of ‘early differentiated’ CD8+ T-cells and increase in the 
percentage of ‘intermediately differentiated’ CD8+ T-cells in the EBV infected CMV negative 
donors compared to non-infected donors. The differentiation phenotype of co-infected 
Gambian children’s total CD8+ T-cells mirrored that of solitary CMV infection. 
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Table 4-3 Two-way table illustrating EBV and CMV status of Gambian children aged 14-
18mths at visit one (Day 0).  
 CMV infected  
 
CMV 
uninfected  
Total  
EBV infected  
  
64 (56%) 10 (9%) 74 (65%) 
EBV uninfected   32 (28%) 8 (7%) 40 (35%) 
 
Total  96 (84%)  18 (16%) 114 
 
Number of children stated, percentage of total population given in brackets.  
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P values calculated using Dunn’s Multiple Comparison Test (one way analysis of variance 
(ANOVA)). * p<0.05 ** P<0.01 *** P<0.001 
 
Percentages of total CD8+ T-cell population given in top right-hand corner of plots. 
 
Figure 4-6 CD8+ T-cell differentiation determined by CD27 and CD28 co-staining in 
CMV!EBV!, CMV+EBV!, CMV!EBV+ and CMV+EBV+ (left to right) children. 
Values indicated percentage of total CD8+ T-cells expressing early (CD27+CD28+), 
intermediate (CD27+CD28!), and fully differentiated (CD27+CD28+) phenotypes. Below 
are representative flow cytometry plots from individual donors of CD27 (y-axis) and CD28 (x-
axis) co-staining of the total CD8+ T-cell populations in CMV!EBV!, CMV+EBV!, 
CMV!EBV+ and CMV+EBV+  (left to right) Gambian children.  
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4.3.5 Interferon gamma (IFN-") responses to EBV lytic and latent-cycle antigens in 
Gambian children 
Next, identifying and measuring the size of the responses to immunodominant epitopes 
examined the impact of EBV infection in childhood on the CD8+ T-cell response to this 
virus. In order to describe the immunodominant responses in Gambian infants, IFN-& 
ELISPOT assays were performed using 21 peptide pools of between 10 and 11 individual 
peptides combining 63 latent and 43 lytic-cycle epitopes, covering a broad range of HLA 
types (Methods section 2.12, Tables 2.4 and 2.5). Briefly a two dimensional matrix was 
constructed using the 21 pools, with each peptide appearing in two pools only. Deconvolution 
of the matrix enabled identification of the individual peptide that the donor was likely to be 
responding to. The pools contained peptides from only one protein whenever practically 
possible. Where this was not the case responses have been expressed as coming from either 
protein. Although the assays were conducted with PBMCs, the peptides used focused on 
known CD8+ T-cell epitopes including those restricted through relevant Gambian alleles, 
A*0201, B*0801, B*3501, B*5301 and B*5801, as previously reported ((Allsopp et al., 
1992) Louis Marie Yindom, unpublished data). The cell numbers acquired from these 
children were limited and therefore CD4+ T-cell depletion was not practical. Responses were 
regarded as positive if they were if >3 times the mean of the quadruplicate negative control 
wells on the plate and !50 SFU/106 PBMCs. If the negative background wells had !30 
SFU/106 or the positive control wells were negative the assay would have been classified as 
‘failed’, although this was not the case for any of the donors screened (Methods Section 2.12).   
 
Work on adult Caucasian donors has identified a range of CD8+ T-cell restricted epitopes. 
The lytic antigen responses tend to be focused on IE and E proteins of which there are 13, 8, 4 
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and 6 peptides included to BRLF1, BZLF1, BMLF1 and BMRF1 proteins respectively. The L 
lytic cycle expressed antigens generally induce weak responses but five L proteins with 1-4 
epitopes per protein have been included in this panel. For the latent antigens, strong responses 
are detected to the EBNA3A, 3B and 3C proteins of which between 8 and 14 peptides are 
included in the panel for each protein. LMP-2 is generally a sub-dominant antigen, but 
contains many epitopes, which were included in the panel. LMP-1 is a poorly recognised 
target of which six epitopes were included. This pattern of immunodominance has been 
demonstrated in adult Caucasian donors. It is not known what children in the setting of The 
Gambia will predominantly respond to.  
 
Out of the 114 children enrolled in the study 96 (84%) children at the visit one time point had 
sufficient cell numbers to perform IFN-& ELISPOT assays. Of these, 58 (60%) were 
IgM'IgG+ and 38 (40%) IgM'IgG ' donors, these were included as controls. As expected all 
IgM'IgG ' donors produced no IFN-& in response to EBV peptide pools in the ELISPOT 
assay. There were 38 (66%) out of the 58 IgM'IgG+ children screened that produced an IFN-
& response to at least two EBV peptide pools in the matrix (corresponding to one peptide), and 
20 (34%) that were non-responders (did not produce a response to any pool lytic or latent). Of 
these responders, while nine (24%) and five (13%) responded to either the lytic or latent pools 
respectively, the majority, 24 (63%), responded to both. Figures 4.7 and 4.8 illustrate the 
pattern of immunodominance identified in the 38 IgM'IgG+ Gambian children that 
responded. The late protein BALF4 had a single responder with a high magnitude response 
(440 SFU/106). For the latent antigens, the highest responses were seen to EBNA 3A, 3B and 
3C proteins, with none detected to LMP1. EBNA3B responses were of the highest magnitude 
among responders to latent proteins (Median 320 SFU/106). Interestingly, there was no 
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significant difference in the size of response to lytic versus latent peptides (p=0.07). However, 
there were more IgM'IgG+ children that did not respond to the latent pool but responded to 
the lytic pools (n=15) than children that did not respond to the lytic pool but responded to the 
latent pools (n=5) (Figure 4.7 B). The magnitude of the response did not correlate with the 
percentage of children that responded (Figure 4.8). For example EBNA3A was the most 
recognised latent antigen (22% of children) however it did not elicit the highest response 
(Median 160 SFU/106) (Figure 4.7A and 4.8).   
 
Assessment using intracellular cytokine staining and flow cytometry analysis was performed 
to determine whether there was prominent production of cytokines other than IFN-& or 
markers of degranulation, after overlapping peptide stimulation. There were very few donors 
identified as responders to overlapping peptide pools of lytic protein, BZLF1, and latent 
protein, EBNA3A, therefore the results of this are detailed in Appendix I. With the caveat of a 
small sample size, the magnitude and proportion of children that had any detectable PBMC 
response to antigen stimulation did not significantly differ between lytic and latent protein 
stimulations.   
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Figure 4-7 IFN-" ELISPOT responses from PBMCs stimulated with lytic and latent-cycle 
antigens in Gambian children.  
Size of IFN-" (SFU per 106 PBMCs) response produced following antigen stimulation with 
pools of known CD8+ restricted peptides expressed according to A. proteins and B. lytic and 
latent cycle epitopes. 
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Figure 4-8 Percentage of children with PBMCs producing IFN-" in response to antigen 
stimulation with pools of CD8+ restricted peptides.  
 
There were 20 IgM'IgG+ children that produced no response to the peptide pools and this 
could be because they do not have an HLA type of interest. Although the HLA types of these 
children were not known, previous data from The Gambia give HLA frequencies of 25%, 
17%, 24%, 18% and 15% for HLA A*0201, B*0801, B*3501, B*5301 and B*5801 alleles 
respectively (Louis-Marie Yindom, unpublished data) (Allsopp et al., 1992). Figure 4.9 shows 
the percentage of children with IFN-& ELISPOT responses for each of the likely individual 
lytic and latent peptides that were responded to in the peptide pools following deconvolution 
of the two-dimensional peptide matrix, alongside their HLA restrictions. Most of the 
responses are to epitopes restricted through alleles known to be of high frequency in The 
Gambian population. However, there were not many A*0201 responders despite this being an 
allele of relatively high frequency in the population. 
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Figure 4-9 Percentage of children producing an IFN-! ELISPOT response from PBMCs stimulated with known CD8+ restricted lytic (red) 
and latent cycle (black) pooled epitopes.  
Percentage of children for likely epitope responded to following deconvolution of the two dimensional matrix of peptide pools, grouped by HLA 
restriction.  
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4.3.6  EBV-specific responses in IgM!IgG+ children visualised with tetramers 
To further analyse the impact of EBV infection in this cohort MHC class I tetramers were 
used to identify and analyse the surface marker phenotype of epitope specific CD8+ T-cells. 
From the aforementioned IFN-! ELISPOT data we selected the following epitopes, B*0801 
RAKFKQLL, B*3501 EPLPQGQLTAY and A*0201 GLCTLVAML for tetramer 
manufacture, as they were frequent targets of the immune response. Tetramers were first 
tested for specificity against HLA-matched and mismatched seropositive and seronegative 
donors (Figure 4.10). There was some non-specific background staining noted in the HLA 
mismatched and seronegative donor for B*0801 RAKFKQLL, but a clearly distinguishable 
CD8+ tetramer positive population was present in the HLA matched donor only. 
 
Fifteen IgM"IgG+ children identified as responders to the above three epitopes in the 
previous section were further tested by tetramer staining to determine the phenotype of EBV-
specific CD8+ T-cells compared to the total CD8+ T-cell population. Alongside the tetramer 
staining where cell numbers permitted (n=12), individual IFN-! ELISPOT assays were 
performed using the same peptide epitopes (B*0801 RAKFKQLL, B*3501 EPLPQGQLTAY 
and A*0201 GLCTLVAML), as a single antigen stimulus providing a functional comparison 
to the tetramer response detected.  Figure 4.11 shows that the IFN-! ELISPOT responses 
positively correlated with the number of tetramer positive cells, although the precursor 
frequencies were much higher by tetramer staining suggesting that they may produce 
cytokines other than IFN-! or be non-functional. Out of the subset of 15 children tested by 
tetramer staining four were CMV negative. One donor dropped out at the visit four, six-month 
time point and therefore could not be included in the analysis of phenotypic changes over 
time. 
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Figure 4-10 Example of tetramer staining for B35 EPLPQGQLTAY (BZLF1) and B8 
RAKFKQLL (BZLF1) on seronegative (A), seropositive HLA mismatched (B) and HLA 
matched (C) donors.  
Percentage indicates tetramer as a proportion of CD8+ T-cells. 
 
Figure 4-11 Number of tetramer positive cells (x-axis) correlates with IFN-! production (y-
axis) in ELISPOT assays stimulated with the single epitopes corresponding to tetramers 
used, B*0801 RAKFKQLL, B*3501 EPLPQGQLTAY or A*0201 GLCTLVAML.  
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As there was an observed decrease in EBV viral genome loads in donors sampled at visit one 
and visit four time points, the subset of 15 donors available for tetramer analysis were further 
examined to see if this decrease altered EBV-specific CD8+ T-cell proportions over time. As 
figure 4.12 illustrates, there was a significant decline in both the EBV viral genome load 
(p=0.0001) and percentage of EBV-specific CD8+ T-cells (p=0.0052) over the six month time 
period. By contrast there was no significant difference in the total CD8+ T-cell population 
over time (data not shown). 
 
Figure 4-12 EBV genome loads and dynamics over time.  
A. EBV genome load (dotted line represents limit of detection of the assay) and B. percentage 
of EBV-specific CD8+ T-cells at Visit one (Day 0) and Visit four (six months) later in 
IgM!IgG+ Gambian children. Line and symbol graphs (right column) illustrate the dynamics 
of each individual’s response over time.  
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As these donors showed virological evidence of recent infection, EBV-specific CD8+ T-cells 
were examined for evidence of recent activation. Phenotyping of the EBV-specific CD8+ T-
cells detected using Class I tetramer staining was also performed on this subset of IgM"IgG+ 
Gambian children (n=15).  The following markers, CD38, HLADR, bcl-2, ki-67, Perforin, 
Granzyme B, CD57 and T-bet were assessed allowing for some comparisons to be made with 
cellular phenotypes seen in Caucasian adult long-term carriers. A comparison of expression of 
the above phenotypic markers on EBV-specific and the total CD8+ T-cell populations in these 
IgM"IgG+ children was performed at the visit one time-point. To further assess whether 
expression developed or disappeared over time the phenotype at visit one was compared with 
the phenotype six months later at visit four.  
 
The literature on Caucasian long-term carriers with no history of AIM shows that the EBV-
specific CD8+ memory T-cells display a resting phenotype, most lack activation markers and 
express high levels of bcl-2, with low level perforin expression and cytolytic activity. (Callan 
et al., 1998b, Catalina et al., 2002, Dunne et al., 2002, Faint et al., 2001, Hislop et al., 2001). 
CD38 was used in combination with HLADR as a marker of activation, as CD38 is expressed 
on almost all infant T-lymphocytes throughout the first year of life (de Vries et al., 2000). The 
anti-apoptotic marker bcl-2, marker of cell cycling Ki-67, cytolytic marker Granzyme B and 
marker of senescence CD57 were also used. In addition, expression of T-bet was also 
assessed which in relation to HIV infection has been shown to play an important role in CD8+ 
T-cell effector function, with higher levels detected in elite controllers compared to 
chronically infected progressors (Hersperger et al., 2011). It was therefore of interest to see if 
this was expressed by EBV-specific CD8+ T-cells from children in The Gambia where EBV 
viral load set-points are known to be higher.  
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For a subset of these IgM"IgG+ children (n=12), where cell numbers permitted a second 
panel of markers assessing for co-expression of multiple inhibitory receptors (PD-1, 2B4, 
CD160) on the surface of EBV-specific CD8+ T-cells was examined. The co-expression of 
these markers has recently been correlated with HIV loads, suggesting that they represent an 
‘exhausted’ cellular phenotype (Yamamoto et al., 2011, Petrovas et al., 2006, Petrovas et al., 
2009). However, higher co-expression of these ‘inhibitory receptors’ also occurs in HIV-2 
infected individuals, with largely undetectable viral loads who have polyfunctional Gag 
responses, and may therefore better reflect cellular differentiation status rather than 
exhaustion (T de Silva, Unpublished data). This is in keeping with data in healthy adults 
showing PD-1 expression correlates with differentiation markers and does not inhibit the 
capacity to secrete cytokines upon stimulation (Duraiswamy et al., 2011). The role these 
markers might play in EBV infection in childhood is not known and one could hypothesise 
that they may correlate with the higher EBV viral loads seen in Gambian children if up-
regulated on EBV-specific CD8+ T-cells.  
 
Analysis of activation, proliferation and anti-apoptotic marker expression on EBV-specific 
CD8+ T-cells showed that they were significantly different from the total CD8+ T-cell 
population, with a clear change in expression over time. There were significantly more 
HLADR+CD38+ (p = 0.002) and Ki-67+ (p = 0.01) EBV-specific CD8+ T-cells compared to 
the total CD8+ T-cell population in the same donors, with lower levels of the anti-apoptotic 
marker, bcl-2, compared to the total CD8+ T-cell population in the same donors (p <0.001) 
(Figure 4.13). A further comparison was made of the total CD8+ T-cell populations in the 
IgM"IgG+ group with the total CD8+ T-cell populations in a subset of control IgM"IgG" 
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Gambian children (n=16) and no significant differences in the percentage of HLADR+CD38+ 
and Ki-67+ expressing cells were found. There was however significantly more bcl-2 
(p=0.0001) expressed by the total CD8+ T-cell population in the IgM"IgG" children (Figure 
4.14).  The percentage of HLADR+CD38+ EBV-specific CD8+ T-cells in the IgM"IgG+ 
children declined significantly over time (p=0.003), whereas cellular expression of bcl-2 
significantly increased (p=0.013), with a non-significant decline seen in frequency of cells 
expressing Ki-67 (Figure 4.14). Of note one donor dropped out at the visit four and therefore 
it was not possible for them to be included in this analysis.   
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P value calculated using Wilcoxon matched-pairs signed rank test for paired IgM"IgG+ donor values,   
P values calculated using the Mann-Whitney U comparison of unpaired data for comparisons between 
IgM"IgG+ and IgM"IgG" donors. 
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Figure 4-13 Frequency of cells expressing HLADR+CD38+(A), Ki-67 (B) and bcl-2 (C) on 
total and EBV-specific CD8+ T-cells from IgM"IgG + Gambian children (n=14) and total 
CD8+ T-cells from IgM"IgG " Gambian children (n=16).  
 
The left columns show percentage of marker positive cells for all donors for the total CD8+ 
T-cells from IgM!IgG ! children (black symbols) and total CD8+ T-cells  (blue symbols) and 
EBV-specific CD8+ T-cells (red symbols) from IgM!IgG + children. The right hand panels 
show histograms from a representative donor illustrating the expression of the three markers 
by EBV-specific CD8+ T-cell  (red) and the total CD8+ T-cell population (blue). 
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P value calculated using the Wilcoxon matched-pairs signed rank test for paired data  
Figure 4-14 Expression of HLADR+CD38+(A), Ki-67 (B) and bcl-2 (C) by total and EBV-
specific CD8+ T-cells from IgM"IgG+ (n=13) Gambian children over a six-month time 
period.  
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The left columns show percentage of marker positive cells for all donors for the total CD8+ 
T-cells (grey symbols) and EBV-specific CD8+ T-cell (red and black symbols) from 
IgM!IgG+ children at visit one and visit four, six months later. The right hand panels show 
histograms from a representative donor illustrating the expression of the three markers by 
EBV-specific CD8+ T-cell at visit one (red) and visit four (black). 
 
 
Analysing markers associated with effector function namely perforin, Granzyme B, T-bet and 
CD57 showed there was no difference in expression among the EBV-specific CD8+ 
population compared to expression on the total CD8+ T-cell population. For the majority of 
these phenotypic markers, perforin, Granzyme B and T-bet, there was also no change over 
time by the total or EBV-specific CD8+ T-cells. However, CD57 expression was significantly 
up regulated on the EBV-specific CD8+ T-cells over time (p = 0.04) but not on the total 
CD8+ T-cell population (Figure 4.15).  
 
Analysis of markers associated with inhibition of T-cell function on EBV-specific CD8+ T-
cells from Gambian children showed they were up regulated in comparison to the total CD8+ 
T-cell population and remained elevated over time (Figure 4.16). There was no correlation 
between the percentage of EBV-specific CD8+ T-cells expressing all three of these multiple 
inhibitory co-receptors and IFN-! production from PBMCs in response to single peptide 
stimulation, viral genome loads and CD8+ T-cell differentiation status (data not shown).   
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P value calculated using the Wilcoxon matched-pairs signed rank test for paired data  
 
Figure 4-15 Expression of T-bet and CD57 and production of perforin and Granzyme B on 
total and EBV-specific CD8+ T-cells from IgM"IgG + children (n=11) over a six month 
time period. 
 Graphs of cytolytic markers Perforin (A) and Granzyme B (B), T-box transcription factor, T-
bet (c) and marker of senescence CD57 (D) in total CD8+ T-cells (grey) and EBV-specific 
CD8+ T-cells at visit one (red) and visit four (black).   
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P value calculated using the Wilcoxon matched-pairs signed rank test for paired data  
Figure 4-16 Expression of CD160, PD-1 and 2B4 on total and EBV-specific CD8+ T-cells 
from IgM"IgG + children (n=11) over a six month time period.  
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Graphs (left column) of 2B4 (A) CD160 (B) and programmed death-1, PD-1, (C) expressing 
cells in the total CD8+ T-cell (grey) and EBV-specific CD8+ T-cell populations at visit one 
(red) and visit four (black). Histograms on the right from a representative donor illustrating 
expression of 2B4 (A), CD160 (B) and PD-1 (C) on total CD8+ T-cells (blue) and EBV-
specific CD8+ T-cells (red).  
 
 
This completes the section relating to IgM"IgG+ children who are likely to have been 
infected with EBV in the last six months to a year. The following data set refers to children 
with serological evidence, IgM+IgG "/+ of recent infection.  
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4.3.7 EBV VCA IgM+IgG!/+ Children: Size of lymphocyte populations and EBV 
loads in PBMCs 
Six children in total were identified as being EBV VCA IgM+IgG"/+ out of 114 children 
screened: five identified in Table 4.2, and a further donor ID087 was found to be 
IgM+IgG"/+ at visit three. Three of these children were identified as IgM+IgG"/+ at visit 
one: donor ID061 for whom data are available from all three-time points, while donors ID013 
and ID053 were both non-responders in IFN-! ELISPOT assays and therefore no tetramer 
staining was performed. A further two donors ID007 and ID082 were identified as 
IgM+IgG"/+ at visit four, but had been seronegative at visit one and finally donor ID087 who 
was identified at visit three was seronegative at visit one (there were no cells available at the 
visit three time point for this donor).  The serological IgM+ findings suggest that these 
children were more recently infected (in the last 120 days) than the IgM"IgG+ children, 
discussed previously. All were asymptomatic for classical symptoms of acute EBV infection 
(fever, lymphadenopathy, malaise) at the time of recruitment based on maternal history and 
clinical evaluation. As these donors showed serological evidence of recent infection, the size 
of the peripheral B- and T- lymphocyte compartments were examined. Figure 4.17 and 4.18 
show lymphocyte subset numbers and viral loads in PBMCs respectively, taken from the time 
point at which these children were first identified as being IgM+IgG"/+. Surprisingly despite 
serological evidence of recent infection there was no significant distortion in total T- or B-cell 
populations in these children (Figure 4.17). Furthermore their viral genome loads did not 
significantly differ from the IgM"IgG+ Gambian children. On comparison with UK 
Caucasian donors the viral genome loads were significantly higher than past infected UK 
medical students and equivalent to those seen during AIM (Figure 4.18). 
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Figure 4-17 Size of lymphocyte populations in the blood of IgM+IgG "/+ (n = 6) compared 
to IgM"IgG+ Gambian children (n=35) and IgM"IgG " children (n=70).  
Horizontal lines indicate median number of cells.  
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P values calculated using Dunn’s Multiple Comparison Test (one way analysis of variance 
(ANOVA)).  *** P<0.001 
 
Figure 4-18 EBV genome loads at visit one IgM"IgG+ (n=70) and in IgM+IgG-/+  
Gambian children (n=6), adolescent asymptomatic Caucasian medical students (n=94), and 
Caucasian adults with a diagnosis acute infectious mononucleosis (AIM) (n=6).  
The dashed line represents the lower limit of detection for EBV genomes in the assay. Donors 
below the dashed line had undetectable viral loads. Horizontal bars indicate the median.   
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4.3.8 EBV-specific CD8+ T-cell responses in IgM+IgG!/+ children visualised with 
tetramers 
To analyse the impact of recent EBV infection in this subset of children and explore whether 
this differed from the IgM"IgG+ children, MHC class I tetramers were used to identify 
epitope specific CD8+ T-cells and analyse the surface marker phenotype of these cells. Of the 
six IgM+IgG"/+ donors, ID061, who was HLA*B0801, seroconverted at the first time point 
and had a detectable tetramer response to the lytic RAK epitope that was monitored serially 
over time. The other two donors whose seroconversion was detected at the final time point, 
donors ID007 and ID082, were HLA B*0801 and A*0201 respectively. PBMCs from these 
donors showed significant EBV-specific CD8+ T-cell expansions at visit four, which were 
noticeably absent at visit one. The last donor ID087 was an HLA B*3501 donor that 
converted at visit three and again shows evidence of an EBV-specific CD8+ T-cell response at 
visit four with no detectable response at visit one. Figure 4.19 illustrates the EBV-specific 
tetramer staining of CD8+ T-cells for the four aforementioned children’s PBMCs. Figure 4.17 
shows no significant increase in the total CD8+ T-cell count in these IgM+IgG"/+ children, 
however, for donors ID082 and ID007 both had CD8+ T-cell percentages that increased from 
18.2% to 50.3% and from 19.8% to 40% respectively from visit one to visit four. Thus, 
significant EBV-specific CD8+ T-cell expansions were observed following seroconversion. 
Donor ID061 had a CD8+ T-cell percentage of 41% and a white cell count of 10.8x109/L with 
a lymphocyte count and percentage of 7.29x109/L and 67.5% respectively, at the visit one 
time point.  
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Figure 4-19 Serial EBV-specific CD8+ T-cell staining in IgM+IgG"/+ children.  
Time-points are illustrated with sequential viral loads (grey boxes) and serological status 
(grey boxes), with time point of detection of IgM positivity highlighted (red box). 
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 Where cell numbers permitted, phenotyping of the EBV-specific CD8+ T-cells using the 
previously described panel was performed on stored PBMCs from IgM+IgG"/+ children. 
Unlike the IgM"IgG+ children, the total CD8+ T-cell population demonstrated high levels of 
generalised activation as illustrated by Figure 4.20, with 18%, 22% and 49% of total CD8+ T-
cells expressing activation markers in donors ID061, ID082 and ID007 respectively. Focusing 
on the EBV-specific CD8+ T-cells in these IgM+IgG"/+ children at the time of 
seroconversion, these expressed markers associated with activation, where up to 85% of 
tetramer+CD8+ T-cells co-expressed HLADR and CD38 at their IgM+ time-points (Figure 
4.21). Donor EBV-specific CD8+ T-cells at the time of seroconversion also expressed high 
levels of Ki-67 (Figure 4.22). Ki-67 expression was higher in acute compared to convalescent 
samples for donor ID061 who had 12-13% Ki-67+ when IgM+ but only 3% when IgM". 
Tetramer positive cells also express significantly lower levels of anti-apoptotic factor, bcl-2, 
compared to IgM"IgG+ Gambian children at visit one (p=0.03) consistent with the phenotype 
described during AIM (Figure 4.23 versus Figure 4.14). 
 
For donor ID061 for whom we had serial samples from IgM+IgG"/+ to IgM"IgG+ status 
staining was performed with further markers. The EBV-specific CD8+ T-cells were 
predominantly Granzyme B producing (60%) and expressed T-bet (50%) with minimal 
perforin production (20%). This did not alter over time. The percentage of cells expressing 
CD57 slightly increased over time, with 36%, 36% and 44% of EBV-specific CD8+ T-cells 
being CD57+ at visits one, three and four respectively. The expression of ‘inhibitory markers’ 
on the EBV-specific CD8+ T-cells mirrored the pattern seen for the IgM"IgG+ children, with 
the tetramer positive cells being of a predominantly CD160+PD-1+2B4+ phenotype at visit 
one and remaining so at visit four, six month later (data not shown). 
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Figure 4-20 Serial dual expression of activation markers, HLADR and CD38, on the total 
CD8+ T-cell population in IgM+IgG"/+ children. 
 Time-points are illustrated with sequential viral loads (grey boxes) and serological status 
(grey boxes), with time point of detection of IgM positivity highlighted (red box).  
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Figure 4-21 Serial expression of activation markers, HLADR and CD38, on the tetramer 
EBV-specific CD8+ T-cell population in IgM+IgG"/+ children.  
Time-points are illustrated with sequential viral loads (grey boxes) and serological status 
(grey boxes), with time point of detection of IgM positivity highlighted (red box).  
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Figure 4-22 Serial expression of cell cycling marker, Ki-67, on the EBV-specific CD8+ T-
cell populations in IgM+IgG"/+ children.  
Time-points are illustrated with sequential viral loads (grey boxes) and serological status 
(grey boxes), with time point of detection of IgM positivity highlighted (red box).  
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Figure 4-23 Serial expression of anti-apoptotic marker, bcl-2, on the EBV-specific CD8+ T-
cell populations in IgM+IgG"/+ children.  
Time-points are illustrated with sequential viral loads (grey boxes) and serological status 
(grey boxes), with time point of detection of IgM positivity highlighted (red box).  
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4.4  Discussion  
This study provides a detailed description of EBV-specific CD8+ T-cell responses, viral 
genome loads and IFN-! responses to known lytic and latent EBV antigens in West African 
children. Through serial sampling of 114 children in The Gambia aged 14-18 months, 78 
(84%) children were identified as being EBV infected or subsequently becoming infected 
during the six-month study period. There were six children that asymptomatically 
seroconverted during the study period and a subset of a further fourteen recently EBV 
infected children at Day 0 for whom EBV-specific Class I tetramer staining was performed. 
This work brings to light some new findings in relation to asymptomatic primary EBV 
infections in childhood. Firstly, it provides evidence that in subclinical primary infections, 
there is a lack of the massive peripheral CD8+ T-cell response observed in AIM patients, as 
evidenced by lack of significant lymphocytosis and distortion of total T- and B-cell 
populations within the blood. Furthermore, EBV-specific CD8+ T-cell expansions identified 
by Class I tetramer staining are of a lower magnitude than has previously been described 
during AIM (in Caucasian adolescents) despite high EBV viral genome loads and high levels 
of both tetramer-staining and total activated CD8+ T-cells. Secondly, asymptomatic EBV 
infection in infancy drives differentiation of total and EBV-specific CD8+ T-cells with 
expansion of the ‘intermediately differentiated’ (CD27+CD28") CD8+ T-cell population 
rather than the expansion of ‘terminally differentiated’ (CD27"CD28") CD8+ T-cells 
observed with CMV infection (Miles et al., 2007). Lastly, the responses to EBV latent 
antigens were of a similar magnitude to the responses identified to lytic antigens, which 
contrasts to what has been observed in donors with AIM and healthy UK carriers in whom 
lytic antigen responses have been shown to dominate (Hislop et al., 2007b).  
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The six asymptomatic IgM+IgG"/+ children in this study did not have a lymphocytosis, 
which is consistent with previous literature on silent EBV seroconversion (Biggar et al., 
1978a, Fleisher et al., 1979, Silins et al., 2001). Furthermore, they had no distortion in the 
total CD8+, CD4+, B-cell and memory B-cell counts when compared to EBV IgM"IgG" 
(uninfected) and IgM"IgG+ (recently infected) Gambian children from the same study site. In 
the six IgM+IgG"/+ children there was direct evidence of an EBV-specific CD8+ response, 
which, although broadly speaking, was low compared to AIM donors, was still significant in 
number and identified with no large total CD8+ expansion. This is in keeping with the 
hypothesis that EBV is controlled by a primary CD8+ response.  
 
Phenotypically the EBV-specific CD8+ T-cells identified were broadly consistent with what 
has been described in AIM donors, being highly activated (HLADR+CD38+), in cell cycle 
(Ki-67+) and pro-apoptotic (low bcl-2 expression) (Callan et al., 2000, Catalina et al., 2001, 
Dunne et al., 2002, Hislop et al., 2002, Hislop et al., 2005, Tamaru et al., 1993). This is in 
contrast to what is seen in long-term carriers where EBV-specific CD8+ T-cells display a 
resting phenotype, lack high levels of activation markers, and express high levels of bcl-2 
(Callan et al., 1998b, Catalina et al., 2002, Dunne et al., 2002, Faint et al., 2001, Hislop et al., 
2001).  
 
The EBV-specific CD8+ T-cells in IgM"IgG+ EBV-infected Gambian children displayed a 
highly activated, proliferative and pro-apoptotic phenotype, consistent with recent antigen 
stimulation. This is likely to be due to these Gambian children all having undergone relatively 
recent primary infections in the last six-months to a year. This premise is supported by several 
factors. Firstly, prior epidemiological data from the Sukuta field site has shown that only 18% 
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of Gambian children are EBV infected at nine months of age (Holder et al., 2010). Secondly, 
there were high EBV viral genome loads detected in these children, equivalent to those seen 
in AIM, which declined over the six-month time period and lastly the aforementioned EBV-
specific CD8+ T-cell phenotypic data from tetramer staining. Furthermore, there is also a 
reduction in CD8+ T-cell activation with a concurrent increase in expression of the anti-
apoptotic marker, bcl-2 over time on EBV-specific CD8+ T-cells from these recently EBV 
infected children. The EBV-specific CD8+ T-cells in the IgM"IgG+ donors had high levels of 
expression of CD57, a marker usually expressed on highly differentiated cells such as CMV-
specific cells, which significantly increased with time. Interestingly, low frequencies of 
CD57-expressing EBV-specific CD8+ T-cells are observed in adult Caucasian populations 
(Khan et al., 2004, Tan et al., 2000), suggesting that in Gambian children, these EBV-specific 
cells are more differentiated compared to Caucasians. Although viral genome loads do not 
necessarily equate to antigen load, given that these children have higher EBV genome loads 
and thus may have higher levels of antigen stimulation, this may explain why their cells 
appear more differentiated in terms of CD57 expression. A further analysis of EBV-specific 
cells using a more extensive panel of differentiation markers (e.g. CD45, CD27, CD28, 
CD62L, CCR7) would help correlate differentiation status with CD57 expression.   
 
There were two noticeable differences between the IgM+IgG"/+ children and the IgM"IgG+ 
Gambian children. The first being the level of CD8+ T-cell activation (HLADR+CD38+) 
observed in the total CD8+ T-cell population, which was higher in the IgM+IgG"/+ (Figure 
4.20), but not in the IgM"IgG+ infected children, who had similar levels to IgM"IgG" 
children (medians of 22% (Figure 4.20), 6.5% and 5.6% (Figure 4.13) respectively, p=0.03). 
This could suggest the presence of EBV-specific CD8+ T-cells to a predominant epitope(s) 
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other than that of the Class I tetramers used, or alternatively reflect non-specific by-stander 
activation of T-cells. During AIM, large expansions of a few monoclonal or oligoclonal 
CD8+ T-cell responses have been shown to dominate (Callan et al., 1996), therefore the 
activation seen in the total CD8+ T-cell population could be EBV-specific. However, 
expansion and activation of the total CD8+ T-cell compartment during heterologous viral 
infections has also been previously well recognised and herpesvirus specific CD8+ T-cells 
have been shown to consistently contribute to this expansion (Sandalova et al., 2010). Despite 
the aforementioned acute by-stander activation described, the numbers of heterologous virus-
specific T-cells, in the case of CMV and flu, have been shown to remain the same pre- and 
post- AIM (Odumade et al., 2012).   
 
The second difference was that the IgM"IgG+ children did not display an increase in 
cytotoxic capability as evidenced by the lack of up-regulation of perforin and Granzyme B, 
but this was observed for one of the IgM+IgG"/+ children, ID061, for which further staining 
was possible, consistent with the literature on the phenotype of EBV-specific CD8+ T-cells 
seen during AIM (Hislop et al., 2007b).  
 
Primary CMV infection has been shown to significantly alter the differentiation of the total 
CD8+ T-cell compartment (Miles et al., 2007). A significant expansion in the total 
CD8+CD27+CD28" ‘intermediately differentiated’ phenotype was seen in the recently EBV 
infected children compared to those that were uninfected. This differs from CMV, which has 
been shown to drive the majority of CD8+ T-cells to a CD27"CD28" ‘terminally 
differentiated’ status (Miles et al., 2007). The current data also show that when CMV and 
EBV co-infection is present the differentiation status of the total CD8+ T-cell population 
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mirrors that seen in CMV infection alone, thus the CMV effect seems to dominate in dual 
infected children. CMV has been shown to skew the differentiation status of the total CD8+ 
T-cell population for several years post primary infection (Miles et al., 2008c) and has been 
implicated in the perpetuation of chronic immune activation (van de Berg et al., 2010), but 
whether EBV effects are similarly long lasting is not known. Whether the order of acquisition 
of EBV and CMV infection has any impact on differentiation status also remains to be seen. 
However, in our setting CMV infection is generally acquired prior to EBV infection, indeed at 
nine months 66% and 18% of children from Sukuta were infected with CMV and EBV 
respectively in a previous study (Holder et al., 2010). 
 
In an in vitro model, immune activation has been shown to suppress initiation of lytic EBV 
infection through triggering of the innate immune system specifically via Toll-like receptor-9 
(TLR-9), the ligand of which is unmethlylated bacterial CpG DNA (Ladell et al., 2007). In 
African settings levels of immune activation are known to be high secondary to the high 
prevalence of co-infections such as the previously discussed CMV (Miles et al., 2007), but 
also malaria, intestinal helminthes and frequent respiratory tract and diarrhoeal infections. 
African children are therefore likely to have been exposed to a multitude of pathogens in early 
life, including bacterial CpG, which may in vivo influence the nature of early EBV infection 
in these children by triggering the innate immune system. This could, for example, potentially 
suppress the initiation of lytic EBV infection via TLR-9 triggering and lead to early 
establishment of latency. TLR responses in early infancy have been shown to be population 
dependent and differ between children in North American and Sub-Saharan African 
populations (Burl et al., 2011, Reikie et al., 2012).  
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It has been hypothesised that the difference between asymptomatic seroconversion and 
symptomatic AIM could be related to EBV establishing a different pattern of gene expression 
during early infection. One possibility is that asymptomatic infection results from an increase 
in the number of latently infected B-cells in the peripheral blood, whereas during AIM there is 
more lytic viral replication (Silins et al., 2001). Our data go some way to supporting this 
notion. Thus IFN-! ELISPOT responses in our study showed a similar pattern of 
immunodominance to that seen in Caucasian donors (lytic responses were skewed towards the 
IE, then E proteins with consistently high latent responses to EBNA3). However, it should be 
borne in mind that this could be a reflection of the numbers of epitopes screened for each 
protein, as a greater number of IE and E proteins were screened than late proteins. 
Interestingly, the lytic and latent IFN-! responses detected were of a similar magnitude. This 
is in contrast to what is seen in AIM and in healthy Caucasian long-term carriers where lytic 
responses are significantly more frequent and of greater magnitude than latent responses 
(Hislop et al., 2007b).  This may be a reflection of the EBV antigens being dominated by viral 
expression of predominantly latent proteins during acute infection in West African children, 
although this remains to be confirmed. One way to resolve this would be to look at the virus 
in peripheral blood during AIM and acute infection in Gambian children using Gardella gel 
analysis and determine whether the virus is in lytic or latent cycle. It will be difficult to 
resolve this issue, because in AIM at the time of clinical presentation, the detectable virus in 
both tonsils and peripheral blood is in latent cycle (Kurth et al., 2000, Tierney et al., 1994). 
Therefore it is still not known where the EBV lytic antigens are driving the predominantly 
lytic response that is seen in AIM. It is plausible that by the time patients present with AIM, 
the lytic burst has been missed or that the virus is harboured in epithelial cells. Studying the 
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oropharynx, through analysis of oral secretions and assessing viral shedding in the throat may 
provide a greater insight into early infection in these patients.  
 
There are some limitations to this study, which are worth discussing. Firstly, for the majority 
of the children in the study, the precise timing of the primary EBV infection cannot be 
determined. However, from previous data on infants at the same study site, only 18% of 
infants were found to be EBV infected at nine months of age and from this one can assume 
that the majority of children would have been infected in the last six-months to a year. 
Furthermore, the IgM+IgG"/+ could have been infected anytime within the last 120 days and 
therefore this group could all be at different stages of infection. Secondly, ensuring children 
are truly asymptomatic in this setting can be challenging as reliance on maternal perception 
may not be reliable. To combat this, the children all underwent a health screen by the study 
clinician, including baseline clinical observations such as weight, height, temperature and 
heart rate and where indicated a rapid malaria test. Recent work by Balfour et al. has 
suggested that 89% of primary EBV infections in a cohort of University students are in fact 
symptomatic, although they may not fulfil all classic symptoms of AIM, which is somewhat 
contradictory to our observations (Balfour et al., 2013). However, older children are more 
likely to exhibit symptoms. Furthermore, potential confounding, intercurrent infections which 
could also cause the symptoms screened for (sore throat, lymphadenopathy, fever and fatigue) 
such as streptococcal pharyngitis, respiratory syncytial virus, parvovirus and adenovirus were 
not controlled for, and the incidence of symptoms detected in continually EBV negative 
students was not reported. Lastly, it was not possible to perform HLA typing on all the 
children studied and therefore HLA mismatching may have skewed the responses that were 
detected. However to minimise this multiple known epitopes were screened providing a broad 
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HLA coverage. Furthermore the children studied responded to HLA types which are known to 
be of a high frequency, A*0201, B*0801, B*3501 and B*5801, in The Gambian population 
(Allsopp et al., 1992).  
 
These data describe a lack of the typical lytic dominant immune responses seen in AIM with 
more conservative EBV-specific CD8+ T-cell expansions and minimal distortion of the total 
T- and B-cell compartments despite high levels of circulating EBV genome loads and 
activated EBV-specific CD8+ T-cells.  The large atypical total CD8+ T-cell expansions seen 
during AIM did not occur in these IgM+IgG"/+ Gambian children despite high detectable 
EBV viral genome loads. This work further supports the notion that AIM is an 
immunopathological disease and that symptoms are caused by the significantly expanded 
CD8+ responses to the virus rather than the virus per se (Silins et al., 2001). The lack of a 
predominantly high lytic antigen response compared to latent reactivity in these children 
suggests that the form of EBV infection may also differ during asymptomatic infection in 
childhood compared to AIM. If would be of further interest to explore the tetramer responses 
to latent antigens in these children, for example using a B*0801 latent epitope such as 
FLRGRAYGL or QAKWRLQTL MHC Class I tetramer to identify whether latent EBV-
specific CD8+ T-cell responses are of an equivalent magnitude and phenotype as those 
detected to lytic epitopes in these children.  
 
Future work looking at the gene expression of the virus during asymptomatic infection in 
African children would directly identify whether the virus is in a lytic or latent form. 
Although case identification would be challenging, a comparison of viral gene expression 
using RT-PCR in adolescent symptomatic and asymptomatic EBV seroconverters in a 
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developed country setting may provide further insights into whether the form of EBV 
infection varies depending on age of infection, and how this might relate to the clinical 
presentation of primary EBV infection. Assessment of oropharyngeal infection analysing 
virus shedding through throat washings may provide an idea of how the immune response is 
primed in early infections and whether this differs with age.  
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CHAPTER 5 : CONSEQUENCES OF EBV INFECTION IN INFANCY: ANTIBODY 
RESPONSES TO VACCINE ANTIGENS FROM DIPHTHERIA, TETANUS, 
PERTUSSIS, HAEMOPHILUS INFLUENZAE B AND HEPATITIS B 
 
5.1 Introduction  
There are very few data in the literature on how chronic viral infections might alter cellular 
and humoral responses to vaccination or co-infection. The work of Miles et al. demonstrated a 
dramatic alteration in the total and CMV-specific CD8+ T-cell compartment, driving T-cells 
into a more terminally differentiated phenotype (Miles et al., 2007). These CMV infected 
infants were however shown to still mount a CD8+ T-cell response to measles vaccine 
equivalent to those of uninfected infants (Miles et al., 2008b). More recent work on infants in 
the Sukuta cohort in The Gambia has shown that EBV infected infants have lower antibody 
responses to measles and meningococcus polysaccharide antigens compared to uninfected 
children, but in contrast the CMV only infected children showed no decline in their antibody 
responses (Holder et al., 2010). It is also observed for reasons, which are unclear, that in sub-
Saharan Africa some childhood vaccines, such as Measles, are less effective than in high-
income settings (Aaby et al., 1990, Vitek et al., 1999).  
 
This study set out to determine if antibody responses to other childhood vaccine antigens were 
also decreased in EBV infected infants compared to EBV naïve or CMV infected infants. 
Thus, the impact of infection, with the B-cell tropic EBV, in childhood on B-cell phenotypes 
and responses to a vaccine challenge with a pentavalent (DTP, HepB and Hib) booster 
vaccination given at 14-18mths of age were studied. B-cell subset disruption has been 
described during chronic viral infections, such as HIV, based on markers CD19, CD20, CD21 
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and CD38 (Moir and Fauci, 2009, Moir et al., 2008). Moir et al. previously looked at the 
distribution of B-cell subpopulations in HIV infected and uninfected adults (Moir et al., 2008) 
using the aforementioned markers. They describe two expanded populations of B-cells in HIV 
viraemic individuals, firstly ‘tissue-like’ or ‘atypical’ memory B-cells 
(CD19+CD20+CD21"CD27") and secondly plasmablasts (CD27+CD21"CD20"CD38+). 
They have demonstrated that the first of these populations represents an exhausted B-cell 
phenotype with reduced proliferative ability and decreased capacity to differentiate into 
antibody secreting cells. An expansion in these B-cell subsets could potentially reduce 
antibody responses to vaccination so these B-cell subsets were enumerated in the peripheral 
blood of both IgM" IgG" and IgM"IgG+ Gambian children. 
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5.2 Methods  
5.2.1 Vaccination, Multiplex immunoassays and ELISAs 
The vaccination in this study was administered as part of the routine schedule in The Gambia 
and all children enrolled in the study had received their initial primary immunisations as per 
the current vaccine schedule including Hep B at birth and three doses of DTP, Hep B and Hib 
at two, three and four months.  A commercial ELISA kit was used to measure serum IgG 
antibodies to Hep B details of which are given in Chapter 2 section 2.8.3. The details of the 
methods for the Multiplex immunoassay for simultaneous quantification of serum IgG 
antibodies to Bordetella pertussis, Hib, diphtheria toxoid and tetanus toxoid are given in 
Chapter 2, section 2.9.  
 
The study time line in Chapter 4 Figure 4.1 summarises the timing of vaccination, blood 
sampling and assays performed. The details of the study population demographics and 
categorisation are provided in Chapter 4 sections 4.3.1 and 4.3.2.  
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5.3 Results  
5.3.1 B-cell subset distributions in IgM!IgG+ children compared to IgM!IgG! children 
To initially investigate the impact of EBV infection on antibody responses to vaccine 
antigens, the distribution of B-cell subsets in IgM"IgG+ children was compared to those of 
IgM"IgG" children. Figure 4.2 in Chapter 4 (section 4.3.2) shows that the total (CD19+) and 
classical memory B-cell populations (CD19+CD27+) do not differ between IgM"IgG" and 
IgM"IgG+ Gambian children. To further investigate B-cell subsets in these populations, we 
examined the distribution of ‘tissue-like’ or ‘atypical’ memory B-cells 
(CD19+CD20+CD21"CD27") and secondly plasmablasts (CD27+CD21"CD20"CD38+) in 
these donors. Figure 5.1A demonstrates that there was no difference in B-cell subpopulations 
between IgM"IgG" and IgM"IgG+ Gambian children expressing these markers. Three 
IgM+IgG"/+ children similarly had B-cells subsets that did not significantly differ from the 
IgM"IgG+ children (Fig. 5.1A).  
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B. 
 
Figure 5-1 B-cell subsets in of IgM"IgG", IgM"IgG+ and IgM+IgG"/+ children. 
A. Frequency of B-cell subpopulations in the blood of IgM!IgG! Gambian children (n=40) 
compared to IgM!IgG+ children (n=70) and IgM+IgG!/+ children (n=3). B. Illustration of 
flow cytometry staining of B-cell subpopulations from a representative Gambian child gated 
on CD19+ B-cells. Colour coded gating: green (CD20+CD21!) activated (CD27+) and 
tissue-like (CD27!) memory B-cells; red (CD20+CD21+) resting memory (CD27+) and 
naïve (CD27!) B-cells; and blue (CD20!CD21!CD27+) plasmablasts. Populations are 
given as a percentage of total CD19+B-cells in bold. 
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5.3.2 Antibody responses to pentavalent Bordetella pertussis, Diphtheria, Tetanus, 
Haemophilus influenzea B and Hepatitis B vaccination in IgM!IgG+ children compared 
to IgM!IgG! children 
Children aged nine months from the same study site in The Gambia who are infected with 
EBV have been shown to have lower antibody responses to measles and meningococcus 
polysaccharide antigens when infected with EBV compared to EBV uninfected children 
(Holder et al., 2010). To determine whether this phenomenon also occurred in response to 
other vaccine antigens, antibody responses in terms of titre were measured to DTP, Hib and 
Hep B following a pentavalent booster vaccination given at 12-14mths of age, and compared 
between IgM"IgG+ and IgM"IgG" children where plasma samples were available (n=101). 
Figures 5.2 and 5.3 show that there were no significant differences in the final boosted 
antibody levels nor fold changes overtime between IgM"IgG", IgM"IgG+ and IgM+IgG"/+ 
Gambian children for Bordetella pertussis (Ptx, FHA, Fimbriae and Prn) (Figure 5.2), 
Diphtheria toxin, Tetanus toxoid, Hib and Hep B antibody levels (Figure 5.3). P values were 
all non-significant > 0.05. (P values calculated using Dunn’s Multiple Comparison Test (one 
way analysis of variance [ANOVA]) 
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Figure 5-2 Bordetella pertussis antibody levels 
A. One-week post vaccination and B. Fold change in antibody level post vaccination in EBV 
IgM!IgG! (grey circles), EBV IgM!IgG+ (black circles) and EBV IgM+IgG!/+ (red circles) 
Gambian children. 
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Figure 5-3 Diphtheria, tetanus, Haemophilus influenzae b and Hepatitis B antibody levels 
A.  one-week post vaccination and B. Fold change in antibody level post vaccination in EBV 
IgM!IgG! (grey circles), EBV IgM!IgG+ (black circles) and EBV IgM+IgG!/+ (red 
circles) Gambian children. 
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A potential confounder here is CMV status. Table 5.1 gives the breakdown of EBV and CMV 
status of children for who paired pre- and post vaccination antibody levels were measured 
(n=101). There was no significant difference in post vaccination antibody levels for 
Bordetella pertussis, DTP, Hib or Hep B between the following four groups, CMV"EBV" 
(n=7), CMV+EBV" (n=27), CMV"EBV+ (n=9), CMV+EBV+ (n=58) (P values calculated 
using Dunn’s Multiple Comparison Test (one way analysis of variance [ANOVA])  (Figure 
5.5) 
 
 
Table 5-1 Two-way table illustrating EBV and CMV status of Gambian children tested for 
vaccine antibody responses  
 
 CMV infected  
 
CMV 
uninfected  
Total  
EBV infected  
  
58 (57%) 9 (9%) 67 (66%) 
EBV uninfected   27 (27%) 7 (7%) 34 (34%) 
 
Total  85 (84%) 16 (16%) 101 
 
Number of children stated, percentage of total population given in brackets.  
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Figure 5-4  Boosted antibody levels displayed according to EBV and CMV status. 
Pertussis antigens: Pertussis toxin (A), Filamentous Haemagglutination (B), Pertactin (C), 
Fimbriae (D), Diphtheria toxoid (E), Tetanus toxoid (F), Haemophilus influenza B (G) and 
Hepatitis B (H) antibody levels one week post pentavalent (DTP, Hib and Hep B) vaccination 
booster displayed according to EBV and CMV infection status, from left to right CMV! 
EBV!, CMV+EBV!, CMV!EBV+, EBV+CMV+.  
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5.4 Discussion  
In this chapter B-cell subsets in Gambian children aged 12-14 months known to be EBV anti-
VCA IgM"IgG+ were explored and compared to those of EBV VCA anti IgM"IgG" 
Gambian children. These data show that there is no significant alteration in peripheral blood 
B-cell phenotypes, and furthermore, no apparent defect in functioning of memory B-cells in 
producing a rapid antibody response to a pentavalent vaccination booster (DTP, Hib and Hep 
B).  
 
Classical memory B-cell (CD27+) populations were not found to be expanded in the 
IgM"IgG+ children compared to those that were IgM"IgG". Furthermore although numbers 
were small, the frequency of this population in IgM+IgG"/+ children did not significantly 
differ either. As EBV is a gamma herpesvirus that resides in the B-cell compartment 
specifically in memory B-cells one might have expected to see an expansion in this B-cell 
population (Hislop et al., 2007b). Indeed, healthy EBV seropositive adults are known to have 
10 - 100 in every 106 B-cells infected with EBV (Khan et al., 1996). The lack of expansion of 
the B-cell compartments in these Gambian children may be a reflection of the form of EBV 
infection occurring with the virus being in a latent rather than a lytic proliferative state (Silins 
et al., 2001) as discussed previously in Chapter 4.  
 
Gambian children did appear to have an expansion of ‘tissue-like’ or ‘atypical’ memory B-
cells’ (CD19+CD20+CD21"CD27"), a population previously described in the lymphoid 
tissue of healthy individuals (Ehrhardt et al., 2005) and more recently noted to be expanded in 
the peripheral blood of HIV viraemic individuals (Moir et al., 2008). This B-cell subset has 
been shown to undergo isotype class switching and somatic hypermutation. However these 
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cells proliferate less well in response to BCR-crosslinking with or without CD40L and the 
Toll-like receptor (TLR9) agonist CpG and have a reduced ability to differentiate into 
antibody secreting cells compared to naïve (CD27"CD21+) or classical memory B-cells 
(CD19+CD27+). In contrast to the literature on adult B-cell subsets there was a considerably 
greater proportion of ‘tissue-like’ or ‘atypical’ memory B-cells in EBV infected Gambian 
children in the total B-cell population, median 13.40% compared to 1.4% previously found in 
US adults (Weiss et al., 2009). The expansion of ‘tissue-like’ or ‘atypical’ memory B-cells 
seen in these Gambian children was also found to be the case in Mali in West Africa with 
adults and children having ‘atypical’ memory B-cell populations of 15.5% and 9.8% 
respectively (Weiss et al., 2009). It has been suggested that these ‘atypical’ memory B-cell 
populations are expanded in response to cumulative malaria exposure (Weiss et al., 2009, 
Nogaro et al., 2011). This would seem unlikely in our cohort as the incidence of malaria in 
The Gambia has declined (Ceesay et al., 2008) and only one case of P.falciparum malaria was 
detected during the six-month recruitment period among the 120 children. As this B-cell 
subset was also identified in HIV infected individuals this could have been a potential 
confounder. A survey in 2000-2001 of pregnant women in Serekunda, an urban settlement 
10km from the Sukuta study site, estimated the prevalence of HIV to be 1.0% (CI: 0.9-2.4%), 
which would make HIV infection unlikely to be causing an elevation in the levels of these 
circulating B-cells in the peripheral blood of these Gambian children. Similarly nutritional 
status is unlikely to explain the expansion of this B-cell subset as in this study population 
children were excluded if they were underweight. Further work to assess the functional 
significance and explore reasons behind the expansion of this ‘atypical’ B-cell subset in 
African populations needs to be conducted, considering the role of other possible recurrent 
infections and other factors such as nutritional status.   
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The lack of impairment in antibody response to the pentavalent booster vaccination are in 
contrast to the findings of Holder et al. who previously showed that EBV infected children 
recruited from the same study site, Sukuta, had reduced responses to meningococcal 
polysaccharide and measles vaccine compared to uninfected infants (Holder et al., 2010). A 
number of possibilities could account for this difference. The children in this study were three 
to six months older than those in the Holder study, thus their findings may relate to the 
relative immaturity of the immune system and not be a long-lasting effect. Indeed Holder et 
al. did note a reduction in the differences detected when their children reached 11 months of 
age. The effect could also be vaccine specific as diphtheria and tetanus are toxoid vaccines, 
pertussis is a whole bacterial cell killed vaccine, while measles a live attenuated vaccine. 
Furthermore, Haemophilus influenza type b and Meningococcus A and C despite both being 
polysaccharide vaccines, the later is a conjugate vaccine whereas the former is unconjugated. 
Further analysis of the antibody responses to Measles and Meningococcus A and C, exploring 
the longevity of the alteration identified by Holder et al. would be a useful addition to the 
literature. Lastly, due to the increasing age of the children in this study by default a greater 
proportion were CMV infected and Holder et al. found that CMV co-infection reversed the 
effects of EBV infection and elevated antibody responses to levels similar to infants that were 
EBV and CMV uninfected. However in an analysis of these data according to CMV and EBV 
status no such differences where seen, with the caveat of small sample sizes for the CMV 
uninfected groups. Similarly to Holder et al. only 10% of the children were in the EBV 
infected and CMV naïve (CMV"EBV+) category.  
 
These data show no evidence that the phenotype of B-cells is altered as a result of EBV 
infection. Likewise the ability of B-cells to produce an antibody response to vaccination was 
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not affected. This is an encouraging result as it would be of concern if this ubiquitous viral 
infection had a significant impact on common vaccinations given in childhood. It would be of 
interest to determine which B-cell subset EBV is residing in in these Gambian children in 
view of this lack of expansion of memory B-cells.  
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CHAPTER 6 : CONCLUSIONS AND FUTURE DIRECTIONS 
 
Although EBV was discovered some 50 years ago, we still do not fully understand its 
pathogenesis. This ubiquitous dynamic virus has the ability to silently infect some human 
hosts causing little or no apparent clinical disease at the time of initial infection and remain in 
a dormant state. At the other end of the spectrum are those individuals in whom the initial 
acute infection causes a picture of severe clinical disease with significant symptomatology 
known as AIM. The likelihood of a symptomatic clinical presentation alters with the age of 
primary infection: AIM is extremely rare in children, with most cases described in 
adolescence or adulthood. Why this is the case remains to be elucidated. It could be due to an 
alteration in the form that the virus takes in early EBV infection (dominance of lytic or latent 
infection) or the host response, but is likely to be multifactorial.  
 
In West African children, EBV infections occur at a much earlier age than in developing 
countries, and by three years of age most children are EBV seropositive. Aside from recent 
modelling of the infection in Kenyan children, demonstrating that those infected at an earlier 
age have a higher viral load set-point in infancy (Piriou et al., 2012), little is known about the 
implications of early EBV infection on the immune system. Indirectly, EBV-related tumours 
are known to be prevalent in this population group, the classical example being eBL. 
Therefore, development of a vaccine against EBV to prevent establishment of a latent 
infection in early childhood, or perhaps more realistically alter the virus host balance in 
favour of the host upon infection, would be of value in reducing the incidence of EBV-related 
tumours in countries often lacking adequate facilities to provide sufficient treatment of them. 
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Studying the immune response to EBV in a setting where infection is highly prevalent at a 
young age is of importance in informing this process.  
 
The other well-recognised co-factor involved in the pathogenesis of eBL is P. falciparum 
malaria infection. Chapter 3 of this thesis has built on previous work conducted in The 
Gambia exploring the interaction between these two pathogens and the host immune response 
in children. The previous findings of Whittle et al. some 30 years ago initially established that 
there was a loss of EBV-specific immune responses in children with acute P. falciparum 
infection. In this thesis both the original assays described by Whittle et al. were used in 
addition to the more contemporary techniques of peptide-MHC class I tetramer staining and 
IFN-! ELISPOT analysis to directly identify EBV-specific CD8+ T-cells. Both of these failed 
to show a reduction in EBV-specific immune responses during acute P. falciparum infection 
in Gambian children. This present study was conducted on the background of a significant 
and well-documented decline in the incidence of malaria in The Gambia (Ceesay et al., 2008, 
Ceesay et al., 2010). This supports the hypothesis that it is not purely a single episode of acute 
malaria that alters the host virus balance in EBV infection, but rather the effect of cumulative 
malarial episodes. The work by Moormann et al., who studied two cohorts with differential 
malaria exposure in the Kisumu and Nandi areas of Western Kenya, is relevant here. They 
noted higher EBV genome loads in children, one to four years of age, living in areas 
holoendemic for malaria compared to those only sporadically exposed (Moormann et al., 
2005). This is consistent with this data and supports the idea that chronic repeated exposure to 
malaria throughout a child’s early years may be required to alter the EBV-host balance.  This 
is yet to be directly confirmed and would require a longitudinal study, comparing immune 
responses to EBV at the time of first and subsequent acute malaria infections.  
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These findings do have more general implications, supporting the notion that the decline in 
malaria seen in some parts of sub-Saharan Africa has wider implications than a reduction in 
morbidity and mortality from malaria alone. Indeed, studies have shown changes in the rates 
of invasive bacterial disease such as non-typhoidal salmonella in The Gambia (Mackenzie et 
al., 2010, Obaro and Greenwood, 2011), and reduced all-cause mortality in children in regions 
where a reduction in malaria has been demonstrated (Snow and Marsh, 2010). 
Epidemiological studies to establish whether reduced malaria exposure also translates into a 
reduced incidence of eBL are needed. 
 
To further understand the impact of EBV infection on children, antibody responses to 
constituent antigens of a pentavalent childhood vaccine were examined. Previous studies had 
suggested that nine month old children vaccinated with live attenuated measles vaccine or 
meningococcal polysaccharide vaccine made relatively poor antibody responses to these 
antigens if they were EBV infected, compared to uninfected or EBV/CMV co-infected 
children (Holder et al., 2010). The clear conclusion from the current study is that antibody 
responses to a booster dose of DTP, HepB and Hib vaccination are not altered by the presence 
of EBV. Why antibody responses to measles and meningococcal vaccines were reduced in the 
previous study in EBV infected infants is unclear, but encouragingly for children, these 
findings do not extend to this older age group immunised with DTP, HepB and Hib. One may 
speculate that the effects of EBV infection on vaccine responses are less apparent in an older 
age group. A way to test this would be to find children who had missed their measles and 
meningococcal vaccinations at the time of administration of the pentavalent booster, 
immunise these children with measles and meningococcal vaccines and follow responses to 
these two antigens in parallel with the others.  
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Primary EBV infections that occur sub clinically or silently are difficult to identify and 
therefore difficult to study. Thus, the majority of the EBV literature to date focuses on the 
immune response during acute symptomatic infection, AIM, or persistent infection in patients 
in whom there is no history of AIM. What causes someone to develop AIM, as opposed to 
silently seroconvert, is not yet known. In Chapter 4 we were able to identify two groups of 
recently EBV infected children: one group who showed serological evidence of recent 
infection (including the production of EBV-specific IgM antibodies), while the other were 
children likely to have been infected within the previous six months, based on 
epidemiological (Holder et al., 2010) and viral load data. A significant difference was seen in 
the immune responses in most of these Gambian children, when compared to those described 
in Caucasian donors, with or without a history of AIM: the lack of a dominance of lytic 
responses, with latent responses that were of a similar magnitude to lytic responses. This 
should be interpreted with caution, as epitopes used in this study have been defined based on 
work with type 1 EBV strains in Caucasians. However, while the Gambian strains of EBV in 
our donors were not sequenced, Njie et al. described previously that 90% of Gambian donors 
they studied carried type 1 EBV (Njie et al., 2009). This indicates that the use of peptides 
derived from type 1 EBV is a reasonable choice. In addition, there is extensive homology 
between the two subtypes and cross-reactive responses have been recognised (Bornkamm et 
al., 1980, Sample et al., 1990, Zimber et al., 1986, Brooks et al., 2000). It would be prudent to 
undertake further sequencing of local circulating EBV strains. Designing peptide libraries to 
these local strains for screening responses would increase the validity of these findings. This 
lack of lytic dominance in Gambian children’s responses contrasts with those detected in 
AIM, where they are predominantly lytic. During AIM, significant EBV loads are shed from 
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the oropharynx and this persists for sometime. Exploring EBV-specific responses in Gambian 
children with latent epitope-specific class I tetramers, such as B*0801 restricted FLR or 
QAK, would enable a direct comparison of the number of specific CD8+ T-cells to lytic and 
latent epitopes. One would predict, based on the current findings, that these would be of a 
similar order to the lytic EBV-specific populations detected. Furthermore, it would be of 
interest to examine tonsillar tissue or secretions from the oropharynx of children undergoing 
asymptomatic primary EBV infections using RT-PCR to determine if the degree of viral 
shedding differs from that seen in AIM, where the level of viral shedding has been noted to be 
high and persistent (Balfour et al., 2005, Hislop et al., 2005).  
 
It has previously been shown that blocking of full virus replication with acyclovir (ACV) does 
not affect the clinical course of AIM once the disease is underway, although it reduces viral 
shedding in the oropharynx (Tynell et al., 1996). This, however, is not surprising if the initial 
phase of virus replication in B-cells has passed by the time a patient presents with symptoms 
of AIM. If ACV could be administered sufficiently early, it could potentially prevent the 
massive activation/expansion of lytic antigen-specific CD8+ T-cells by reducing EBV 
replication and lytic antigen load. The recombinant soluble gp350 EBV vaccine has been 
shown to prevent AIM (reduced the rate by 78% in young adults) but not to prevent EBV 
infection. The postulated mechanism behind this is that the induced neutralising antibodies 
reduce the initial phase of viral replication (Sokal et al., 2007). This has been explored in the 
similar rhesus Lymphocryptovirus (LCV) animal model, a naturally endemic virus in Rhesus 
monkeys (Moghaddam et al., 1997). High levels of antibody to gp350 were associated with 
better protection against viral challenge (Sashihara et al., 2011).  This model could be used to 
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further explore the balance of lytic and latent cellular responses during primary EBV infection 
(Rivailler et al., 2002).  
 
Another question, which arises from this thesis, is whether infant human B-cells are less 
permissive for EBV replication than adults B-cells, and whether this is why EBV-specific 
responses to latent proteins are elevated in childhood infection, but not in adults. This is an 
interesting possibility as it is known that EBV-transformed cord blood B-cell lines in vitro are 
predominantly latent, where as adult B-cell lines usually have between 1-3 % of cells in lytic 
cycle (Alan Rickinson, personal communication).    
 
The EBV genome load in recently infected Gambian children was as high as those found in 
patients suffering with AIM, despite these children being clinically asymptomatic. This 
corroborates the findings of Njie et al. where genome loads in healthy control children were 
of a similar order. In addition they found that EBV genome loads in Gambian adults were 
significantly higher than UK carriers (Njie et al., 2009). What leads to both Gambian adults 
and children having higher viral load set-points, through alteration in the virus: host balance, 
is not clear. Parallels can be drawn with what has been shown in the aging Caucasian 
population, where EBV genome loads in the peripheral blood B-cell compartment are 
elevated (Snider et al., 2012, Stowe et al., 2007). EBV-specific CD8+ T-cells directed against 
latent epitopes assessed in the elderly have been readily detected and even predominate over 
lytic in some instances (Khan et al., 2004, Vescovini et al., 2004), reminiscent of the 
equivalent frequencies of EBV-specific latent and lytic CD8+ T-cells observed in this study. 
Thus one may hypothesise that there is suboptimal EBV-specific immune control in African 
children or elderly populations: in Africans this may manifest as an increased susceptibility to 
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eBL when the co-factor of malaria is present, while in the elderly, other diseases may 
manifest such as EBV-associated diffuse large B-cell lymphoma of the elderly, which occurs 
in patients greater than 50 years with no known history of immunodeficiency or lymphoma.  
 
In children identified as having serological evidence (IgM positive) of recent infection, it was 
possible to identify significant EBV-specific CD8+ T-cell populations, but not of the order of 
magnitude (in terms of absolute numbers) of EBV-specific CD8+ T-cells described in patients 
with AIM. They also lacked the total lymphocytosis classically associated with AIM patients. 
EBV viral genome loads in these Gambian children were substantially elevated to levels that 
did not significantly differ from AIM patients, and therefore symptomatic infection could not 
be explained by reduced viral load. One possible explanation worth exploring to explain these 
contrasting courses of primary infection could be differing levels of circulating inflammatory 
cytokines elicited. It is possible that during AIM the predominating lytic immune responses 
drive the production of high levels of circulating cytokines, which in turn drives the 
inflammatory response and results in symptomatic disease. In the asymptomatic primary 
infections the virus may be in its latent form and relatively protected from 
immunosurveillance, hence result in a less aggressive inflammatory response, leading to 
minimal clinical symptomology. Rare EBV infections of NK and T-cells have been described, 
such as EBV-associated haemophagocytic lymphohistiocytosis, where clinical manifestations 
are due to the release of pro-inflammatory cytokines causing dysregulation of the 
inflammatory response (Fox et al., 2011). This is, however, due to direct infection of NK and 
T-cells, rather than immunopathology due to virus-specific responses. X-linked 
lymphoproliferative disease (XLP) patients are vulnerable to severe primary EBV infection, 
often leading to lethal AIM. They have mutations in signalling lymphocytic activation 
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molecule (SLAM) associated protein (SAP), an adaptor that binds and recruits signalling 
molecules to SLAM family receptors expressed on T-cells and NK cells. The mechanism of 
increased susceptibility is thought to be driven by an EBV-induced overactive T/NK-cell 
response that is ineffective when engaging B-cells, and thus unable to clear the source of 
antigen leading to immune pathology (Hislop et al., 2010).   
 
Further evidence may be required to determine whether a different form of infection is 
occurring in these children undergoing apparently primary asymptomatic infection, in terms 
of a more latent versus lytic infection (Silins et al., 2001). In this case, examining these 
asymptomatic patients for virus loads shed from the oropharynx, indicative of lytic virus 
replication, could be undertaken. Clearly further studies are required as to how the immune 
response differs in these children compared to AIM patients. Most of the primary infection 
donors made responses to EBV-epitopes, which were smaller than those seen to epitopes in 
AIM patients. However at least one donor showed a clear expansion of EBV-specific T-cells 
in response to a lytic epitope which, when measured in terms of percentage tetramer binding 
CD8+ T-cells, was comparable to what is seen in AIM patients. Crucially this and other 
donors did not show a lymphocytosis when compared to age matched controls. At face value, 
this may suggest EBV infection could elicit strong CD8+ T-cell responses, but the repertoire 
stimulated or expansion of responses in these donors are highly focused in contrast to AIM 
and thus a lymphocytosis is not observed in these children. Examining co-resident EBV-
specific responses in such asymptomatic donors would go some way to resolve this issue.  
 
Could the difference in the lytic:latent balance of EBV-specific T-cell responses and the 
presence or absence of a lymphocytosis in Gambian children compared with adolescent AIM 
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donors be an age related phenomenon? Infection during adolescence may result in a greater 
propensity for a lytic-biased response, as well as a significant lymphocytosis, with AIM being 
at the extreme end of a clinical spectrum. Indeed, recent data from the Balfour et al. study 
found that viral load and CD8+ T-cell percentage correlated with a severity of illness index 
(Balfour et al., 2013). Exploration of immune responses in asymptomatic primary Caucasian 
adolescent donors (with a similar approach to that taken in the current study) may shed further 
light on this finding. However, if there were equivalent lytic and latent responses and an 
absence of a lymphocytosis seen in both asymptomatic adolescent seroconverters and 
Gambian children, this would suggest factors other than age result in a lytic-biased response 
and therefore symptomatic infection/AIM.   
 
Overall it is clear that there is still much we do not understand about what dictates the clinical 
phenotype of primary EBV infection. A greater understanding of the immunopathology and 
consequences of infection will provide further targets for immune therapy and potential 
vaccine candidates. This body of work furthers our understanding of the impact of EBV 
infection in childhood in West Africa, an area where eBL is well recognised. It adds to the 
body of literature surrounding EBV and malaria co-infection. Age related differences in 
primary infection are highlighted, and important insights provided regarding the cellular 
immune response to EBV infection in otherwise healthy Gambian children. 
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APPENDIX I.  INTRACELLULAR CYTOKINE STAINING (ICS) 
 
Co-expression of four cytokines (IFN-!, IL-2, TNF-# and MIP1$) and capacity to degranulate 
(surface expression of CD107a) following stimulation with overlapping peptide pools 
spanning EBV lytic protein, BZLF1 and EBV latent protein, EBNA3A was assessed. 
 
Polyfunctional analysis of CD8+ and CD4+ EBV-specific T-cells.  
So called ‘polyfunctional cells’ based on their ability to produce multiple cytokines and 
possession of cytotoxic capacity have become increasingly thought to provide correlates of 
immune protection against pathogenic viruses. Some recent work performed on healthy Hong 
Kong Chinese adult long-term EBV carriers demonstrated that IFN-! producing EBV-specific 
T-cells accounted for only 40-50% of the total EBV-specific CD8+ and CD4+ T-cell 
populations, therefore half the EBV-specific T-cells did not produce IFN-! (Ning et al., 
2011). This suggests that by focusing on IFN-! alone many cell responses may be missed. 
Ning et al. also studied two children with PTLD showing that they produced less IFN-! and 
IL-2, but more TNF-# with retained ability to degranulate compared to adult EBV carriers. 
This could be an age-specific effect or a consequence of immunosuppression, as these 
children were on continuous immunosuppressive therapy (Ning et al., 2011).  
 
In this section IgM"IgG+ donors were assessed for the co-expression of cytokines (IFN-!, 
TNF-#, MIP1$ and IL-2) and the surface degranulation marker, CD107a, in both CD8+ and 
CD4+ T-cells by stimulating with overlapping peptide pools spanning BZLF1 lytic and 
EBNA3A latent proteins (n=40 and 39 donors respectively). The ICS assays were performed 
only on children at the baseline first time point. The majority of EBV-specific CD8+ T-cells 
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in IgM"IgG+ Gambian children were not polyfunctional. Indeed, the majority of CD8+ T-
cells failed to produce any cytokines in response to stimulation with BZLF1 lytic (30 donors) 
or EBNA3A latent (26 donors) peptide pools (Figure 1.0 A and B). The few responders that 
were detected tended to have monofunctional populations (n=8 BZLF1, n=7 EBNA3A) with 
only two (20%) and six (46%) of responding donors producing polyfunctional responses to 
stimulation with BZLF1 and EBNA3A peptide pools respectively (Figure 1.0 A).  Of the 
monofunctional responders three different donors for BZLF1 (38%) and EBNA3A (43%) 
produced IFN-!. There were only four (21%) donors that produced responses to both BZLF1 
and EBNA3A peptide pools. The rest responded either to the BZLF1 pool (6, 32%,) or the 
EBNA3A pool (9, 47%).  
 
As there were so few responders it did not make sense to analyse the polyfunctionality of the 
cells (number of cytokines individual cells were producing (mono-, bi- or triple- functionality 
etc.), as a proportion of the overall response using averages as the overwhelming majority of 
responses were zero.  Therefore SPICE software was not used for further analysis. Figure 1.2 
gives the proportion of donors with cells that were monofunctional, bi-functional or triple 
functional or a combination of the aforementioned as indicated in the Figure legend.  
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Polyfunctional cell populations: +1 = monfunctional cells, +1, +2 = mono and dual-functional cells,  +2 = dual functional 
cells, +1 +3 mono and triple functional cells 
 
Figure 1 A. Breakdown of donor CD8+ T-cell responses when stimulated with BZLF1 lytic 
(left, n=40) and EBNA3A latent (right, n=39) protein overlapping peptides pools. Displayed 
are absolute numbers (percentages in brackets) of donors with either no response, 
monofunctional or polyfunctional responses.  B. Total (mono- and polyfunctional) percentage 
of cytokine (IFN-?, TNF-?, MIP1? and IL-2) secreting CD8+ T-cells in response to 
BLZF1 (left) and EBNA3A (right) overlapping peptide pools and percentage of CD8+ T-cells 
co-expressing CD107a in addition to secreting at least one other cytokine in response to 
stimulation with BZLF1 (left) and EBNA3A (right) overlapping peptide pools. C. 
Representative donor illustrating a CD8+ T-cell IFN-? response mounted to the BZLF1 
overlapping peptide pool.   
Negative SEB BZLF1 
IL-2 
IF
N
! 
C. 
0.01 
0.07 
0.14 0.28 
0.12 
4 0.01 
0.05 
0.43 
 211 
Similarly the majority of EBV-specific CD4+ T-cells in IgM"IgG+ Gambian children were 
not polyfunctional. A slightly greater number of donors had cytokine producing CD4+ T-cells 
compared to the number of donors that had detectable EBV-specific CD8+ T-cells responses 
to BLZF1 lytic protein (10 CD8+ responders versus 16 CD4+ responders) and EBNA3A 
latent protein (13 CD8+ responders versus 17 CD4+ responders) (Figure 1.2 A and B). The 
responders that were detected again tended to have monofunctional populations (n=12 
BZLF1, n=9 EBNA3A) with four and eight of responding donors producing polyfunctional 
responses to stimulation with BZLF1 and EBNA3A peptide pools respectively (Figure 1.2 A).  
Of the monofunctional responders there was a greater proportion of responders producing 
TNF-#, (58% BZLF1, 44% EBNA3A), with only three (25%) and two (22%) donors 
producing IFN-! in response to BZLF1 and EBNA3A peptide pools respectively.  There were 
only seven (27%) donors that produced responses to both BZLF1 and EBNA3A peptide 
pools. The rest responded either to the BZLF1 pool (9, 35%) or the EBNA3A pool (10, 38%). 
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Polyfunctional cell populations: +1 = monfunctional cells, +1, +2 = mono and dual-functional cells,  +2 = dual functional 
cells, +1 +3 mono and triple functional cells  
 
Figure 1.2 A. Breakdown of donor CD4+ T-cell responses when stimulated with BZLF1 lytic 
(left, n=40) and EBNA3A latent (right, n=39) protein overlapping peptides pools. Displayed 
are absolute numbers (percentages in brackets) of donors with either no response, 
monofunctional or polyfunctional responses.  B. Total (mono- and polyfunctional) percentage 
of cytokine (IFN-?, TNF-?, MIP1? and IL-2) secreting CD4+ T-cells in response to 
BLZF1 (left) and EBNA3A (right) overlapping peptide pools and percentage of CD4+ T-cells 
co-expressing CD107a in addition to secreting at least one other cytokine in response to 
stimulation with BZLF1 (left) and EBNA3A (right) overlapping peptide pools. C. 
Representative donor illustrating a CD4+ T-cell TNF-? and IL-2 response mounted to the 
BZLF1 overlapping peptide pool.  
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There were three IgM+IgG"/+ donors for which there were sufficient cell numbers to 
perform the ICS.  Donor ID053 produced no response to either of the overlapping peptides 
pools, BZLF1 and EBNA3A. However, two donors both had CD8+ T-cells that responded to 
the BZLF1 lytic overlapping peptide pool and not to the EBNA3A latent pool. For donor 
ID061 the response was monofunctional, with cells producing either IFN-! or MIP1$ and the 
second donor ID013 again produced a monofunctional MIP1$ response, but in addition to this 
there were cells with some dual functionality producing both IL-2 and MIP1$. The EBV-
specific CD4+ T-cells in these donors were similar to the responses seen for the CD8+ T-
cells. The CD8+ non-responder ID053 also had no CD4+ T-cell response. Donors ID013 and 
ID061 which had CD8+ responses also had CD4+ T-cells that responded to the BZLF1 lytic 
overlapping peptide pool but not to the EBNA3A latent pool. For donor ID061 the response 
was again monofunctional, but with CD4+ T-cells producing either IFN-! or TNF-#. Donor 
ID013 also produced monofunctional MIP1$ and IL-2 responses, with some cells showing 
dual functionality by producing both IL-2 and MIP1$, similar to the CD8+ T-cell response. 
These findings are consistent with the ELISPOT reactivity, which detected an IFN-! response 
in donor ID061, the donor that produced an IFN- ! by ICS. 
 
